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1-1 The intrathecal pump is implanted in an abdominal pocket and the 
catheter is subcutaneously routed around the side, up the back, and 
inserted into the intrathecal space. 
5
1-2 Left: The SynchroMed EL made by Medtronic.  Center: The IsoMed 
intrathecal pump made by Medtronic.  Right: The CODMAN 3000 
continuous flow pump manufactured by Codman. [Med08] 
6
1-3 Gold membrane silicon microreservoirs originally developed by Santini 
et al. and now being commercialized by MicroCHIPS. [San99] 
11
1-4 Various sizes of the single use implantable osmotic pump made by Alzet. 
[Alz08] 
12
1-5 Current drug delivery devices trade functionality and control for size.  
This work seeks to develop a new topology that improves the intrathecal 
implant class of devices in both functional control and volume efficiency.  
Device specifics can be found in Table 1-2. 
13
2-1 Conceptual design of an implantable intrathecal drug delivery device that 
uses two valves to independently regulate the medication delivered from 
spring pressurized reservoirs.   
17
3-1 Microvalve concepts: The valve consists of ceramic-PZT-Si-glass 
structure.  A PZT stack actuator moves the silicon plate to open or close 
the valve.  Micro-groove patterns are fabricated on the silicon plate to 
increase the flow area 
39
3-2 Si-glass micromachining process: The buried oxide layer in a SOI wafer 
acts as an etch stop for DRIE.  A three-step DRIE process is illustrated 
for the SOI wafer.  A glass wafer undergoes a wet etch process and 
electrochemical discharge machining (ECDM) for inlet and outlet hole 
creation.  Finally, an Al metal layer is deposited and patterned in 
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3-3 Photographs of the fabricated device. (a) SEM photograph of the silicon 
valve plate with groove patterns right after the three-step DRIE process.  
(b) Picture of a die after the anodic bond.  (c) Close-up view near the 
hole with serpentine groove patterns for perimeter augmentation.  (d) 
Completely assembled valve structure.  Two valves (front and back) are 
shown. 
42
3-4 Schematic of the test setup for the He gas flow measurement.  Flow rate 
through the valve is measured while monitoring the inlet and outlet 
pressure.  For low or high temperature testing, heat exchangers are 
placed to cool or heat the He gas.  
44
3-5 Flow rates as a function of voltage at room temperature from 
experimental results (a) and analytic model (b).  As the actuation voltage 
increases, the valve is closed and results in a decreased flow rate.   
45
3-6 Flow rates as a function of actuation voltage measured at room 
temperature with an inlet pressure of 345 kPaG and an inlet to outlet 
pressure differential of 34 kPa.  Experimental data is shown with the 
numerical modeling results.  Flow rate measurements show the hysteretic 
behavior of the PZT actuator. 
46
3-7 Flow rate through un-actuated valve (0 V) across various pressures.  At 
lower pressures the flow rate changes linearly with pressure. 
47
3-8 Flow rate versus voltage actuation from -30 V to 60 V.  Results are 
recorded for two inlet pressures, while the outlet is held constant at 101 
kPa. Actuation is more pronounced with greater inlet pressure. 
48
3-9 Flow rate changes versus duty cycle for two inlet pressures.  The 
actuation voltage was a 50 Hz square wave from 0-60 V.  This method 
does not rely on the linearity of piezoelectric actuation. 
48
3-10 Microvalve concepts: (a) A cut away view of assembled ceramic-PZT-
Si-glass valve structure. (b) A valve plate suspended by Si membrane 
with integrated sensors viewed from the bottom.  RTD sensor is located 
on the back of the wafer 
50
3-11 Si-glass micromachining process: sensors are formed on the device layer 
of the SOI wafer by various surface micromachining techniques.  The 
buried oxide layer in SOI wafer acts as an etch stop for DRIE when 
forming membranes.  A two step DRIE process is illustrated for SOI 
wafer.  A glass wafer undergoes two wet etch steps for a recess and 
through-hole formation.  Next, the two wafers are bonded and diced.   
52
3-12 (a) Photograph of the top of the SOI wafer showing metal contact layer 
with (b) an expanded view of the platinum RTD. (c) Wide and (d) 
53
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expanded views of the circular serpentine groove patterns for perimeter 
augmentation from the bottom of the SOI wafer.  This side bonds to the 
glass wafer 
3-13 Assembly process can result in either normally closed or normally open 
valve.  Energizing the PZT actuator during assembly results in normally 
open configuration (top), while no PZT actuation during assembly yields 
normally closed valve (bottom).  For normally closed valve 
configuration, reverse polarity actuation voltage is applied to the 
piezoelectric actuator to shorten the PZT stack and open the valve.   
55
3-14 Assembled valve from the glass side with US penny.  The pressure 
sensor cavity is connected to the inlet through a passage.  The valve is 
1.5×1.5×1.1 cm3. 
56
3-15 Flow rates as a function of voltage measured. (a) normally open valve, 
and (b) normally closed valve measured at differential inlet pressure of 
52 kPa. 
57
3-16 Output voltage from piezoresistive pressure sensor at various differential 
pressures.   
58
3-17 Starburst manifold concepts: (left) A top and back side view of the SOI 
wafer with the centralized inlet, dual pressure sensors, and starburst valve 
seat arrangement. (b) A manifold designed with the starburst valve seat 
used to regulate flow from two inlets.  The manifold has a common 
outlet with a single pressure sensor for mixing in the device and common 
flow control. 
60
3-18 Si-glass micromachining process: sensors are formed on the device layer 
of the SOI wafer by implanting boron and making ohmic connections 
through a field oxide to gold contact pads on the device perimeter.  The 
buried oxide layer in SOI wafer acts as an etch stop for DRIE when 
forming membranes.  A two step DRIE process is illustrated for SOI 
wafer.  A glass wafer undergoes two wet etch steps for a recess and 
through-hole formation.  Next, the two wafers are bonded and diced.   
62
3-19 Photographs of the top and back sides of a fabricated valve manifold.  
The glass inlets and outlets, the two valve seats, and the pressure sensor 
cavities are clearly visible on the top.  The gold contact pads and traces 
for the pressure sensors, and the gold to define the PZT locations are 
clearly visible on the back side of the device. 
63
3-20 Assembled starburst valve looking from the glass side.  The pressure 
sensor cavities are clearly visible for both the inlet and outlet.  The valve 
is 1.5×1.5×1.1 cm3. 
64
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3-21 Photograph of an assembled starburst manifold.  Both valve plates are 
clearly visible and the common outlet port is located in the center of the 
die.  The manifold measures 3×1.5×1.1 cm3. 
65
3-22 Photograph of an assembled starburst manifold with the attached fluidic 
header.  The inlets and outlet tubes interface with the valve through a 
Macor connector piece. 
66
3-23 Generalized flow pattern of the valves: Fluid flows from the inlet to the 
high-pressure grooves, across the land region, the low-pressure grooves, 
then to the outlet. 
66
3-24 An overview of the parameters used during the analysis of the valve seat 
geometry, 
67
3-25 Mass balance terms for the control volumes of the numerical solution. 68
3-26 A representation of a saw-toothed valve seat that relies on larger groove 
openings on the inlet side of the valve.  A saw-tooth valve geometry can 
yield up to 10 times the flow for set valve seat length. 
70
3-27 A graphical representation of the increase in relative flow rates through 
valves with different groove ratios but the same valve seat perimeter.  
The more pronounced the saw-tooth effect, the greater the flow rate.  
Valve parameters for the simulation are summarized in the table in Fig 3-
22. 
71
3-28 Analysis of the relative flow rates of similar valves with a change in the 
width of the valve seat.  Valve parameters for the simulation are 
summarized in Fig 3-23. 
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3-29 Analysis of the flow rate variations for valves with identical parameters 
except for the depth of the groove that resides on either side of the valve 
seat.  Valve parameters for the simulation are summarized in the table in 
Fig 3-23. 
72
3-30 A graphical representation of the parameters used to optimize the 
starburst pattern designs. 
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3-31 The total effective perimeter length (left axis) as a function of the inlet 
width of a single valve wedge for different wedge lengths.  Simulations 
are for valves with a boss radius of 4500 µm, wedge tip width of 10 µm, 
and a valve seat width of 30 µm. 
74
3-32 FEA simulated diaphragm stress for sensor membranes of varying 
thickness and radius at 20 kPa of differential pressure.  The circle 
represents the operating point of the membrane suspended valve. 
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3-33 Simulated diaphragm deflection for sensor membranes of varying 
thickness and radius at 20 kPa of differential pressure.  The circle 
represents the operating point of the membrane suspended valve. 
76
3-34 (a) A profile of the valve showing the boss, diaphragm, and bulk silicon 
on the perimeter of the device.  The boss will experience significant 
pressures during fabrication, and because it is unsupported it will deflect 
and cause stress at the boss/ring joint that could cause mechanical failure 
(b) A profile of the valve  showing a boss supported by a PZT stack.  
Pressure differences between the operating fluid and the ambient 
environment will cause diaphragm ring around the boss to deflect.  This 
deflection and associated stress may cause mechanical failure during 
valve operation. (c) Stress induced on the membrane caused by boss 
deflection for 20 kPa of processing pressure for different ring radii and 
diaphragm thicknesses (d) Boss deflection under the same conditions. 
79
3-35 (a) Stress induced in the diaphragm ring for operating pressures of 100 
kPa with varying diaphragm thicknesses and ring radii (b) Deflection of 
the center of the diaphragm ring for the same operating conditions 
80
3-36 Schematic of the gas tests.  Nitrogen is routed to both sides of the 
manifold and is controlled by inlet valves.  The manifold regulates flow 
rates for pressures, and the flow meter detects the actual rate.  Single 
starburst valves are tested in a similar manner with only a single inlet 
channel used for testing. 
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3-37 Flow rates in a normal-flow starburst valve for actuations voltages 
ranging from -30 – 90 V with differential pressures up to 23.5 kPa and a 
maximum flow rate of 521 ml/min 
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3-38 Flow rates in a normal-flow starburst valve for actuations voltages 
ranging from -30 – 90 V with differential pressures up to 23.5 kPa and a 
maximum flow rate of 521 ml/min 
82
3-39 left: hysteresis of a high-flow starburst valve for increasing and 
decreasing actuation voltage with flow ranging from 445 to 57 ml/min; 
right: hysteresis of a normal-flow valve at 14 kPa with flow ranging from 
336 to 64 ml/min 
82
3-40 Normal and high-flow valve performance at 14 kPa of differential 
pressure.  High-flow valves provide greater dynamic range using 
actuation voltages preferred by the drug delivery system design. 
83
3-41 Schematic of the liquid tests.  Nitrogen is used to pressure fluid in a large 
reservoir.  The pressurized fluid is independently routed to each side of 
the manifold, and a video camera records the travel of bubbles through a 
84
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1 m catheter tube to determine the flow rate through the valve. 
3-42 Normalized flow rate of one side of a normal-flow starburst manifold at 
14 kPa differential pressure for varying actuation voltage.  The target 
dynamic range is realized in the preferred 80 volt operating range. The 
flow is regulated from 100% down to below 10%. 
84
3-43 Flow rate of alcohol through individual and combined valves in a 
manifold at 14 kPa.  Catheter resistance is greater than valve resistance at 
low voltages outside preferred operating region.  This results in reduced 
modulation.  Mixing also functions as expected, and is particularly 
evident in the lower flow rate regimes. 
85
3-44 Characterization of pressure sensors with nitrogen gas.  Typical 
differential voltage from a piezoresitive pressure sensor Wheatstone 
bridge in a manifold has sensitivity of 698 ppm/kPa and an average error 
of 1.99% of the expected value. 
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4-1 Process for spring SOI wafer with DRIE etch to define springs and 
backside release DRIE etch and HF dip 
91
4-2 SEM of the torsion springs showing twists of torsion beams 92
4-3 Setup to measure deflection of springs using z-axis focal adjustment 93
4-4 Photo of springs after balloon insertion showing 4 mm out of plane 
deflection 
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4-5 Measured and predicted z-axis spring deflection and resultant force and 
pressure. 
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4-6 The springs are designed as flat mesh sheets that are rolled around the 
balloon to compress the liquid inside and generate pressure 
95
4-7 Four Cells of a balloon mesh are shown.  Stiffer springs have dimensions 
(A: 6 mm; B: 600 µm).  More expandable springs have dimensions (A: 
10 mm; B: 600 µm) 
96
4-8 (a) The compressive sleeve and the polymer balloon used to form an 18.8 
mL reservoir. (b) A reservoir filled with green water inside an expanded 
sleeve demonstrating the expansion of the diamond shape cells. (c) 
Relaxed Elgiloy® spring mesh showing the springs cells in an un-
actuated rectangular shape. (d) Stretched springs in a diamond shape.  In 
all cases, the cell windows are each 600 µm x 6 mm. 
98
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4-10 (a) Measured load characteristics of the mesh springs as a function of 
linear conditioning (stretching). The unconditioned spring constant is 
407.3 N/m and the pre-conditioned spring constant is 305.7 N/m. (b) 
Measured reservoir pressure generated for various balloon/sleeve 
distension.  From 12 mm to 19 mm, the pressure is generated by the 
springs. Beyond 19 mm, the balloon elasticity changes the profile. Fully 
inflated, the reservoir is 20 mm in diameter and generates almost 15 kPa. 
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monitoring and reprogramming. 
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actual control PCB that is 4 cm X 6 cm and powered from a 3V battery.  
The pressure sensor input is amplified and read by an ADC.  This data is 
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microcontroller.  The PCB is capable of independently controlling two 
valves and has the circuitry necessary to enable wireless communication 
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5-3 (top) Calculated voltage needed to actuate the valve to maintain a set 
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change in flow rate over time due to changes in valve constriction at 
various error rates.  The frequency of valve adjustments decreases over 
time due to non-linearity in the reservoir 
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5-4 Microvalve regulated fluorescent dye diffusion from a spring pump into 
agar gel.  The setup is on top and typical fluorescent images taken for 
different valve actuation voltages are shown over time.   
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5-6 Extracted Dt values for infinite source diffusion plotted with modeled 
diffusion Dt values showing close fit validating the model 
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5-8 A drug delivery prototype pictured during assembly.  A polymer 
reservoir is pressurized with Elgiloy compressive sleeve springs and 
regulated by the PZT microvalve to control drug delivery rates.  The 
entire device takes up about 130 cm3.  The inset is a photograph of the 
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VALVE REGULATED IMPLANTABLE INTRATHECAL DRUG 









Chair: Yogesh B. Gianchandani 
 
 
Chronic pain afflicts an estimated 100 million people in the United States with annual 
costs exceeding $100 billion.  Treatment modalities for severe chronic pain include 
implantation of an intrathecal drug delivery device (IDDD).  Conventionally, these 
devices are of two types: passive, permitting the delivery of a single analgesic mixture at 
a fixed rate; or active, permitting variable delivery by virtue of a peristaltic pump.  This 
thesis presents an implantable system for medication delivery from multiple reservoirs 
with micromachined components.  These components permit the use of an architecture 
that can provide superior volume efficiency and permit complex multi-drug delivery 
protocols.  The system comprises three main components: regulatory valves, pressurized 
reservoirs, and control electronics.  Important design considerations for each of these 
components are emphasized. 
 xx
Piezoelectric microvalves were designed and tested for use with aqueous flows.  Two 
types of spring pressurized reservoirs were also designed and tested for feasibility in an 
IDDD.  Reservoirs were pressurized using springs fabricated from silicon and generated 
up to 80kPa of pressure.  Alternative reservoirs were pressurized using compressive 
metal springs and generated up to 18kPa of pressure.   
A first-generation system was developed that demonstrated controlled diffusion into 
agar gel.  Water flow was regulated from 0.2-5mL/day, and bolus delivery was 
demonstrated.  A second-generation system utilizing a two-valve manifold with 
embedded sensors was used to independently regulate isopropyl alcohol flow at set rates 
between 0.05-1mL/hr.  Both systems demonstrated liquid delivery at intrathecal flow 
rates using continuous and duty-cycle flow regulation.  Outlet pressure sensors were used 
to detect acute catheter occlusions and disconnects.  A smart refill port was developed to 
allow for power transfer rates necessary to recharge batteries during a reservoir refill 
session.  Recharging at current rates up to 500mA was demonstrated.   
The proposed valve-regulated architecture and two preliminary prototypes allowed 
evaluation of potential solutions to challenges for application of the architecture in an 
IDDD.  Recommendations for future systems and plans for bench-top and in vitro testing 
are detailed.  The proposed work may lead to a system that provides the functionality of 
commercially available implantable drug delivery devices with high volume efficiency, 









The focus of this work is the development of a new drug delivery system for the 
treatment of severe chronic pain.  The work is motivated by the need to advance 
treatment for a condition that has wide ranging impact on all levels of society.  Chronic 
pain afflicts an estimated 100 million people in the United States with annual costs 
exceeding $100 billion [JCT99, Phi03].  The continuum of treatment modalities for 
severe chronic pain may include implantation of an intrathecal drug delivery device 
(IDDD) [Win96, Wer05, Sch06, Rau03, Deer07].  The system level design aspects of 
these devices have remained relatively unchanged for over 20 years.  An IDDD that 
allows active control of the delivery rate is comprised of several components like a 
battery, a peristaltic pump, and control circuitry that occupy a significant portion of the 
system volume.  The inclusion of these components reduces the ratio of the medication in 
the system as compared to the volume of the system itself; this is considered the volume 
efficiency ratio (VER).  A system implemented using throttles to regulate flow from drug 
reservoirs allow for systems with greater volume efficiency (~70%) than current 
architectures (~30%).  Improvements in the VER of an IDDD will allow for systems that 
have the functionality and drug volume of current solutions in a housing that is half the 
size.     
Delivery of multiple drugs into the intrathecal space is utilized in clinical practice 
when mono-drug therapy with opioids fails, either due to tolerance, opioid non-
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responsiveness (neuropathic pain) and/or hyperalgesia [Has04, Kra99].  Current practice 
consists of mixing multiple drugs in a single chamber for simultaneous delivery into 
spinal fluid [Rai07, Gra01, And99].  This imposes limitations on the type and 
concentration of drugs that can be administered.  A system with multiple independently 
regulated drug reservoirs may permit combination therapy in a manner that will improve 
drug synergistic effects.  This method of combination therapy also limits side effects 
because it uses the lowest possible doses of each drug.  A multiple reservoir design can 
improve analgesic efficacy, reduce cost and improve patient satisfaction [ASH00].  The 
primary goal of this research is the development of a volume efficient IDDD with the 
capacity for multi-drug protocols that could allow further study of clinical pain treatment 
with combination therapy.  
In section 1.1, the benefits and limitations of various chronic pain management 
techniques are discussed.  Section 1.2 describes advantages and disadvantages of various 
implantable drug delivery devices and their topologies with regard to intrathecal delivery.  
In section 1.3, the focus of the current and proposed work is discussed.  Additionally, 
past work in valve regulation is highlighted with a view toward application in 
implantable drug delivery. 
 
1.1 Chronic Pain Management Techniques 
1.1.1 Overview of Chronic Pain 
Although pain is a symptom of many diseases, it might be regarded as the primary 
disorder in conditions such as migraines, trigeminal neuralgia and other forms of nerve 
damage.  In these conditions, pain is the overwhelming predominant symptom.  The 
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International Association for Study of Pain (IASP), a body concerned with pain research 
and clinical management of pain, has classified at least 600 types of pain syndromes.  
The IASP also defines pain based on its duration: acute being less than one month, 
subacute lasting one to six months, and chronic lasting six months or more.  Pain is 
generally catergorized as being either harmful stimulus induced in sense receptors or the 
nervous system (nociceptive pain) or pain not related to the activation of pain receptor 
cells (neuropathic).  Common types of chronic pain include back pain, headaches, 
arthritis, cancer pain, and neuropathic pain resulting from nerve injuries. 
Neuropathic pain is caused by actual damage or altered function of nerves or nerve 
pathways.  Neuropathic pain is most often described by patients as electrical-like 
sensations.  Examples of these pathological changes that may cause chronic pain include 
the sensitization of nociceptors, central sensitization (or “wind-up”), abnormal 
sympathetic somatic nervous system interactions, and abnormal activation of N-methyl-
D-aspartate (NMDA) receptors.  Some common examples include failed back syndrome, 
neuralgias, neuropathies, etc. 
Nociceptive pain is defined as pain mediated by nociceptors, widely distributed in the 
soma of the body.  The pain is often described by patients as a dull, aching, sharp, or 
throbbing pain.  Nociceptive pain is often responsive to opioid therapies, whether 
delivered orally, parenterally, or spinally.  Examples include bone pain (fractures, 
arthritis, metastatic). 
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1.1.2 Impact and treatment of Chronic Pain 
Comprehensive management of chronic pain involves multiple medical disciplines 
which often use pharmacological and non-pharmacological methods [Rai07, Tur07].  
When pain is not well controlled with oral pain medications, or if a patient develops side 
effects, treatment options like intrathecal drug delivery are considered [Kra97]. 
The continuum of care pain therapy ranges from conservative to more advanced 
treatments.  Conservative non-invasive options include use of various medications (non-
steroidal anti-inflammatory drugs, muscle relaxants, opioids), physical therapy, and 
psychological counseling.  Not all patients respond to these measures; some require more 
advanced treatment like nerve blocks, steroid injections, neurolysis, neurostimulation and 
intrathecal drug delivery devices. 
Intrathecal drug delivery is a safe and effective therapy for well selected patients 
[Erd06].  It improves spastic symptoms, provides pain relief, reduces drug-related side 
effects, decreases the need for oral analgesia, and enhances quality of life in a segment of 
chronic pain patients whose pain has not been controlled with more conservative 
therapies [Lik06].  The benefits of IDDDs include potent analgesic response with stable 
therapeutic drug levels, decreased latency, increased duration of action, and decreased 
pharmacological complications like sedation, constipation, nausea and vomiting.  
 
1.1.3 Current Implantable Intrathecal Drug Delivery Technology 
Implantable pain pumps function by delivering medication into the cerebrospinal 
fluid (CSF) that is in the intrathecal space (Figure 1-1).  Pumps are significantly more 
efficient then other forms of medication delivery because they have a direct path into the 
CSF.  Drug pumps require about 1/300th of the amount of medication used in oral 
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delivery to achieve the same level of analgesia.  The central action on opioid receptors of 
the substantia gelatinosa of Rolando allows intrathecal opioids to significantly affect pain 
anywhere inferior to the cranial nerves.  These medications have a low coefficient of 
distribution in lipids and do not cross the blood-brain barrier; resulting in prolonged 
action.  This is a major advantage for patients who require higher order mental faculties 
and control.   
Current pumps generally range from 100-180 cm3, contain a single reservoir, and are 
implanted beneath the skin of the abdomen.  A catheter is connected to the pump and is 
inserted into the spine.  The implantation is done in an operating room under sterile 
conditions.  A new catheter is inserted into intrathecal space.  The catheter tubing is 
tunneled underneath the skin to the abdomen where it is connected to the implanted pump.  
A 4-6 inch incision is made in the abdomen, and a cavity for the pump is made between 
the patient’s skin and muscle tissue.  The pump is connected to the catheter, placed inside 
this cavity, and sutured to the fascial tissue above the stomach muscles.  The entire 
operation generally takes 2 to 4 hours. 
 
Fig. 1-1:  The intrathecal pump is implanted in an abdominal pocket and the catheter is 
subcutaneously routed around the side, up the back, and inserted into the 
intrathecal space.  
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Fig. 1-2: Left: The SynchroMed EL made by Medtronic.  Center: The IsoMed intrathecal 
pump made by Medtronic.  Right: The CODMAN 3000 continuous flow pump 
manufactured by Codman. [Med08] 
 
Several companies have developed intrathecal implantable pumps (Figure 1-2), the 
specifications of which are summarized in Table 1-1.  IsoMed from Medtronic and the 
CODMAN 3000 series do not require a battery, provide long implant life, and require 
fewer replacement surgeries than active pumps.  However, the flow rate is restricted to 
one of a few default delivery rates, and the only method of adjusting dosing after 
implantation is to alter the concentration of the medication.  The SynchroMed is the most 
versatile system in terms of programmability.  It uses a peristaltic pump controlled by 
microprocessor that can be programmed for infusion mode (bolus, multi-step bolus, 
continuous, etc.) and delivery rate depending on patient needs.  The battery life is 
dependent on the infusion rate, but it exceeds three years at a delivery rate of 1.5 mL/day. 
Table 1-1: Comparison of current commercial intrathecal implantable pumps. 
 SynchroMed II SynchroMed EL IsoMed CODMAN 3000 
Manufacturer Medtronic Medtronic Medtronic Codman 
Volume (cm3) 91, 121  123, 156.7 111.7, 135,172 94,  219.3 
Weight (empty, g) 165, 175 185, 205 113, 116, 120  98, 173 
Reservoir Size 
(mL) 20, 40 10, 18 20, 35, 60 16, 50 
Battery Life 5-7 years 5-7 years No battery No battery 
 
The most effective pain relief generally comes from drug combinations.  This is 
typically a mix of an opiod, like morphine, and a local anesthetic.  Providing combination 
therapy is very challenging because single reservoir pump technology requires manually 
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mixing of the medications.  This has to be done at a pharmacy under the physician’s 
direction before the mixture can be injected into the refill port of the intrathecal pump.  
Not all pharmacies do this because of issues like the lack of a clean room facility, 
liabilities associated with unknown long-term drug stability, and unknown interactions 
mixed medications may undergo between implant refills.  Additionally, any change in the 
delivery ratio of the mixed medications requires the pump and the delivery catheter to be 
completely emptied and re-filled with the new mixture.  Greater infection risks may occur 
during the early adjustment phase of an implant.  This is due to an increased frequency of 
needle punctures required to empty and refill the system to the medication constitution 
[Lob07].  Additionally, applying a bridge bolus necessary to clear the delivery catheter is 
a process that has direct access to the CSF and is often conducted if significant changes to 
the medication are made.  Changing pump technology to allow for simultaneous delivery 
of two or more medications would make drug combination therapy safer and easier.  
Current implantable drug delivery device architectures do not allow for easy adaptation to 
multiple independently regulated drug reservoirs.  An alternative device architecture 
allows for the development of an intrathecal drug pump that actively delivers an 
adjustable ratio of mixed medications from separate reservoirs.   
 
1.2 Other Drug Delivery Devices 
There are several different types of devices - implantable and external - that have 
been used to deliver medication.  Exploring these possible alternative devices may yield 
insight into potential architectures for an alternative IDDD.   
Over the last decade, advances in subcutaneous and implantable reservoirs and pumps 
have assisted with long term drug management.  Various treatment technologies may be 
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implanted under the skin or deliver medication subcutaneously, often through a catheter 
[Rai07].  Some drug delivery mechanisms that do not consume electrical power, like 
polymer implants, allow for the medication rate to be pre-programmed for the duration of 
delivery between refills or replacement [Gra01, And99, ASH00, Cra80, Bar82, Coo91, 
Has00].  These medication technologies deliver solid-phase medication and are unable to 
respond to changes in the patient’s needs.  This type of drug therapy is not as effective as 
active pumping for treating some medical conditions like chronic pain because patients’ 
needs may adjust daily in ways that are difficult to anticipate.  Active devices, like the 
SyncroMed II, generally pump an aqueous medication from a reservoir at a very 
controlled rate that allows for precise dosing [Pai96, Sau94, Deer02, Sak05].  These 
pumps allow for flexible control over the medication rate, but are increased in both size 
and weight because of pump and battery needs.  This is particularly apparent for 
medications that require a relatively large amount of solution because the power 
consumption is related to the volume that must be pumped.  These active systems present 
significant opportunity for miniaturization, power savings, and increased versatility while 
maintaining precise dosing control [Mer01]. 
Many other passive delivery devices, like the CODMAN 3000, use a pressurized 
reservoir in conjunction with a restrictive opening to regulate dosing [Mer03].  If the 
restrictive opening is replaced with an active valve, electronic control of the delivery rate 
can be achieved [Eva07, Eva08, Par07].  This throttled device allows active delivery rate 
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1.2.1 External Drug Delivery Devices 
External drug pumps are in common use for the regulation of insulin in diabetics 
[FDA08].  These typically work with disposable infusions sets that include a cannula and 
small reservoirs that are either replaced or re-filled regularly.  Insulin pumps can deliver 
both basal and bolus deliveries according to a pre-set schedule.  Recent devices advance 
delivery ease by monitoring glucose levels and using feedback to provide well balanced 
therapy regardless of consumption or the daily lifestyle of the patient. 
Insulin pumps typically operate using a peristaltic pump to deliver medication from a 
reservoir into subcutaneous space via tubing connected to the disposable cannula.  The 
infusion set is replaced every 2-3 days, and the battery lasts 2-10 weeks depending on the 
pump and manufacturer.  Some devices, particularly the Paradigm series by Medtronic, 
have the capacity to wirelessly communicate with sensors that detect glucose levels.  
These sensors have a permanent component that processes the information and transmits 
to the insulin pump, and a disposable glucose sensing element that is replaced every three 
days.  When using this feedback mechanism, the Paradigm drug pumps respond to the 
patients needs in real-time with no user input.  This allows for therapeutic regulation of 
the insulin glucose cycle while providing no inconvenience beyond the act of physically 
wearing the pump. 
External insulin pumps have less battery life and smaller reservoirs than current 
intrathecal pumps of a similar size.  They do, however, provide greater delivery 
flexibility and exhibit more pump and physiological sensor sophistication that might be 
adaptable to implantable therapy.  There are several other external devices that are used 
to deliver medication to patients, like the gravity powered intravenous (IV) bag.  These 
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types of devices are generally too large to consider when determining advantages that can 
be gleaned for use in intrathecal pumps, and other external, portable delivery mechanisms 
tend to lack the sophistication of insulin delivery systems.     
 
1.2.2 Implantable Drug Delivery Devices 
Research into implantable drug delivery mechanisms is multi-disciplinary and has 
generated several new approaches to regulation.  Advances in the integration of 
medication into biodegradable polymers for delayed targeted release were achieved by 
Langer et al. [Lan76].  This type of polymer delivery technology has continued in 
development since inception [Gra03].  In short, polymers that have a known degradation 
and release rate are combined with a concentration of a targeted medication, and are 
inserted into the location where release is desired.  Initial polymer delivery systems 
provided uncontrolled dissolvable release, but advances that incorporate varying 
concentrations, well depths, or polymer thicknesses allow the ability to pre-program a 
release profile [Lan90].  A commercial realization of this type of drug delivery is the 
Norplant contraceptive implant.  The most recent contraceptive implant in this family of 
devices is Jadelle by the Population Council [PoC08].  It has an outer biodegradable 
sheath, and an internal drug imbued polymer that slowly dissolves over the lifetime of the 
device (5 years).  Dissolving polymeric implants are generally small and provide no 
dynamic control, feedback, and are not refillable.   
Another type of implantable drug delivery devices are silicon microreservoir systems.  
This delivery mechanism (Figure 1-3) was introduced in 1999 by Santini et al. [San99].  
The device utilized reservoirs fabricated in silicon wafers that were filled with the desired 
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drug.  The reservoirs were covered with a gold membrane that was dissolved by applying 
an anodic voltage to the membrane when chloride ions were present.  The membrane 
could also be removed by rapid heating.  The reservoirs could each be filled with 
different medications or even sensors.  Programmed release from these types of devices 
requires either an internally programmed controller, or it can be achieved via wireless 
communication [Mal05].  Additionally, work has been done to create microreservoir 
delivery devices from substrates other than silicon [Gra03].  This implantable technology 
offers greater release control than polymer devices, but it requires embedded electronics 
that complicate the device.  It is also not refillable.  Microreservoir drug delivery is 
currently being commercialized for subcutaneous delivery by MicroCHIPS [Mic08]. 
 
Fig. 1-3: Gold membrane silicon microreservoirs originally developed by Santini et al. 
and now being commercialized by MicroCHIPS. [San99] 
 
Several other technologies are being developed for implantable drug delivery.  In 
some other systems, osmotic force is used as a pressure generation mechanism to drive 
delivery (Figure 1-4) [Won07].  The pumps available from Alzet [Alz08] are cylindrical 
with an outer semi-permeable layer, followed by a salt layer, an inner impermeable layer, 
and a core that functions as the reservoir for the drug to be delivered.  The salt layer 
creates an osmotic pressure that drives water from the body into the salt layer.  This 
forces medication out of the device by compressing the inner reservoir core.  The 
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delivery rates of these types of pumps are determined by the permeability of the outer 
layer.  They are implantable but are difficult to refill or reprogram once they are 
implanted. 
 
Fig. 1-4: Various sizes of the single use implantable osmotic pump made by Alzet. 
[Alz08] 
 
Several drug delivery techniques provide controlled delivery to a target location, but 
they are difficult to regularly refill and replace.  Adjustments of the delivery profile after 
implantation are also difficult to achieve without wireless communication and/or 
embedded circuitry.  The advantage of polymer and microreservoir delivery is the 
volume efficiency that results from the large percentage of device volume that is utilized 
for medication.  Current intrathecal drug pumps may be improved by increasing volume 
efficiency to approach these devices. 
           
1.3 Focus of the Current and Proposed Work 
As described in section 1.1, techniques for providing intrathecal drugs for the 
treatment of chronic pain are reaching device limits.  Thus, a new drug pump architecture 
should be developed that provides the ability to control delivery to facilitate current 
therapy practices.  Ideally, the system should have greater functional control than current 
solutions, but it should also improve upon general safety, and increase volume efficiency.  
Functional control of a drug implant can be qualitatively defined across a range of 
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devices based upon the relative capacity to be utilized in a specific way.  For example, a 
gravity driven IV bag with no regulation would have a functional control metric of 1 and 
a volume efficiency of almost 100%.  An insulin pump that automatically detected and 
delivered insulin to regulate glucose levels in a diabetic would have a function control 
metric of 10.  As illustrated in Fig. 1-5, current drug delivery devices either provide a 
very high level of control, or they sacrifice control to improve the volume efficiency to 
make it practical for implantation.  The focus of this work is to design a novel drug 
delivery architecture and develop an implantable pump that allows for greater control 
over intrathecal treatment while improving volume efficiency. 
  
Fig: 1-5: Current drug delivery devices trade functionality and control for size.  This 
work seeks to develop a new topology that improves the intrathecal implant 
class of devices in both functional control and volume efficiency.  Device 
specifics can be found in Table 1-2. 
 
As illustrated with the brief review in section 1.2, current intrathecal drug delivery 
devices can be modified to offer greater functionality with significant size reduction.  
 
-  - 
14
Notably, an architecture utilizing multiple regulatory mechanisms with separate 
reservoirs may allow clinicians to dose medications as described in section 1.1.  The 
work documented here focuses on developing a pump architecture with multiple 
reservoirs that improves safety and volume efficiency.  Early prototypes target a VER of 
25% and specific functional control of 8 with the potential for commercial devices to 
have a VER of at least 60% and specific functional control of 10.  Focusing the work in 
this way allows detailed design specifications to be developed and addressed in order to 
create a device that will allow physicians to implement and further evaluate the medicinal 
benefits of multiple chamber drug regulation into the intrathecal space.   
Table 1-2: Overview of the drug delivery devices in Figure 1-5 
ID Tag Name Description Ref 
INS1 Paradigm 522 Insulin pump made by MiniMed [Dia08] 
INS2 Paradigm 722 Insulin pump made by MiniMed   [Dia08] 
INS3 IR-2020 Insulin pump made by Animas [Dia08] 
INS4 Deltec Cozmo 1800 Insulin pump made by Smiths Medical [Dia08] 
INS5 Spirit Insulin pump made by Disetronic [Dia08] 
INS6 Diabecarell Insulin pump made by Sooil USA [Dia08] 
INS7 OmniPod Insulin pump made by Insulet [Dia08] 
EDS1 Alpha Infusion Pump External intrathecal drug pump from Advanced Infusion [Adv08] 
EDS2 Alpha Infusion Pump External intrathecal drug pump from Advanced Infusion [Adv08] 
IDS1 Synchromed II Internal intrathecal drug pump made by Medtronic [Med08] 
IDS2 Synchromed II Internal intrathecal drug pump made by Medtronic [Med08] 
IDS3 Synchromed EL Internal intrathecal drug pump made by Medtronic [Med08] 
IDS4 Synchromed EL Internal intrathecal drug pump made by Medtronic [Med08] 
IDS5 Jo2004 Reseach intrathecal drug pump done in Seoul [Hon04] 
IDS6 Codman 3000 Internal intrathecal drug pump made by Codman [Cod03] 
IDS7 IsoMed Internal intrathecal drug pump made by Medtronic [Med08] 
IDS8 Codman 3000 Internal intrathecal drug pump made by Codman [Cod03] 
IDS9 IsoMed Internal intrathecal drug pump made by Medtronic [Med08] 
OC1 Meng08 Research ocular drug implant done at USC [Lo08] 
DG1 Walt2007 Dissolving gold research drug implant done in Edinburgh [Smi07] 
DG2 Lang99 Dissolving gold research drug implant done at MIT [Lan99] 
P1 Lang03 Dissolving polymer research drug implant done at MIT [Gra03] 
P2 Jadelle Contraceptive implant made by Population Council [PoC08] 
OSM1 Alzet 1003D Osmotic drug pump made by Alzet [Alz08] 
OSM2 Alzet 2003D Osmotic drug pump made by Alzet [Alz08] 
OSM3 Alzet 2ML1 Osmotic drug pump made by Alzet [Alz08] 
OSM4 Fasch2007 Research osmotic drug pump made at Stanford [Won07] 
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1.3.1 Structure of this Work  
Chapter 2 of this work presents a conceptual vision for a new implantable drug 
delivery architecture and the key system components for achieving this vision.  
Subsequently, each component and the related design considerations are discussed in a 
more detailed manner.  Additionally, analytical and finite element design tools that have 
been developed are described and important results highlighted.  Chapter 3 presents the 
design, fabrication, and testing of three generations of piezoelectric microvalves.  This 
includes the development of a two-valve manifold with embedded sensors.  Chapter 4 
presents the design, fabrication, and testing of two variations of spring pressurized drug 
reservoirs.  Chapter 5 contains the assembly, testing, and characterization of a prototype 
device utilizing a single valve to demonstrate feasibility.  Chapter 6 presents the assembly, 
testing, and characterization of a second prototype device utilizing a two-valve manifold 
and multiple reservoirs to demonstrate protocol versatility.  Chapter 7 presents a battery 
recharging mechanism using power transfer across a reservoir refill port.  Finally, 
Chapter 8 summarizes and discusses continuation of this work. 
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CHAPTER 2: 
GENERAL DESIGN CONSIDERATIONS  
As noted in Chapter 1, a new implantable drug pump architecture could improve 
intrathecal medical therapy and improve on the volume efficiency of current devices.  
The device architecture outlined in Fig. 2-1, potentially achieves both goals [Eva08].  In 
this concept, two independently regulated microvalves throttle drug flow from separate 
mechanically pressurized reservoirs.  Mechanically pressurized reservoirs allow for 
mechanical power to be recharged when the reservoir is refilled.  This, coupled with low-
power valves, reduces the overall electrical energy required; this allows for longer device 
lifetimes from a smaller battery.  Regulating pressurized reservoirs allows for a full flow 
range and a high VER.  Reduced flow controller size allows for multiple reservoirs to be 
regulated independently while maintaining volume efficiency.  Independent regulation of 
multiple medications increases the therapeutic returns from a set volume of different 
drugs. 
There are three main components of this system that warrant detailed design 
consideration.  First and foremost, the throttle valves need to be able to regulate flow at 
rates necessary for intrathecal drug delivery.  Additionally, they must be able to 
withstand reservoir pressures, have a small form factor, and be energy efficient.  The 
second component of the system is the mechanical pressurization of the reservoir.  The 
reservoirs have to be mechanically recharged when the medication is refilled.  The third 
component of the system is the power management and control circuitry and that 
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regulates the operation of the throttles.  The circuitry must minimize power consumption 
and could include a mechanism for recharging the battery.  Each of these components 
will be described in more detail in the following sections. 
 
Fig. 2-1: Conceptual design of an implantable intrathecal drug delivery device that uses 
two valves to independently regulate the medication delivered from spring 
pressurized reservoirs. 
   
2.1 Regulatory Microvalve Design 
Microvalves for this system are designed to regulate medication and flow rates 
necessary for clinical efficacy.  Device size and power consumption are minimized 
within this constraint.  Embedded sensors can be included in the valves to simplify the 
integration of multiple system components and reduce overall device volume.  All 
elements of the valve that come into contact with the medication are biologically 
compatible. 
An active valve is necessary to regulate flow from a varying pressure source.  Active 
microvalves are generally composed of a variable flow channel and an actuator.  Current 
microvalve designs yield insight into valve mechanisms that meet the needs of a drug 
 
-  - 
18
delivery system.  For convenience, the valves are categorized by their actuation 
mechanisms.  Various actuation methods have been explored for use in active 
microvalves: electromagnetic, electrostatic, piezoelectric, and thermal actuation.  These 
will be discussed in more detail in the following subsections. 
 
2.1.1 Electromagnetic Actuation    
Electromagnetic actuation utilizes force generated by magnetic induction.  The 
magnetic field is often applied by a permanent magnet or an external electromagnetic coil.  
The main advantage of magnetic actuation is the ability to create a relatively large force 
and large deflections with low driving voltages.  One of the first active micromachined 
valves was reported by Terry et al. in 1979, to be used in an integrated gas 
chromatography system [Ter79].  The valve consisted of an etched silicon orifice, a 
nickel diaphragm, and a solenoid actuator and plunger assembly.  When the solenoid was 
energized, the plunger was pulled, allowing the diaphragm to relax and gas to flow.  
Other examples of early work in magnetically actuated microvalves are described in 
references [Ike97, Shi97, Smi90, Hir97, Yan95].  These valves utilized external magnetic 
fields provided by external coils or permanent magnets to actuate flow blockers made of 
magnetic material.  More recent work involves fully integrated electromagnetic actuation 
without the aid of any other external components [Bin05, Sut06, Sad98].  A ball-type 
microvalve using an iron ball driven by external solenoid has been reported by Fu et al. 
[Rum03].  Bae et al. developed a pressure-regulating microvalve as an implant for use in 
the treatment of glaucoma [Bae04].  Electromagnetic actuation typically generates forces 
in the range of 1-100 mN with supply of 100-600 mA of DC current.  Flow rates as large 
as 8.8 L/min have been successfully modulated with this actuation scheme with a valve 
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stroke of 0.1 mm [Ike97], but high power consumption (up to 6 W [Rum03]) is a 
drawback of electromagnetically driven valves.  Electromagnetic actuation also 
demonstrates relatively slow response time ranging from 3 ms [Ike97] to 10 ms [Bin05, 
Sut06, Rum03]. 
 
2.1.2 Electrostatic Actuation  
Electrostatic actuation is frequently employed in microvalves.  The electrostatic force 
generated between two conductors depends on the applied voltage and the separation 
distance between them.  The force is generally small (microNewtons) and requires a 
small gap between two conductors.  This small displacement may hinder the microvalve 
performance by limiting the flow rate.  Electrostatic valves generally consume little 
power, but they require high voltages and have small displacements.  Ohnstein et al. has 
demonstrated an electrostatically actuated microvalve with a cantilever closure plate 
[Ohn90].  The closure plate was made from silicon nitride by surface micromachining; a 
metal electrode was embedded in it.  The valve provided up to 150 sccm flow  with a 30 
V drive.  An electrostatically actuated microvalve with an S-shaped film was 
demonstrated by Shikida et al. [Sat94, Shi94].  The conductive film between a pair of 
planar electrodes was elastically bent in an S-shape and the S-bend moves back and forth 
as voltage is applied.  This particular type of valve demonstrated a large vertical 
displacement by utilizing the electrostatic force at the edge of the S-bend.  A flow rate 
variation of several sccm was obtained under a pressure difference of 100 Pa with an 
actuation voltage of 150 V.  A pressure-balanced microvalve was reported by Huff et al. 
[Huf90, Huf93]; this overcame the limited force generated by the electrostatic method, 
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and closed against high pressures.  The valve was tested up to 80 psi differential pressure 
with an applied voltage of 210 V.  A polymer microvalve with a flexible membrane was 
presented by Goll et al. [Gol97].  A voltage of 60-150 V was needed to modulate the 
membrane and flow rates of 12 mL/min at a differential pressure of 110 kPa have been 
measured.  Wijngaart et al. [Wij02] combined a pressure balancing concept with a 
flexible membrane to demonstrate a large stroke electrostatic microvalve for high 
pressure control.  Simulation showed that it is possible to control 500 kPa of air pressure 
while ensuring a 15 μm gas flow gap at an actuation of 366 V.  A Ta-Si-N membrane was 
used to achieve fast switching valves by Dubois et al. [Dub01, Dub01-2].  Such valves 
were developed to be used at differential pressures greater than 200 kPa.  Pulse width 
modulation was used to control the flow rate up to 30 mL/min with an actuation voltage 
of 30 V.  A bulk-micromachined integratable electrostatic microvalve with a curved-
compliant structure was demonstrated by Yobas et al. [Yob03, Yob01] for a tactile 
display system.  Due to its unique curved-compliant structure, the valve required a 
relatively low closing voltage of 72.9 Vrms for 19.3 kPa of pressure with 86 mL/min 
flow.  A group from MIT demonstrated an electrostatic microvalve for gas fuel delivery 
of a microengine [Yan94].  The valve was fabricated using direct bonding of three wafers 
and deep reactive ion etching techniques.  A 136 V actuation was required to open the 
valve against a 0.9 MPa pressure difference, and a flow rate of 45 sccm was measured 
when opened.  Electrostatic microvalves are often used as binary valves due to pull-in 
characteristics.  Robertson et al. [Rob98, Rob94] integrated an array of electrostatic 
microvalves with a micromachined 3 μm thick silicon beam to build a gas modulator.  
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The gas flow modulator was able to deliver sub-sccm gas flow in the range from 3.8×10-3 
sccm to 0.7 sccm.   
 
2.1.3 Piezoelectric Actuation  
Certain crystals have the ability to produce mechanical deformation by a change in 
the electrical polarization of the crystal.  This is referred to as a piezoelectric effect.  This 
effect has been widely used in microvalve and micropump fabrication because it can 
generate large forces.  Piezoelectric actuation has an added advantage in power 
consumption because DC actuation only draws power when the actuator is adjusted to 
turn on or off the valve.  One of the earliest works on fabrication of a piezoelectric 
microvalve was presented by Esashi et al. [Sho91, Esa89, Esa90].  The valve was 
constructed from a silicon mesa suspended with a flexible silicon diaphragm.  The 
diaphragm was pressed against a glass plate by a stack piezoelectric actuator with 
dimensions of 3×1.4×9 mm3.  The valve was capable of modulating gas flow from 0.1 to 
85 mL/min with 73.5 kPa inlet pressure.  It exhibited a response time of less than 2 ms.   
A major disadvantage of piezoelectric actuation is the small stroke for even large 
voltages.  This drawback can be overcome by hydraulic amplification of the piezoelectric 
actuator [Rob03, Li04].  A compact, high-frequency, high differential-pressure 
microvalve reported by Roberts et al. utilized a hydraulic amplification mechanism to 
achieve 40-fold amplification of the limited stroke provided by the piezoelectric material.  
The valve had a nine layer structure composed of glass, silicon, and silicon on insulator 
(SOI) layers assembled by wafer-level fusion bonding, wafer-level anodic bonding, die-
level anodic bonding, and eutectic bonding.  Valve strokes as large as 20 μm were 
realized and a flow rate of 12.6 mL/min was realized.  Another microvalve with a 25-fold 
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hydraulic amplification was reported by Rogge et al. [Rog04, Sha04].  A valve made 
from a surface macromachined piezodisk actuator was described by Watanabe et al. 
[Wat97].  The valve was constructed in a thin beam with a round valve cap at the center 
and a valve seat comprised of a thin film piezoelectric.  Each valve, smaller than 1×1 
mm2, handled up to 2.4 mL/min of flow.  NASA’s Jet Propulsion Laboratory has 
developed piezoelectric microvalves for space applications [Cha00, Lee04, Yan04-2, 
Lee06].  A series of concentric rings was defined around the orifice to create a leak-tight 
seal.  An extremely low leak rate of 5×10-3 mL/min at an inlet pressure of 5.5 MPa was 
demonstrated.  At an inlet pressure of 2 MPa, flow rates of 52 mL/min were measured 
with 10 V actuation.  
 
2.1.4 Thermopneumatic Actuation  
Bi-metallic, thermopneumatic, and shape memory alloy actuation mechanisms use 
thermal properties of materials to generate displacements.  These actuation schemes 
generally produce considerable force while simultaneously achieving large strokes.  
However, they have relatively high power consumption rates (100 mW) and slow 
response times (100 ms).  In some bi-metallically actuated valves, thin-film heater 
elements are placed on a diaphragm.  When they are heated, a difference in thermal 
expansion coefficients bends the diaphragm.  Bi-metallic actuators are often easy to 
fabricate, but they draw relatively large amount of power and are sensitive to ambient 
temperatures.  Jerman [Jer94] showed Al/Si bi-metallic driven diaphragms in a valve 
structure and demonstrated flows up to 100 mL/min using 400 mW of power.  Barth et al. 
[Bar94] developed a Ni-Si bi-metallic microvalve which successfully opened against 
1300 kPa of pressure and achieved a 600 mL/min flow rate with power consumption of 1 
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W.  Messner et al. [Mes98] demonstrated a bi-metallically actuated 3-way microvalve 
which successfully achieved flow rates up to 800 mL/min at 600 kPa with power 
consumption of about 1 W. 
The shape memory effect is due to a crystalline transformation between a high-
temperature phase and a low-temperature phase.  It is an attractive actuation mechanism 
because it allows simple and compact structures to generate high forces which can be 
used in high pressure applications.  Further advantages of shape memory alloys (SMAs) 
are low voltage operation, high reliability, no additional moving parts, and high chemical 
resistance.  Kohl et al. demonstrated gas microvalves using Ti-Ni SMA thin films 
[Koh00, Koh99, Koh99-2, Skr97].  Maximum gas flows of 1.6 L/min and work output of 
35 μN-m were achieved with a driving power of 210 mW at a pressure difference of 120 
kPa.  The response time for closing the valves varied between 0.5 and 1.2 s, and between 
1 and 2 s for opening.  This response depends on the applied pressure difference. 
Thermopneumatic microvalves are operated by volumetric thermal expansion or a 
phase-change phenomena coupled to membrane deflection.  This actuation method can 
provide relatively large deflections.  However, this type of valve typically has a relatively 
longer response time, and the fabrication process is often complicated due to the 
necessity to fill the chamber with fluid and provide a hermetic seal.  Zdeblick et al. 
demonstrated the idea of heating an encapsulated liquid with a miniature resistive heater 
in order to move a diaphragm [Zde87].  Takao et al. employed PDMS as a diaphragm 
material for a long stroke actuation and demonstrated good sealing performance [Tak05].  
At 50 kPa of inlet pressure, a microheater powered with 100 mW was required to cut-off 
the flow, and a flow rate of 17 mL/min was achieved when the valve was fully open.  The 
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transient time necessary to open the valve was about 23 s and the transient time necessary 
to close the valve was 1.5 s.  Rich et al. also reported a high-flow thermopneumatic 
microvalve constructed from a three-wafer stack with a corrugated diaphragm [Ric03].  
Flow rates as high as 400 mL/min were achieved at 200 kPa differential pressure; 500 
mW of input power raised the cavity pressure by 260 kPa.  Potkay et al. used a 
combination of thermopneumatic actuation with an electrostatic hold so that the valve 
only required power during the transition from open to closed and consumed no static 
power [Pot05].  The thermopneumatic actuator closed the valve in 1 second at 200 mW 
of input power and the open flow rate was 3.3 mL/min at 17 kPa. 
As highlighted in section 2.1.1-2.1.4, electrostatic and piezoelectric actuation 
mechanisms consume much less power than electromagnetic or other thermal actuation 
mechanisms. However, the reported electrostatic and piezoelectric microvalves provide 
much lower flow rates than the other actuation mechanisms.  Piezoelectric actuation is 
appealing for implantable systems because it offers high force that can overcome high 
reservoir pressure and low power consumption.  The principal drawback of the lower 
flow rates due to a reduced displacement can be overcome with proper design.  One 
aspect of this research is to develop microvalves that meet the requirement of delivering 
intrathecal medication at medically viable delivery rates.  These microvalves should 
regulate the flow of saline from 0.1 - 5 mL/day.  Additionally, the valves should 
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2.2 MECHANICALLY PRESSURIZED RESERVOIR SPECIFICATIONS 
There are several factors that need to be accommodated in the design of refillable 
pressurized reservoirs.  These include the pressurization mechanism, the pressure-volume 
relationship (PVR), and the dead volume.  The force mechanism that generates pressure 
can either be actively controlled, like a motorized screw, or it can be passive, like the 
constriction of a balloon.  The PVR is the relationship between the liquid pressure in the 
reservoir compared to the volume remaining in the reservoir.  The unusable reservoir 
volume is related to the PVR because it represents the volume of liquid in the reservoir 
that is not deliverable.  The dead volume of the reservoir is the unusable reservoir volume 
and the volume of the reservoir that is not liquid.  The various design constraints for these 
elements are detailed in the following subsections. 
 
2.2.1 Pressurizing Mechanism 
Active mechanisms are often liquid pumps that generate a pressure gradient, physical 
systems that squeeze the reservoir in a manner similar to a toothpaste tube, or systems 
that create volume expansion within the reservoir itself like a bubble generator [Coo04].    
These systems all require power for increases in reservoir pressure, but they can create 
precise reservoir pressures because of the monotonic relationship between reservoir 
pressure and volume.  This controllable pressure can be used to regulate drug delivery 
through a fixed aperture.  An architecture that utilizes an active throttle is volume 
efficient because it does not need controlled reservoir pressures or the associated active 
mechanisms. 
Passive reservoir pressure is often generated by mechanical compression, pressurized 
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gas, osmotic pressure gradients, or surface tension effects like capillary pressure [Bor06].  
Capillary pressure is relatively difficult to use to create a large reservoir with uniform 
pressures.  Osmotic pressure is used in the Alzet drug pumps to pressurize reservoir 
liquid and drive it through a fixed aperture; this technique takes advantage of interactions 
with the subject across a permeable membrane.     
Current intrathecal drug devices use a combination of mechanical constriction and 
gas pressure across a membrane to pressurize medication in the reservoir.  The un-
powered devices like the CODMAN 3000 and the IsoMed utilize a propellant gas in 
conjunction with a bellows spring network to create a relatively constant pressure over 
most of the delivered volume of the reservoir.  Additionally, this bellows mechanism is 
reversible, and the energy used to drive delivery is mechanically stored and recharged 
every time the reservoir is refilled from a higher pressure source.  One problem with this 
style of reservoir is that the loss of one element (gas or spring) or the other causes serious 
deviations from the set PVR and subsequently results in faulty medication delivery to the 
patient [Med06].  Additionally, the bellows and propellant are designed such that a 
relatively constant pressure is generated and driven through a flow restrictor [Eth05].  
This sophisticated mechanisms requires significant volume that does not contain 
medication.  The dead volume can be reduced by eliminating the constraint that the 
reservoir has to generate a constant pressure.   
 
2.2.2 Pressure Volume Relationship (PVR) 
Current intrathecal pumps have reservoirs that aim at maintaining a constant pressure 
regardless of the undepleted drug volume.  This constant pressure is necessary to 
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maintain a constant flow rate through a set aperture, in the case of passive devices; or to 
maintain a set pressure differential for a pump, in the case of active devices.  This is no 
longer a necessary constraint when using an active throttle.  The benefits of potential 
pressure to volume relationships can be explored. 
PVR allows the throttle to be characterized before system assembly.  Flow can then 
be modulated by setting the throttle to a particular effective aperture size without needing 
any information about the state of the reservoir.  Constant pressure reservoirs require 
significant dead volume, and do not allow the PVR to be used as an indicator of the 
undepleted drug volume. 
 Reservoirs with a repeatable PVR in which the reservoir generates decreasing 
pressure with decreasing volume can be used to indirectly measure the undepleted drug 
volume by measuring the pressure.  MEMS pressure sensors can be integrated into either 
the reservoir or the flow channel to provide feedback about the remaining volume and 
average flow rate.  Reservoirs with this type of PVR can be easily fabricated and realize 
volume efficiencies greater than 80%.  A varying pressure reservoir requires feedback 
control to account for pressure variations and achieve accurate dosing.  A passive, 
variable pressure reservoir works well for implantable systems because it is volume 
efficient and allows for accurate dosing using embedded sensors.         
 
2.2.3 Dead Volume 
Almost every reservoir has both unusable liquid volume in the reservoir and dead 
volume created by the mechanisms used to pressurize the reservoir.  The unusable liquid 
volume, in the case of intrathecal drug pumps, is the volume below which the drug can no 
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longer be properly delivered.  The dead volume also includes all the volume of the device 
that is not occupied by medication.  In the case of a bellow pressurized reservoir, the dead 
volume would be the volume of the bellow springs, the space taken up by the propellant 
gas, and the volume of the reservoir casing.  The most volume efficient reservoir is one 
that minimizes dead volume while meeting the application needs. 
Unusable volume in a valve-regulated drug delivery device is dictated by the pressure 
below which medication can no longer be delivered across the entire flow rate range.  
Worst case delivery conditions for an intrathecal drug pump involve the delivery of 
medication into a spinal column at pressures of 15 cm/H2O (1500 Pa) [Hea08].  The 
medication is delivered through a one meter long catheter with a 0.5 mm diameter 
[Med06].  Assuming the throttle valve is much less constrictive than the catheter when 
fully open, and the maximum necessary flow rate for clinical efficacy is 5 mL/day; the 
minimum necessary reservoir pressure can be estimated using hydraulic resistance theory 
- further detail in Section 5.2.2 [Bra03].  The minimum reservoir pressure necessary to 
ensure the full delivery range is 200 Pa, if the system is not throttle limited.  Anything 
less than this is considered unusable volume.   
Dead volume includes the volume that the pressure mechanism requires.  This is the 
significant limiting factor in the volume efficiency of intrathecal pumps that utilize 
constant pressure reservoirs.  In order to maintain a constant pressure across the delivery 
volume, space is utilized for a propellant gas, bellows, and a unique housing.  This 
creates a situation in which devices like the CODMAN 3000 have reservoirs that hold 50 
mL of medication but require 220 cm3 of total volume.  As previously discussed, 
reservoir designs with non-uniform pressures are more volume efficient.  An example of 
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this type of reservoir is a compressive balloon.  The only dead volume is the thickness of 
the elastic polymer that contracts against the volume inside of the balloon.  The reservoirs 
represent a large portion of the volume of an intrathecal drug delivery device, and the 
dead volume should be minimized. 
In summary, sections 2.2.1-2.2.3 cover issues related to reservoir design for a 
throttled intrathecal drug delivery device.  The proposed system architecture requires a 
reservoir designed for use in valve regulated delivery.  Various compressive mechanical 
pressure generation systems that use springs have been reported.  Current intrathecal 
pumps have unusable reservoir volumes that vary from 1-3 mL (10-20% of the total 
volume).  Assuming the throttle is ten-fold more constrictive than the catheter and 20% 
unusable reservoir volume is acceptable, the compressive pressure systems should 
generate differential pressures above 600 Pa for 80% of the volume.  Additionally, 
pressures greater than 200 kPa would likely overwhelm the valve.  Reservoirs should 
contain between 10-30 mL of deliverable liquid to be medically viable over a three month 
refill period without being unnecessarily large.  
 
2.3 Electronic Control and Power Management  
In order to regulate delivery from a variable pressure reservoir with an adjustable 
throttle, sensors and related circuitry are needed to control the valve.  These circuit 
elements need to operate from a battery for the lifetime of the device (5 years).  This 
power constraint is imposed upon the control system, and it is the most important design 
factor aside from assuring functionality required for proper medical viability.    
 
-  - 
30
The electronic components include physical sensors with associated analog 
conditioning, central processing, communications, memory, analog amplification for 
valve output, and the power supply.  The physical sensors are embedded in the valve and 
have known output ranges and sensitivities that need to be accounted for in the analog 
readout circuitry for proper data collection.  The central processing unit is the 
microprocessor and associated components that allow the system to utilize sensor 
information to provide feedback regulation of the microvalve.  The communications and 
memory represent the interface for a clinician to receive system data and modify the 
delivery schedule to provide the patient with the best care possible.  Analog amplification 
and power regulation are comprised of the battery regulator and power amplifiers used to 
drive high voltage or current to actuate the valves.  It also regulates the voltage provided 
from the battery to the remaining electronic elements.  Power management electronics 
can be provided to recharge the battery during the refill sessions.  This relaxes energy 
constraints on control circuitry because devices need run from the same battery for 6 
months rather than for five years.  Recharging can be done by wireless power transfer or 
through direct connection mechanisms.  The design constraints for these components are 
detailed in the following subsections. 
 
2.3.1 Physical Sensors and Conditioning 
Physical sensors and the associated analog conditioning are necessary to collect data 
from the system in order to actively control flow via feedback.  Pressure is the most 
important physical property to sense for flow regulation.  Additional sensors may include 
temperature, acceleration, and other devices to sense phenomenon related to patient 
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health.  Temperature sensors can be used to compensate the pressure sensors for small 
variations, and can, along with an accelerometer, provide information about the state of 
the patient.  Regardless, the design constraints for the pressure sensors dominate the 
requirements for sensor conditioning. 
Two common methods of sensing pressure across a membrane are piezoresistive 
sensing of membrane stress and capacitive measurements of membrane deflection.  
Piezoresistive sensors are usually configured in a Wheatstone bridge and tend to have a 
linear voltage to pressure relationship.  Capacitive sensors are more sensitive with 
smaller gaps and generally need conditioning to adjust for non-linearity.  The sensor 
specifics are covered more in depth in section 3.2.3, and it is assumed that the pressure 
sensors are linearized before they interface with the analog conditioning circuitry. 
Piezoresistive pressure sensors can typically operate with a wide power supply that 
includes 3–5 V.  The analog to digital converter (ADC) will share this same voltage 
range; thus, the output of the analog conditioning circuitry can be specified as a 
percentage of the supply voltage (Vdd) rather than as a specific voltage.  Additional 
constraints can be placed on the range of the sensors.  The full scale pressure sensor 
range should be the full range of reservoir pressures.  This is from 50 kPa down to 0 kPa.  
The inputs into the ADC should span the entire supply range for the pressure range in 
order to maximize sensitivity.   
Typical ADCs provide 12-bit resolution.  This allows for 4096 discrete input voltages 
that can be independently determined, with each point separated from the next by 
0.0244% of the supply voltage.  The first requirement of the analog conditioning circuitry 
is that it should not generate noise greater than half of this value.  Assuming a minimum 
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supply of 3V, the noise voltage generated by the conditioning circuitry should be less 
than 0.0244% of 3V (366 µV).  Also, a single bit change (or increase of 0.732 mV) in a 
12-bit ADC equates to a measured change of 12.21 Pa.  The analog circuitry must change 
the output from the sensor for a shift of 12.21 Pa into a voltage change of at least 0.732 
mV.  This will define the amplification necessary between the sensor and the ADC, and 
this could easily be amplification of three orders of magnitude. 
The necessity of a wide dynamic range, high accuracy, and good precision in the 
pressure sensors will dominate the requirements of the analog conditioning circuitry.  It is 
important to meet the necessary requirements, but it is also important to minimize power 
consumption.  This can be accomplished by adding the ability to turn on and off the 
sensors and circuitry.  Pressure will be sampled no more than once a minute, so the 
‘sleep’ mode and startup power costs of the circuitry will dominate the power budget 
allocated to the electronics.  If the system has a sleep state where it draws almost no 
power, time average power consumption should meet the system requirements. 
 
2.3.2 Processing, Communications, and Memory 
Physical sensors provide the data necessary for a central unit to process and alter the 
output.  The algorithm that the central processing unit (CPU) undertakes to adjust the 
output based on current conditions is stored in the memory along with other information.  
The memory and the control process are updated by the clinician through the 
communications system.  Due to the inter-related nature of these elements in function and 
in design, it is important to consider them as a single functional block. 
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There are several different realizations of this functional block.  The processor can be 
independent from the other elements, everything can be integrated in a single chip, or 
partial integration between these components can exist.  Regardless of the specific 
elements within the functional block, the requirements are the same.  The block has to 
read and process the sensor data and the memory information, communicate that 
information, control output, and use as little power as possible.  Minimizing power is 
particularly important for the control elements because they will draw power at all times. 
The power requirement can be specified if it is assumed that the circuitry requires a 
very significant portion of the total power budget (>80%).  Further, assuming that the 
continuous nature of the processor will require half of the total power of the circuitry and 
the supply is the equivalent of two AA batteries, (4800 mAh at 1.8V) allows the 
determination of the power draw for a set time.  The continuous power consumption of 
the processing unit for the device lifetime (5 years) has to be less than 27.5 mW.  This is 
the most significant constraint on this system block, and the communications are 
restricted because of this. 
Most memory elements easily fall within the power consumption requirements, so the 
remaining specifications are applicable only to communications.  The communications 
must be in one of the industrial, scientific, and medical (ISM) bands approved for 
medical devices, and they have to meet all government requirements for medical wireless 
communication.  Aside from that, the communications have very significant power draw.  
To compensate for this, the transmitter has to be completely shut down when not in use 
(it will only be used once every three months).  Additionally, the receiver needs to 
consume as little power as possible while allowing communication at any time.  This 
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‘wake on receive’ functionality is very important in any communications circuitry used in 
this implant.  Initial lifetime of the device can be 100 days for demonstration purposes if 
it can be increased to five years with program optimization.  
 
2.3.3 Power Supply and Valve Output 
The battery, supply regulator, and power amplifiers for the valves are dependent upon 
the other system needs.  It is imperative for space and power efficiency that all circuit 
elements are able to operate from a common supply voltage.  This allows a single power 
supply regulator to provide voltage for every element from a single battery.  This supply 
regulator and the power amplifiers both need to maximize their respective power 
efficiencies before meeting other performance metrics. 
Standard batteries range from 1.2 – 12 V.  Battery selection is dependent upon power 
density and maximum current draw as long as the nominal voltage is within this range.  
The initial batteries selected are not vital in determining overall system performance 
because medical devices of this nature tend to have specifically molded high density 
batteries.  The standard batteries need to accurately mimic the current supply and voltage 
levels of a custom designed battery. 
The supply regulator must provide a relatively level voltage to all of the circuit 
elements.  In sharing a common supply across several circuit elements, digital noise will 
make it very difficult to provide a noise free analog supply.  More importantly, it needs to 
be as efficient as possible in regulating the battery.  A reasonable target for the supply 
regulation is 85% power efficient with the ability to determine the remaining power in the 
battery. 
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Many piezoelectric actuators can require up to 100 V to drive them across their full 
scale range.  Current is required primarily during the transients of activation and 
deactivation.  The power amplifies used to drive the valves should have a programmable 
output from 0 – 100 V, should operate from the supply voltage, and should be as energy 
efficient as possible.  A good topology for controlling piezoelectric valves from a low 
voltage source is a controllable capacitive charge pump.  A circuit of this nature should 
be designed to drive two valves at up to 100 V. 
Power regulation is completely dependent upon the other circuit elements.  Once an 
acceptable supply voltage is determined, the battery, supply regulator, and amplifiers 
must be selected to use this same supply while being as efficient as possible.  In 
maximizing capacitive and inductive regulation topologies, loss can be minimized while 
power is provided across the system. 
 
2.3.4 Recharging Mechanisms 
The battery within current intrathecal drug delivery devices currently takes up about 
one quarter of the total volume.  This is because the current systems are designed to run 
continuously from the same battery for at least five years.  If the battery can be recharged, 
the size of the battery in the device can be reduced.  This would lead to significant 
volume efficiency improvements without sacrificing functionality.  Designing a system 
with a recharging mechanism allows for a smaller implant and more power for 
subsystems. 
Traditionally, implantable devices with rechargeable batteries use wireless power 
transfer [Bov08].  This can be done by using an inductively couple link, RF frequency 
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energy scavenging, or magnetic fields that induce recharge currents in the implantable 
device.  Wireless methods have been developed for several years and are commonly used 
in applications ranging from cell phone stations to nodal sensor networks.  There are two 
barriers to wireless recharging that need to be addressed with an implantable drug pump.  
First, the power necessary to operate the pump is significant.  Wireless recharging would 
have to occur regularly to provide enough energy to continuously run the pump.  Second, 
the device is implanted, and there are federal regulations are the type and density of 
energy that can be transferred into the body. 
An alternative to wireless recharging is to use a direct connection [Vip07].  Typically, 
a patient must go to their clinician every three to six months to have the drug reservoir 
refilled.  This refill is accomplished by inserting a needle into a subcutaneous access port 
located on the implant.  The process usually takes between fifteen and thirty minutes 
[And90, Str86].  The physical connection made between the needle and the system during 
refills can be exploited to also allow for a physical connection for energy transfer.  The 
difficulty with this technique is that the medication and the patient need to be electrically 
isolated from the recharge current.     
Recharging the implant battery allows for the battery size to be reduced and more 
power to be consumed in the operation of the system.  Wireless or physical connections 
are required to provide this functionality.  This comes at the expense of a more 
complicated device and increased circuitry volume.  Providing a recharging mechanism 
that can be activated during a reservoir refill session improves the volume efficiency and 
functionality of the system without adding patient inconvenience.    
In summary, sections 2.3.1-2.3.4 presents an overview of the circuitry necessary for 
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system functionality.  Input pressure sensors need to be linearized across their full-scale 
range and output a voltage from zero up to the supply rail.  The conditioning circuitry has 
to generate less noise than the input ADC.  A CPU needs to be able to process the sensor 
measurements, control output amplifiers, and consume as little power as possible.  Every 
functional block of the circuit needs to conform to a single supply voltage, and power 
regulation has to minimize loss.  A recharging mechanism is necessary to minimize 
battery size.  The circuit needs to provide the full range of clinical functionality as 








VALVE DESIGN, FABRICATION, AND PERFORMANCE 
 
The piezoelectric microvalves used to regulate drug delivery should conform to the 
design constraints for the system (Fig 2-1).  Three types of valves were designed in this 
work.  The first two valve types have similar actuation mechanisms but different 
suspension mechanisms*.  The third type uses the same suspension mechanism as one of 
the former types, but it has a several different features and can be assembled in a 
manifold.  More detail on the design, fabrication, operation and modeling of flexure 
suspended valves, membrane suspended valves, and starburst manifold valves are in the 
following sections.     
3.1 Flexure Suspension Valves 
3.1.1 Device Structure and Operation 
The valve operates by pushing a bulk silicon (Si) micromachined plate against a 
Corning #7740 Pyrex glass substrate that has the inlet and outlet holes in it (Fig. 3-1).  A 
commercially-available multilayered PZT stack is used to drive the silicon valve plate 
(Physik Instrumente, Germany). 
The PZT stack has footprint of 5×5 mm2 and a height of 6 mm.  Macor™, a glass 
mica ceramic, is used as the primary packaging material.  It can be easily machined with 
precision, and has a thermal expansion coefficient of 7.4 ppm/K.  In addition, it has zero 
porosity, does not outgas in vacuum environment, and can be used with epoxy to provide 
                                                 
* This work was done in close collaboration with Dr. Jong Moon Park, while he was a Ph.D. student at the 
University of Michigan 
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a hermetic seal.  The ceramic enclosure measures 1×1×1 cm3, and has 6 mm deep cavity 
with 1 mm thick walls on all four sides. 
 
Fig. 3-1: Microvalve concepts: The valve consists of ceramic-PZT-Si-glass structure.  A 
PZT stack actuator moves the silicon plate to open or close the valve.  Micro-
groove patterns are fabricated on the silicon plate to increase the flow area. 
 
The limited displacement of PZT poses a major design challenge for this microvalve 
in providing sufficient flow rates for drug therapy.  In this case, the flow area is given by 
the product of valve seat perimeter surrounding inlet or outlet hole (p) and the separation 
between silicon valve plate and glass seat (δ).   
   valveA pδ= ⋅                                  (3-1) 
The required flow area is quite large considering that the PZT actuator can provide at 
most 6 μm of displacement at room temperature.  To achieve this large flow area, the 
perimeter of the valve seat is substantially increased by implementing serpentine groove 
patterns on the silicon valve plate (5×5 mm2), as shown schematically in Fig 3-1.  Each 
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groove measures 50 μm wide and 120 μm deep, and the perimeter measures about 127 
mm, allowing much higher flow rates. 
The silicon valve plate is suspended by four flexures in crab-leg formation; each 
measures 500 μm wide, 4200 μm long, and 50 μm thick.  These flexures are flexible 
enough to move freely upon the actuation of PZT (spring constant ≈ 500 N/m) but are 
rigid enough to hold the plate in place.  In addition, the crab-leg formation can relieve 
any stress that is caused by temperature or process variations.  This characteristic was 
verified by finite element analysis of the structure.  Assuming that the anodic bonding 
between the silicon and glass was done at 400ºC, at room temperature, a maximum stress 
of 21 MPa was observed at the corners of bonding rim but the stress on the flexure and 
silicon valve plate was negligible. 
The bonded die, PZT actuator, and ceramic enclosures are joined using Stycast epoxy.  
The PZT actuator is not bonded to the Si plate, which helps to accommodate variations in 
height caused by expansion mismatch between the PZT and the Macor housing. 
 
3.1.2 Device Fabrication 
To ensure control of material properties, the final device is comprised of only bulk 
materials.  Deposited thin films are not used for any structural layer, although they are 
used in intermediate steps.  The fabrication process uses two wafers: a silicon-on-
insulator (SOI) wafer which has device layer, buried oxide layer, and carrier wafer 
thicknesses of 50 μm, 0.5 μm, and 450 μm, respectively, and a 500 μm thick Pyrex glass 
wafer.  The fabrication processes for SOI and glass wafers are illustrated in Fig. 3-2, and 
the assembly with the PZT and the ceramic housing is discussed in Section 3.2.2. 
 


















































Fig. 3-2:  Si-glass micromachining process: The buried oxide layer in a SOI wafer acts as 
an etch stop for DRIE.  A three-step DRIE process is illustrated for the SOI 
wafer.  A glass wafer undergoes a wet etch process and electrochemical 
discharge machining (ECDM) for inlet and outlet hole creation.  Finally, an Al 
metal layer is deposited and patterned in preparation for anodic bonding to 
prevent bonding of the valve seat to the glass substrate. 
 
Deep reactive ion etching (DRIE) of silicon was used to form flexures, the valve plate, 
and groove patterns in the plate.  DRIE provides high etching speed, high aspect ratio 
capabilities, and good selectivity.  However, the uniformity of DRIE is not reliable across 
a full wafer [Tay06, Fas99].  The buried oxide layer in SOI wafers provides an etch stop 
for DRIE, while the epitaxial layer provides a well-controlled flexure thickness, smooth 
surfaces, and bulk Si properties.  The first DRIE step etches down to the buried oxide 
layer from the top and defines the flexure structures.  Then the bottom side is patterned 
with Al and photoresist.  The photoresist acts as an etch mask for the second DRIE step 
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that is approximately 400 μm deep.  Next, the photoresist is removed and Al is used as an 
etch mask for the final DRIE step which engraves serpentine grooves for perimeter 
augmentation.  The Al layer is then removed and the wafer is prepared for bonding.  A 
scanning electron microscope (SEM) image of a valve plate after these three-step DRIE 
is shown in Fig. 5a.  Each groove width is 50 μm, and they are etched approximately 120 







Fig. 3-3:  Photographs of the fabricated device. (a) SEM photograph of the silicon valve 
plate with groove patterns right after the three-step DRIE process.  (b) Picture of 
a die after the anodic bond.  (c) Close-up view near the hole with serpentine 
groove patterns for perimeter augmentation.  (d) Completely assembled valve 
structure.  Two valves (front and back) are shown. 
 
For the glass wafer, a recess of 2 μm is made to accommodate the PZT displacement.  
The recess is formed by wet etching the glass in H2O:HF:HNO3=10:7:3 solution, using 
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Cr/Au/PR layer as an etch mask.  After the recess formation, the etch mask is removed 
and a thin Cr layer (100 nm) is patterned to define the position of inlet and outlet holes 
that are formed using electrochemical discharge machining (ECDM).  ECDM was chosen 
for through-hole formation against wet etching the glass because wet etching results in 
significant undercut.  ECDM of glass is a rapid, low-cost method that provides a near-
vertical profile and is suitable for hole formation.  The procedure is performed in 40% 
NaOH solution at room temperature, and the glass is machined using approximately 300 
μm diameter tungsten cathode and 37 V bias. 
Before performing the bonding of the Si and glass wafers, a thin layer of Al must be 
deposited into the glass recess to prevent inadvertent bonding of the valve plate to the 
glass substrate due to a shallow recess depth and very compliant flexures.  Anodic 
bonding is performed at 400˚C and 800 V, after which the Al layer on SOI wafer is 
dissolved.  The bonded wafers are then diced and prepared for assembly with the ceramic 
structure and PZT.   
The final step is to attach the PZT stack and ceramic cap by epoxy.  The piezoelectric 
actuation provides enough force to displace the Si against inlet pressures that can reach 
several atmospheres for some cases.  The PZT does not need to be bonded to the Si.  This 
may also relieve stress on flexures.  The completed valve structure with final dimension 
of 1×1×1 cm3 is pictured in Fig. 3-3. 
 
3.1.3 Modeling and Experimental Results 
A flow model was based upon the solution of the Navier-Stokes equations using 
computational fluid dynamic (CFD) software applied to the critical valve components.  
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The results of the CFD models were used to generate empirical formulas of these 
components which could be interfaced in order to predict the flow rate through the valve 
and are discussed in more detail in Section 5.2.2.  The valve specific model was obtained 
by assuming that the diameters for the inlet and outlet are 350 µm and the displacement 
of PZT at 60 V is 4 μm.  In addition, a linear relationship between PZT displacement and 
voltage was assumed.  Thus, seat clearance from the glass substrate can be expressed as 
in Eq. (3-2).   
( ) 4 (V) 0.067Clearance m Voltageμ = − ⋅                      (3-2) 
First, room temperature tests were conducted to verify the model and establish baseline 
performance characteristics of the valve at low and high pressures.  Additionally, high 
and low temperature testing was performed to yield more information on dependencies of 





















Fig. 3-4: Schematic of the test setup for the He gas flow measurement.  Flow rate through 
the valve is measured while monitoring the inlet and outlet pressure.  For low or 
high temperature testing, heat exchangers are placed to cool or heat the He gas.  
 
Tests were performed at room temperature with He gas flow.  Figure 3-4 is a 
schematic of the test.  An in-line thermoplastic filter is placed upstream of the device to 
trap any particles or moisture.  Pressure gauges are mounted so that inlet and outlet 
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pressure can be monitored.  Copper piping (6.35 mm diameter) is connected to 0.4 mm 
holes in glass through an aluminum header.  A ball valve is added at the end so that the 
outlet pressure can be controlled if necessary. 
In the first set of tests, the inlet pressure was regulated (21-55 kPa, gauge), and the 
outlet was maintained at atmosphere, while the flow rate was measured over 0-60 V 
actuation.  As shown in Fig. 3-5, as actuation voltage increases, the PZT expands, the 
clearance between the silicon valve seat and glass substrate decreases, and thus, flow rate 
decreases.  With the gauge pressure of 55 kPa at the inlet, flow rate could be modulated 
from 0 to 980 mL/min. At 60 V, the valve leakage was below the measurement limit (< 
0.1 mL/min.). 





























































(a)          (b) 
 
Fig. 3-5: Flow rates as a function of voltage at room temperature from experimental 
results (a) and analytic model (b).  As the actuation voltage increases, the valve 
is closed and results in a decreased flow rate.   
 
In a separate experiment, the valve was tested at a higher inlet pressure of 345 kPa 
gauge pressure to verify high pressure operation, but the pressure difference between the 
inlet and outlet was kept at 34.5 kPa.  A pressure vessel was used to obtain a high 
absolute pressure while maintaining a relatively low pressure differential across the valve 
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at room temperature.  Absolute pressure was measured at the inlet of the valve while the 
pressure difference across the valve and volumetric flow rates were measured.  Multiple 
throttling valves were utilized downstream of the valve to allow precise regulation of the 
pressure difference at high absolute line pressure.  Tests were conducted by holding the 
inlet pressure and differential pressure constant while increasing the valve actuation 
voltage from 0 to 100 V, and then reducing voltage back to 0 V in 10 V increments.  The 
test result comparison with the model prediction is shown in Fig. 3-6.  The flow rate 
measurements reveal the hysteretic behavior of the PZT actuator.  The model and the 
experimental results show good agreement.  



































Fig. 3-6: Flow rates as a function of actuation voltage measured at room temperature with 
an inlet pressure of 345 kPaG and an inlet to outlet pressure differential of 34 
kPa.  Experimental data is shown with the numerical modeling results.  Flow 
rate measurements show the hysteretic behavior of the PZT actuator. 
 
The flow rates from the model tend to be slightly larger than the experimental results, 
but in general, they match reasonably well (Fig. 3-5).  The main discrepancy comes from 
uncertainties in seat clearance and inaccurate inlet and outlet hole sizes used in the model. 
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Compressibility of He gas and hysteretic behavior of PZT also contribute to the 
difference between the model and experimental data. 
Preliminary liquid flow tests were performed at room temperature using oil (viscosity 
4.5 cP) to provide solution viscosity greater then saline water.  For every test, a liquid 
reservoir was pressurized with regulated nitrogen gas to control and simulate varying 
pressures that might be generated from a passive source.  The valve outlet was exposed to 
atmospheric pressure to create a pressure difference across the valve.  Flow rates were 
determined by calculating the mass change in an outlet reservoir over a two minute time 
period. 




















Fig. 3-7: Flow rate through un-actuated valve (0 V) across various pressures.  At lower 
pressures the flow rate changes linearly with pressure. 
 
The liquid flow rate was monitored as input pressure was varied (Fig. 3-7).  The flow 
rate varied linearly with the differential pressure over a range of 250-460 μl/min; the 
corresponding differential pressure drop was 16 - 47 kPa.  Additionally, the valve was 
actuated by increasing and decreasing the voltage with different inlet pressures (Fig. 3-8).  
Flow rates were tested over a range of input pressures (108 - 142 kPa), and could be 
altered from the un-powered, partially open flow rate by as much as 50 µl/min.  
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Frequency tests were conducted in which the microvalve was actuated with a 50 Hz, 
0-60 V square wave with varying duty cycle (Fig. 3-9).  This actuation strategy provided 
more uniform linear control across inlet pressure than DC control.  These results suggest 
that either voltage or frequency can be used to regulate the flow rate.  DC operation 
consumed 0.136 μW and AC operation used 45 mW.  As expected, DC regulation 
consumes less power.  AC modulation is less efficient because of capacitive losses in the 
piezoelectric actuator.  
The liquid flow results fail to exhibit necessary performance characteristics for drug 
regulation.  The valve is unable to completely stop liquid flow when actuated at voltages 
as high as 60 V and regulation range is highly pressure dependent.  Additionally, the 
valve topology has significant dead volume in the cavity of the housing.  The difficulty in 
regulating fluid flow is likely due to the unsealed valve, and dictates the need for a design 
that addresses these issues.  Most performance issues can be addressed by altering the 
suspension mechanism. 
 















































0-60 V sq. wave
 
Fig. 3-8: Flow rate versus voltage 
actuation from -30 V to 60 V.  Results are 
recorded for two inlet pressures, while the 
outlet is held constant at 101 kPa. 
Actuation is more pronounced with greater 
inlet pressure. 
 
Fig. 3-9: Flow rate changes versus duty 
cycle for two inlet pressures.  The 
actuation voltage was a 50 Hz square wave 
from 0-60 V.  This method does not rely 
on the linearity of piezoelectric actuation. 
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3.2 Membrane Suspension Valves with Embedded Sensors 
3.2.1 Device Structure and Operation 
The device consists of three main components; a membrane suspended valve for flow 
modulation, a pressure sensor, and a temperature sensor.  Similar to the flexure 
suspended valves, the valve operates by pressing a suspended silicon plate against a glass 
plate using piezoelectric actuation.  Piezoelectric actuation provides enough force to 
displace the silicon plate against large inlet pressures (above 1 atm) with negligible DC 
power consumption and acceptable performance.  The membrane suspension greatly 
reduces the dead volume of the valve and allows for easy integration of sensors.  The 
shape of the valve seat was altered to a circular shape to evenly distribute the stress on 
the membrane.  The valve and actuator are housed inside a Macor structure.  Macor was 
also used to create the fluidic header that is used to connect the inlet and outlet of the 
valve to the rest of the flow path.   
The limited displacement provided by the PZT actuator has been overcome using a 
valve flow passage design referred to as a perimeter augmentation [Bro07].  The flow 
area for an out-of-plane valve (Avalve) is given by the product of the valve stroke (δ) and 
the perimeter of the valve seat (p). 
                            valveA pδ= ⋅                  (3-3) 
Thus, by increasing the perimeter of the valve seat, flow area can be increased 
substantially, which results in larger flow modulation.  Extended serpentine grooves (> 
30 cm in length) are fabricated on the valve plate as shown schematically in Fig. 3-10, to 
increase flow area.   
 


























Fig. 3-10:  Microvalve concepts: (a) A cut away view of assembled ceramic-PZT-Si-
glass valve structure. (b) A valve plate suspended by Si membrane with 
integrated sensors viewed from the bottom.  RTD sensor is located on the 
back of the wafer  
The embedded temperature and pressure sensors enable closed loop control of a drug 
delivery system.  The most common methods of measuring temperature are 
thermocouples, diodes, and resistance temperature detectors (RTDs) [Yea01].  As the 
entire device is exposed to the operating temperature of the valve, the requirement of 
temperature reference junction prevents the use of a thermocouple for the temperature 
sensor.  Diode thermometry uses the temperature dependence of forward voltage drop in 
a p-n junction biased at constant current.  A platinum RTD is chosen as the temperature 
sensor because of its linear response in the range of our interest, industry standard 
robustness, and ease of implementation.  The RTD is fabricated on the back side of the 
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valve plate to prevent electrical conduction paths from interacting with the fluid channel.  
It is strategically placed on back of the valve to measure the temperature of the inlet.  
Thin silicon between flow path and the sensor element provide a thermal conduction path 
to accurately measure the temperature while preventing direct contact with the fluid. 
The membrane suspension creates a valve with little dead volume in the fluid path.  
The dead volume in the device is only 0.021 cubic centimeters which is less than 1% of 
the total valve volume.  This is an order of magnitude reduction of the dead volume 
compared to the flexure suspended valves despite a slight increase in overall valve size.  
The membrane is also designed to remain closed during a reservoir refill in which back 
pressures of up to 100 kPa may be experienced.  The membrane suspension is fabricated 
using a process that is easy to integrate with a diaphragm pressure sensor.  This allows a 
feedback control circuit to access pressure data without substantial volume increases.  A 
channel routes the medication from the inlet to the pressure sensor diaphragm. 
 
3.2.2 Device Fabrication 
The fabrication process is a variant of the process previously used to create flexure 
suspended microvalves.  Steps have been added to the process to create the embedded 
sensors, and other steps have been altered to increase yield and decrease process 
complexity.  The valve is fabricated from a silicon-on-insulator (SOI) wafer with layer 
thicknesses of 50 µm, 0.5 µm, and 450 µm and a 500 µm thick Pyrex glass wafer.  The 
SOI and glass wafers are independently processed, bonded, and then cut into individual 
die.  The fabrication processes for SOI and glass wafers are illustrated in Fig. 3-11. 
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Fig. 3-11:  Si-glass micromachining process: sensors are formed on the device layer of 
the SOI wafer by various surface micromachining techniques.  The buried 
oxide layer in SOI wafer acts as an etch stop for DRIE when forming 
membranes.  A two step DRIE process is illustrated for SOI wafer.  A glass 
wafer undergoes two wet etch steps for a recess and through-hole formation.  
Next, the two wafers are bonded and diced.   
 
Surface micromachining is done at the very beginning of the process to create the 
embedded sensors.  The SOI wafer is initially patterned with photoresist and exposed to 
create the pattern for the piezoresistors.  The wafer is then sent to Innovion Corporation 
for dopant implantation.  The implantation power level was selected to yield the correct 
carrier profile after implantation and annealing using the T-SUPREM 4 implantation 
simulator. 
After Boron implantation, the wafers are prepared for oxidation and annealing.  An 
oxide layer provides insulation between metals and silicon substrate.  Annealing is 
necessary in order to activate the implanted dopants, and it also heals damage to the Si 
crystal structures that occurred during the high energy ion bombardment.  A thermal 
oxide was grown to both provide the necessary isolation and act as the high temperature 
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anneal needed to activate and diffuse the implanted boron.  A 2000 Å oxide was grown at 
1000°C for 50 minutes and the wafer was left at the temperature additional 20 minutes in 
nitrogen environment to allow for enough diffusion time for the implanted Boron. 
After the thermal oxidation and anneal, vias are etched in the oxide using buffered 
hydoflouric acid (BHF) to create contacts to the buried piezoresistors and metal is 
deposited on the wafers to form the RTD.  A platinum layer with titanium adhesion layer 
are evaporated and put in acetone to pattern via lift off.  Lastly, gold is deposited on the 
contact pads for easier electrical contact with external wiring.  Figure 3-12 shows the 
fabricated die with pressure and temperature sensors.       
 
 
Fig. 3-12:  (a) Photograph of the top of the SOI wafer showing metal contact layer with 
(b) an expanded view of the platinum RTD. (c) Wide and (d) expanded views 
of the circular serpentine groove patterns for perimeter augmentation from the 
bottom of the SOI wafer.  This side bonds to the glass wafer 
 
After the device side is processed, the back side of the wafer undergoes a two step 
Deep Reactive Ion Etch (DRIE) process to create the pressure sensor diaphragm, the 
membrane suspension, and the serpentine groves that increase the flow perimeter.  The 
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two step DRIE process uses aluminum and photoresist masks to achieve desired groove 
and membrane structures.  Figure 3-12(c) and (d) shows the bottom view of the silicon 
die after these processes.  The resulting grooves are 100 µm in depth and provide seat 
perimeter that longer than 30 cm in length to provide larger flow area when the valve 
opens. 
A Pyrex glass wafer is patterned with a recess, and then undergoes an HF etch to 
form through vias that act as the valve inlets and outlets.  A wet etch method was chosen 
instead of ECDM to offer a repeatable batch process.  After a 2 μm recess is formed, both 
sides of the glass wafer are patterned with chrome, gold, and thick photoresist.  The wafer 
is then placed in HF until the through holes are etched.  The SOI wafer and the glass 
wafer are anodically bonded at 400ºC, and the wafers are diced to create the final valve 
die. 
After the valves are fabricated, electrical connections are made to the sensors, and 
they are assembled with a piezoelectric actuator stack and a ceramic Macor cap.  The 
PZT stack is bonded inside the Macor cap using epoxy.  Next, the valve is bonded to the 
PZT stack and the Macor cap using epoxy.  The epoxy not only bonds, but also creates a 
layer that compensates for height differences between the actuator and ceramic housing.  
At this stage, different methods can be used during the valve bond step to create a 
normally open, partially open, or normally closed valve.  Figure 3-13 illustrates this 
process.   
To create a normally open valve, the PZT stack is energized at 100 V during the last 
step so the actuator stack shortens after the epoxy has cured.  To create a normally closed 
valve, a stage is used to press down the valve die until it comes into contact with the 
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unactuated PZT stack.  The voltage produced when PZT stack is pressurized is a good 
indication that contact is made.  For the normally closed valve, a reverse polarity voltage 
is applied to open the valve, so that PZT stack contracts upon actuation.  A partially open 
valve is assembled by using the stage to drive the valve into contact, and then moving the 
stage away from contact the desired initial gap distance.  The final valve structure 



























Fig. 3-13: Assembly process can result in either normally closed or normally open valve.  
Energizing the PZT actuator during assembly results in normally open 
configuration (top), while no PZT actuation during assembly yields normally 
closed valve (bottom).  For normally closed valve configuration, reverse 
polarity actuation voltage is applied to the piezoelectric actuator to shorten the 
PZT stack and open the valve.   
 
3.2.3 Experimental Results 
Room temperature tests were conducted on the normally-open and normally-closed 
valves.  The valves were tested at various pressures and temperatures.  The temperature 
sensor was tested across varying differential pressures at several temperatures.  
 





Fig. 3-14:  Assembled valve from the glass side with US penny.  The pressure sensor 
cavity is connected to the inlet through a passage.  The valve is 1.5×1.5×1.1 
cm3. 
 
The mechanics of the valve diaphragms were studied using a finite element analysis 
(FEA) tool, Ansys®.  The spring constant of the valve diaphragm is about 3.8×106 N/m.  
It is important to note the thermal stress on the membrane as the valve will experience 
large differences in temperature, because the anodic bonding is done at 400 ºC and the 
application of the valve is targeted to body temperatures.  In the worst case scenario of 6 
µm maximum displacement and 10 atmospheres of pressure, the maximum stress was 
about 0.5 GPa, which is a fraction of silicon’s yield strength (≈ 7 GPa), showing the 
membrane has enough structural integrity to be used for the targeted application. 
A normally-open and a normally-closed valve were tested at room temperature with 
N2 gas flow.  The N2 gas was introduced to the inlet of the valve at the gage pressure of 
52 kPa, while the outlet was connected to a flow meter and vented to the atmosphere.  
The flow rate was measured as the valves were actuated from 0−40 V.  The hysteresis 
due to the piezoelectric actuator can be seen in the flow rate variations for various set 
voltages (Fig. 3-15).  Additionally, the difference in the hysteresis curve directions is due 
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to the opposite polarities applied to the normally-open versus normally-closed valves and 
was as expected.  The flow rate went from below the measurement limit (< 1 mL/min) to 
above 200 mL/min in the normally open valve and above 100 mL/min in the normally-
closed valve.   
































































































Fig. 3-15:  Flow rates as a function of voltage measured. (a) normally open valve, and (b) 
normally closed valve measured at differential inlet pressure of 52 kPa.  
 
Liquid flow tests were conducted using the valve as part of a complete system.  These 
results conform to the expectations presented by the gas testing and the initial testing 
using the flexure style valves.  Details on the liquid delivery experiments, system 
modeling, and delivery results are presented in Section 5.1.1 and Section 5.4.1. 
The pressure sensor is comprised of four Boron doped piezoresistors on a silicon 
diaphragm.  T-Supreme 4 was used to simulate the Boron piezoresistors.  .  The pressure 
sensor was powered at 5 V as the differential output voltage was monitored.  Simulations 
of the resistors suggest a sheet resistance of about 2.97×103 Ω/□ and an actual resistance 
of 26.7 kΩ.  Several resistors were tested at room temperature and they averaged a 
resistance around 23.5 kΩ.  This indicates these resistors correspond closely with 
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simulation and suggest successful ion implantation.  The resistors are arranged in a 
Wheatstone bridge configuration  
 
Fig. 3-16:  Output voltage from piezoresistive pressure sensor at various differential 
pressures.   
 
Linearity of the pressure sensor is good.  At room temperature, the sensitivity is 356 
ppm/kPa with an offset of 59 mV.  The device does exhibit a change in offset and 
sensitivity associated with temperature that needs to be accounted for once it is implanted.  





=                                (3-4) 
where S is sensitivity and T is temperature, and measures how much sensitivity changes 
with temperature.  In our case, the TCS is −6507 ppm/K and is referenced to the 
sensitivity at room temperature.  This behavior is almost entirely dominated by 
temperature coefficient of piezoresistive coefficient [Kim83].  
The offset voltage also changes as temperature increases.  Initial offset is introduced 
due to mismatched resistors.  Most mismatches come from geometric difference of 
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splitting the resistor in transverse direction into two segments to have them placed close 
to the rim.  The temperature effects on individual resistor can be represented as 
( )0 ( ), ( )T RR R T R T Tα π σΔ = Δ + Δ                        (3-5) 
where RT0 is resistance at reference temperature, αR is temperature coefficient of 
resistance and the last term describes the change of resistance due to temperature induced 







=                               (3-6) 
where Vcc is supply voltage and Vo is the output voltage when no pressure differential is 
applied.  We calculated the TCO of 652 ppm/K over the temperature range tested.   
 
3.3 Starburst Valves and Manifolds with Embedded Sensors 
3.3.1 Device Structure and Operation 
The valve consists of two main components: a membrane suspended boss with a 
starburst pattern valve seat for flow modulation and multiple pressure sensors.  A 
manifold was made that contains two valve plates with a common outlet and two inlets.  
These devices were very similar to both the flexure and membrane suspended valves in 
that the valve operated by pressing a silicon plate against glass.  The actuating 
mechanism was also a PZT stack because of the high force and low power consumption.  
The membrane suspension maintained the reduction in dead volume, prevented liquid 
from interfering with the actuator, and simplified the integration of multiple pressure 
sensors.  The shape of the valve seat was altered to a starburst pattern, and the outlet was 
moved off of the actuation membrane to evenly distribute the stress on the valve walls 
and increase the flow rate.  Aside from mixing, this change also allowed the manifold to 
 
-  - 
60
function like a single valve (Fig. 3-17).  The valve (or manifold) and actuator were 
housed inside a Macor structure.  Macor was also used to create the fluidic header that 
was used to connect the inlet and outlet of the valve to the rest of the flow path.   
 
Fig. 3-17:  Starburst manifold concepts: (left) A top and back side view of the SOI wafer 
with the centralized inlet, dual pressure sensors, and starburst valve seat 
arrangement. (b) A manifold designed with the starburst valve seat used to 
regulate flow from two inlets.  The manifold has a common outlet with a 
single pressure sensor for mixing in the device and common flow control.  
    
The pressure sensors enable closed loop control of a drug delivery system and have 
the potential to detect dosing errors.  The sensors allow reservoir pressure and the outlet 
pressure to be measured using the same device on the same substrate.  This allows for 
differential pressure measurements across the membrane with two benefits.  First, the 
effects of common error sources like supply drift, thermal effects, substrate noise, and 
geometric mismatches are reduced because the same sensor geometries are powered from 
the same source on the same substrate.  Second, errors do to leakage, the fluidic 
resistance of the catheter, and the fluidic resistance of the reservoir interconnects are 
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eliminated by placing the sensors as close to the valve channel as possible.  This can 
provide usable information even with drift in the patient’s CSF pressure.  Additonally, 
implantation reduces effects related to temperature drift because individuals exhibit 
relatively little internal temperature variation.  Like the membrane suspended valve, 
Wheatstone bridges using piezoresistors are used for all the pressure sensors because they 
are easy to interface and have lower output impedance than capacitive readouts.   
 
3.3.2 Device Fabrication 
The fabrication process is a variant of the process previously used to create 
membrane suspended microvalves.  Steps have been removed from the process because 
temperature sensors are no longer being fabricated on the valve die.  Additionally, other 
steps have been modified to increase yield and decrease process complexity.  The valve is 
fabricated from a silicon-on-insulator (SOI) wafer with layer thicknesses of 20 µm, 2 µm, 
and 450 µm and a 500 µm thick Pyrex glass wafer.  The SOI and glass wafers are 
independently processed, bonded, and then cut into individual die.  The fabrication 
processes for SOI and glass wafers are illustrated in Fig. 3-18. 
Surface micromachining is done at the very beginning of the process to create the 
embedded sensors.  The SOI wafer initially undergoes thermal oxidation.  A 2400 Å 
oxide is grown at 1000°C for 50 minutes and then is patterned with photoresist and 
exposed to create the pattern for the piezoresistors.  The oxide is selectively removed 
with a 9 min BHF etchant step.  The wafer is then sent to Innovion Corporation for 
dopant implantation.  Boron implantation was done with a 1 x 1013 cm-2 dose at an energy 
level of 20 Kev with a 7° tilt.  The implantation parameters were selected to yield a 
carrier profile that makes it twice as sensitive as the sensor on the membrane suspended 
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valve type while measuring pressure in the targeted reservoir range.  The implantation, 
drive-in, and annealing temperatures were calculated using the T-SUPREM 4 
implantation simulator.  
 
Fig. 3-18:  Si-glass micromachining process: sensors are formed on the device layer of 
the SOI wafer by implanting boron and making ohmic connections through a 
field oxide to gold contact pads on the device perimeter.  The buried oxide 
layer in SOI wafer acts as an etch stop for DRIE when forming membranes.  
A two step DRIE process is illustrated for SOI wafer.  A glass wafer 
undergoes two wet etch steps for a recess and through-hole formation.  Next, 
the two wafers are bonded and diced.   
 
After the Boron implantation, the wafers are prepared for oxidation and annealing.  
An oxide layer provides insulation between metals and silicon substrate.  Annealing is 
necessary in order to activate the implanted dopants, and it also heals damage to the Si 
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crystal structures that occurred during the high energy ion bombardment.  A thermal 
oxide was grown to both provide the necessary isolation and act as the high temperature 
anneal needed to activate and diffuse the implanted boron.  A 1000 Å oxide was grown at 
1000°C for 20 minutes and the wafer was left at the temperature additional 5 minutes in 
nitrogen environment to allow for enough diffusion time for the implanted Boron. 
 
Fig. 3-19:  Photographs of the top and back sides of a fabricated valve manifold.  The 
glass inlets and outlets, the two valve seats, and the pressure sensor cavities 
are clearly visible on the top.  The gold contact pads and traces for the 
pressure sensors, and the gold to define the PZT locations are clearly visible 
on the back side of the device. 
 
After the thermal oxidation and anneal, vias are etched in the oxide using BHF to 
create contacts to the buried piezoresistors and metal is deposited on the wafer to make 
ohmic contact with the Boron doped silicon.  A platinum/gold layer with a titanium 
adhesion layer are evaporated onto the wafer and put in acetone to pattern via lift off.  
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Lastly, more gold is deposited to form the conductive traces and contact pads for easier 
electrical interface with external wiring.  Figure 3-19 shows the fabricated manifold with 
a standard starburst pattern.       
After the device side is processed, the back side of the wafer undergoes a two step 
Deep Reactive Ion Etch (DRIE) process to create the pressure sensor diaphragms, the 
membrane suspension, and the serpentine groves that increase the flow perimeter.  The 
two step DRIE process uses aluminum and photoresist masks to achieve desired groove 
and membrane structures.  Figure 3-20 shows the bottom view of the silicon die after 
these processes.  The resulting grooves are 120 µm in depth and provide a seat perimeter 
that is longer than 30 cm in length to provide larger flow area when the valve opens. 
 
 
Fig. 3-20:  Assembled starburst valve looking from the glass side.  The pressure sensor 
cavities are clearly visible for both the inlet and outlet.  The valve is 
1.5×1.5×1.1 cm3. 
 
A Pyrex glass wafer is patterned with a 1.4 µm recess using BHF, and then undergoes 
an HF etch to form through vias that act as the valve inlets and outlets.  After the recess is 
formed, both sides of the glass wafer are patterned with chrome, gold, and thick 
photoresist.  The wafer is then placed in HF until the through holes are etched.  The SOI 
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wafer and the glass wafer are anodically bonded at 400ºC, and the wafers are diced to 
create the final valve die. 
 
 
Fig. 3-21:  Photograph of an assembled starburst manifold.  Both valve plates are clearly 
visible and the common outlet port is located in the center of the die.  The 
manifold measures 3×1.5×1.1 cm3. 
 
After the valves are fabricated, solder connections are made to the pressure sensor 
pads, and they are assembled with a piezoelectric (PZT) actuator stack inside a ceramic 
Macor cap.  The PZT stack is bonded inside the Macor cap using epoxy and assembly 
continues in the same manner in which the other valves are assembled.  The added 
complications in assembly of a starburst manifold are the two PZT stacks need to be 
assembled so they are in alignment, and the extra wiring from the plurality of sensors and 
actuators must be carefully routed.  Care in the assembly steps compensate for these 
difficulties.  The valve plates on the manifold can be individually adjusted during the 
bond step to create a normally open, partially open, or normally closed valve.  The final 
valve structure measures 1.5 x 1.5 x 1.1 cm3 and is pictured in Fig.3-20, and the manifold 
structure measures 3 x 1.5 x 1.1 cm3 and is pictured in Fig. 3-21.  The valve and manifold 
are assembled with a Macor header to provide fluid interconnects (Fig. 3-22). 
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Fig. 3-22:  Photograph of an assembled starburst manifold with the attached fluidic 





Fig. 3-23:  Generalized flow pattern of the valves: Fluid flows from the inlet to the high-




A numerical flow model, specific to the perimeter augmented microvalve was 
developed to examine the flow behavior of the valve [Kle02]†.  The flow through the 
valve was assumed to be isothermal, laminar, and steady flow.  The flow regions are 
further divided into component level: flow along the grooves and across the land (Fig. 3-
                                                 
† Initial flow enhancement was proposed by Prof. Greg Nellis and initial modeling was performed by Dr. 
Tyler Brosten at the University of Wisconsin and includes figures 3-23 to 3-25. 
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23).  The flow within the grooves are also assumed to be no slip and fully developed flow 
while in the land region it is expected that the slip and compressibility will have large 
effect on the flow characteristics. 






dP dVf V V
dx D dx
ρ ρ− = +                            (3-7) 
where Pg and Vg are pressure and velocity of the gas at a particular location x within a 
groove, f is the friction factor, Dh is the groove hydraulic diameter, and ρ is the density 
(Fig. 3-24).  The friction factor f was determined through Computational Fluid Dynamic 
(CFD) model using FLUENT 6.2.  
Variable Description Nominal Value 
d Clearance between land and seat 3.687           µm 
Lg Length of the groove 2800.0         µm 
Wland, Wtip Width of the land and top 50.0             µm 
Wg, Dg Width and depth of the groove 100.0           µm 
PH Inlet high pressure 135.8           kPa 
PL Outlet low pressure 101.3           kPa 
r Density of water (25 °C and 5 atm) 997.1           kg/m3 
m Viscosity of air (25 °C and 5 atm) 0.0008905          kg/m-s 
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Fig. 3-24:  An overview of the parameters used during the analysis of the valve seat 
geometry, 
Component level model for flow through the land is based on rarefied compressible 
gas through parallel plates and can be represented as 
3 2








⎡ ⎤= − + −⎣ ⎦&                      (3-8) 
where 'm&  is the mass flow rate per unit channel width, δ is the gap height, Po is the outlet 
pressure, L is the channel length, R is the ideal gas constant, T is the temperature, Kn is 
the Knudsen number based on δ, and Pr is the ratio of inlet pressure to the outlet pressure. 
The component level model for flow through the land is based on the one-
dimensional flow of a rarefied compressible gas through a channel.  These physical 
groove, y-based component level models are interconnected through the steady state 
numerical solution of interconnected governing equations; these algebraic equations are 
based on satisfying continuity. The resulting system of equations is solved using the 
Engineering Equation Solver (EES) [Kim83]. Differential control volumes within the 
grooves and the land are shown in Figure 3-25. 
 
Fig. 3-25 Mass balance terms for the control volumes of the numerical solution. 
The governing equation for the flow in the high-pressure groove expresses the 
pressure drop in terms of a viscous loss and an inertial term.  The governing equation is 
discretized so that the gas velocity in the groove is related to the mass flow rate.  For a 
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complete discussion of the numerical solution scheme, including boundary conditions 
and the coupling to the manifolds, please refer to [Bro07]. The solution of the system of 
equations provides the flow through the valve given its actuation state (i.e., the valve 
clearance) and operating conditions (i.e., the pressures at the inlet and exit, the inlet 
conditions, and the type of fluid). 
An optimization study was done using the flow model developed for the first 
generation valves to design the valve seat for the starburst pattern‡.  It was found that are 
four primary parameters that can be adjusted to increase flow modulation capabilities of 
the valve.  The arbitrary values used for optimization of the individual parameters are 
listed in the below and graphically represented in Fig. 3-24. (The value of the parameter 
being optimized changes during optimization). 
The model predicts that it would be advantageous to use a saw-toothed groove pattern 
as opposed to the rectangular pattern used for the flexure and membrane suspended 
valves.  The flow modulation is enhanced using a groove pattern because of decreased 
flow pressure losses along the groove.  The mass flow is progressively reduced as it 
proceeds into the groove on the inlet side because some material crosses the land area and 
enters the adjacent groove on the outlet side.  Saw-toothed grooves give the entrance to 
the land, which has the highest mass flow of any point in the groove, the largest amount 
of area.  As the mass flow decreases, so does the groove width.  The flow area is 
proportional to the amount of mass going through the groove.  The model predicts the 
potential increase in flow modulation by using saw-toothed grooves could be 10.4 times 
                                                 
‡ The saw-tooth serpentine valve structure was proposed by Prof. Greg Nellis and initial modeling was 
performed by Nick Guldan at the University of Wisconsin and includes figures 3-26 to 3-29 
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the modulation using rectangular valve seat augmentation.  See Fig. 3-26 for an 
illustration of a saw-tooted valve seat. 
 
Fig. 3-26:  A representation of a saw-toothed valve seat that relies on larger groove 
openings on the inlet side of the valve.  A saw-tooth valve geometry can yield 
up to 10 times the flow for set valve seat length. 
 
The angle applied to create a saw-tooth valve has significant initial impact that 
marginally diminishes with an increasing angle (Fig. 3-27).  The ratio of inlet over outlet 
is an effective measure of the degree the valves are saw-toothed.  A value of one implies 
rectangular grooves.  A value of 200 implies perfectly saw-toothed grooves. 
The model also predicts that flow rate increases with decreasing the land width.  In 
the flexure and membrane suspended valves, the land is 50 micron thick.  The limiting 
factor, outside of manufacturability, is the ability for the thinner valve seat to withstand 
the pressure drop across it.  The valve experiences high pressure on the inlet side and low 
pressure on the outlet side, and it must maintain enough material to support itself against 
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that pressure difference.   A valve land width of 10 µm would provide 2.86 times the flow 
of an identical geometry with a 50 µm width (Fig. 3-28). 




















Fig. 3-27:  A graphical representation of the increase in relative flow rates through valves 
with different groove ratios but the same valve seat perimeter.  The more 
pronounced the saw-tooth effect, the greater the flow rate.  Valve parameters 
for the simulation are summarized in the table in Fig 3-23. 
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Fig. 3-28:  Analysis of the relative flow rates of similar valves with a change in the width 
of the valve seat.  Valve parameters for the simulation are summarized in Fig 
3-23. 
 
Increasing the depth of the grooves provides another mechanism for increasing 
the flow rate through the valve.  Increasing the groove depth reduce loss by allowing 
more flow area for the fluid travelling through the valve.  This groove depth is limited 
primarily by the manufacturing aspect ratio, but also by the same structural limitations 
listed above.  Increasing the groove depth increases the stress on the valve seat.  The 
model predicts increases in groove depth from 100 to 500 µm would increase flow 
modulation by a factor of 1.21 (Fig. 3-29). 





















Fig. 3-29:  Analysis of the flow rate variations for valves with identical parameters 
except for the depth of the groove that resides on either side of the valve seat.  
Valve parameters for the simulation are summarized in the table in Fig 3-23. 
  
 One method of creating saw-tooth valves is to create a pinwheel or starburst 
pattern with the inlet of the valve on the interior of the circle and the outlet of the valve 
located external to the starburst geometry.  This allows for a concentric, uniform design 
that maximizes both the total valve seat perimeter and the inlet to outlet ratio required to 
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gain the benefits of a saw-tooth structure.  The design parameters for a starburst valve 
geometry are summarized below (Fig. 3-30) 
Variable Description Min Max 
A Width of the tip of a valve seat wedge 5 µm 20 µm 
B Width of the base of the valve seat wedge 50 µm 400 µm 
L Length of the valve seat wedge 100 µm 3000 µm 
α The angle that the ends of the wedge form 1° 45° 
r1 This is the outer radius of the boss area 4000 µm 5000 µm 
r2 Imaginary radius of the ends of the wedge 800 µm 4000 µm 
 
 
Fig. 3-30:  A graphical representation of the parameters used to optimize the starburst 
pattern designs. 
 
The total length of the valve seat is and the advantage gained from using saw-tooth 
grooves are the most important factors in maximizing the flow rate through the valve.  An 
analytical model for the total flow area (tF) through the valve with a 30 µm wide seat 
(Eqn. 3-9) was developed that takes into account the total valve seat length (tL) and the 













π  (3-9) 
The total length of the valve seat analytically calculated from the valve geometry and 
is dependent upon the length of a wedge (L), and the total number of wedges (nW) in an 
entire circle.  If the wedge angle (α) is relatively small (<10°) the number of wedges can 
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be approximated (Eqn. 3-10) from the imaginary inner circle radius (r2) and the width of 
the base of a wedge (B). 
 
)30/()2(2 mBrnW μπ +≈  (3-10) 
   The improvement in flow rate the results from the saw-tooth groove structures is the 
“flow multiplier” (fM).  A linear approximation for the flow multiplier was extracted 
from the saw-tooth analysis presented earlier is provided in Eqn. 3-11.  This equation 
only applies for a B/A ratio of 20 or less.  Anything beyond that is considered to have an 
fM of 10.   
)52()(1 ×+= ABfM  (3-11) 
The total flow area for a valve with a boss radius (r1) of 4500 µm and a width tip width 
(A) of 10 µm is graphically represented in figure 3-31 with varying widths of the wedge 




Fig. 3-31: The total effective perimeter length (left axis) as a function of the inlet width 
of a single valve wedge for different wedge lengths.  Simulations are for 
valves with a boss radius of 4500 µm, wedge tip width of 10 µm, and a valve 
seat width of 30 µm. 
 
 
-  - 
75
This diagram suggests that the optimal length of B is approximately 200 µm, but 
this is slightly inaccurate due to the linear assumptions made about the flow multiplier.  
Instead, a wedge gap (B) of about 150 µm was used because it compensates for 
mathematical errors in an adjustment direction that is unlikely to have a negative impact.  
Using these values (B = 150 µm, r1 = 4500 µm, and A = 10 µm) we can solve the value 
of L that yields the maximum effective flow rate.  This value is at exactly one half of the 
length of r1, or 2250 µm.  This dictates a valve geometry with 97 wedges each requiring 
less than 4° of the outer arc. 
In addition to analytically designing the valve geometries to provide high flow rates, 
pressure sensors are simulated to function in the range of system pressures.  This analysis 
allows maximization of the pressure sensitivity while maintaining functionality up to one 
atmosphere of pressure (100 kPa).  The diaphragm stress for 100 kPa of differential 
pressure should not exceed ~600 MPa.  The following table highlights the maximum 
sensor diaphragm radius for various thicknesses (in steps of 250 µm) that have stress at 
differential pressures of 100 kPa of less than 500 MPa. 
Membrane Thickness 
10 µm 20 µm 30 µm 40 µm 50 µm 
S (MPa) Rad S (MPa) Rad S (MPa) Rad S (MPa) Rad S (MPa) Rad 
385 750 385 1500 477 2500 385 3000 245 3000 
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Fig. 3-32: FEA simulated diaphragm stress for sensor membranes of varying thickness 
and radius at 20 kPa of differential pressure.  The circle represents the 
operating point of the membrane suspended valve. 
The membrane suspended valve has a 40 µm thick sensor membrane with a radius 
just under 1750 µm.  This membrane deflects 16 µm and experiences 130 MPa of stress 
at 100 kPa of differential pressure.  The starburst valve must have smaller sensors that 
approach three times the sensitivity to improve delivery control (Fig. 3-32).   
 
Fig. 3-33:  Simulated diaphragm deflection for sensor membranes of varying thickness 
and radius at 20 kPa of differential pressure.  The circle represents the 
operating point of the membrane suspended valve. 
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Figure 3-33 indicates that different geometries may experience different membrane 
deflections for various operating points.  A potential linear approximation error occurs 
when the deflection is larger than a small percentage of the radius. Predictable and linear 
sensor designs should avoid this condition because of the deviations that result. 
When comparing sensitivities to the membrane suspended pressure sensor, relative 
sensitivities can be calculated by comparing simulated stress in various manifold sensor 
designs (Table .  This is accomplished by comparing membrane induced stress at an 
arbitrary operating point (differential pressure of 100 kPa).  The highlighted value is the 
membrane suspended pressure sensor. 
Table. 3-1: Simulated diaphragm stress and deflection comparison for various sensor geometries 
Membrane Thickness 1X 2X 3X 
10 µm    
Radius (µm) Not simulated 500 750 
Stress (MPa) Not simulated 209.5 385.4 
Deflection (µm) Not simulated 6.7 34.4 
20µm    
Radius (µm) 1000 1275 1500 
Stress (MPa) 170 266.7 385.4 
Deflection (µm) 13.6 33.2 68.8 
30 µm    
Radius (µm) 1500 1750 2250 
Stress (MPa) 170 232 385.4 
Deflection (µm) 20.4 237.7 103.2 
40 µm    
Radius (µm) 1750 2500 3000 
Stress (MPa) 130 266.7 385.4 
Deflection (µm) 15.9 66.3 137.5 
 
This analysis assumes the dopant implantation will be near enough to the surface to 
mitigate the effects of variable membrane depths relative t stress.  While this analysis 
suggests the best sensor can be achieved with a 10 µm membrane thickness, a larger 
thickness is used for structural support to increase processing yield.  During processing, 
the ring thickness and radius have to sustain pressures that push against an unsupported 
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boss.  These forces include liquid pressure involved in wet etching or cleaning the wafer.  
Additionally, after assembly, the operational deflection (and stress) occurs across the ring 
membrane when the valve is closed.  The process information is necessary to determine 
the risks associated with various designs, and the device needs to successfully operate 
with at least 100 kPa of differential pressure in typical operation modes. 
Two dimensional axis-symmetric simulations were done using ANSYS to determine 
different device layer sizes with different ring radii that would not mechanically fail 
during processing or device operation.  Failure during processing occurs when the 
pressures on the diaphragm from fabrication steps cause the boss to deflect (Fig. 3-34a).  
If deflection and stress exceed the mechanical limits of silicon, the valve boss and 
membrane would burst; leaving a gap in the wafer and ruining the valve.  The valve can 
also fail during device.  This occurs if the fluid in the valve is at a high pressure; the high 
internal pressure causes the unsupported ring of the diaphragm to bend and potentially 
burst (Fig. 3-34b).  The boss does not deflect in this case because it is mechanically 
supported by the PZT stack actuator.  These simulations are used to determine valve 
geometries that should not experience more than 500 MPa of stress to prevent mechanical 
failure during fabrication or operation.  The simulations assume a boss thickness of 500 
µm, a boss radius of 4500 µm, and a diaphragm radius of 5500 µm.  These values are 
close enough to final geometries that the simulations below are applicable for variations 
of 30% in any dimension. 
Processing pressures on the diaphragm are not likely to exceed 20 kPa if care is taken 
in fabrication steps that involve moving the wafer back and forth when immersed in 
aqueous solutions (like BHF).  Simulations with 20 kPa pressure were done to understand 
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the effects of processing on the entire membrane and boss for determining fabrication 
tolerances.  The simulations assume a boss thickness of 500 µm and a boss radius of 4500 
µm (Fig. 3-34cd).  A wafer with a 10 µm thick diaphragm requires more delicate 
handling during force inducing process steps than a 20 µm diaphragm.  It also suggests 
that a 10 µm device layer should have a ring radius less than 1000 µm to prevent 
mechanical failure due to 500 MPa of stress; a 20 µm thick device could be designed 
with a ring radius of up to 1600 µm without mechanically failing.  Additionally, the 
greater the deflection, the less mechanical resistance the membrane has against valve 
actuation.  It is apparent that a 10 µm membrane with a ring radius of 400 µm or greater 
will not significantly alter the mechanics of the valve.  This is also true of a 20 µm 








Fig. 3-34:  (a) A profile of the valve showing the boss, diaphragm, and bulk silicon on the 
perimeter of the device.  The boss will experience significant pressures during 
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fabrication, and because it is unsupported it will deflect and cause stress at the 
boss/ring joint that could cause mechanical failure (b) A profile of the valve  
showing a boss supported by a PZT stack.  Pressure differences between the 
operating fluid and the ambient environment will cause diaphragm ring 
around the boss to deflect.  This deflection and associated stress may cause 
mechanical failure during valve operation. (c) Stress induced on the 
membrane caused by boss deflection for 20 kPa of processing pressure for 
different ring radii and diaphragm thicknesses (d) Boss deflection under the 
same conditions 
 
Typical inlet pressures during valve operation are expected to range from 0 to 100 
kPa.  The stress induced at 100 kPa differential pressure should not exceed 500 MPa to 
prevent mechanical failure during operation.  To meet these conditions the radius of a 10 
µm thick membrane can not exceed 1000 µm and the radius of a 20 µm device layer can 
not exceed 2000 µm.  Ring deflection with these geometric constraints is less than 20 μm.  
Simulations to determine geometries unlikely to mechanically fail during processing and 
operation suggest the valve should be designed with a 20 μm membrane.   
 
(a)              (b) 
Fig. 3-35: (a) Stress induced in the diaphragm ring for operating pressures of 100 kPa 
with varying diaphragm thicknesses and ring radii (b) Deflection of the center 
of the diaphragm ring for the same operating conditions 
 
3.3.4 Experimental Results 
Partially-open starburst valves and manifolds were tested at room temperature with N2 
gas flow and isopropyl alcohol (IPA).  N2 gas was introduced to the inlet of the valve at 
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varying gauge pressures, while the outlet was connected to a flow meter and vented to 
atmosphere (Fig. 3-36).  The flow rate was measured as both regular and high-flow 
valves were actuated with various voltages.  Normal flow valves were tested with valve 
actuation voltages ranging from -30 to 90V.  Flow was modulated with inlet pressures 
from 0 to 23.5 kPa with a maximum flow rate of 521 ml/min (Fig. 3-37). 
 
Fig. 3-36: Schematic of the gas tests.  Nitrogen is routed to both sides of the manifold and 
is controlled by inlet valves.  The manifold regulates flow rates for pressures, 
and the flow meter detects the actual rate.  Single starburst valves are tested in 
a similar manner with only a single inlet channel used for testing. 
 
In a similar test using the same experimental structure, high-flow valves (assembled 
at 0V) demonstrate flow modulation with lower valve actuation voltages ranging from -
20 to 40V.  Flow was modulated with inlet pressures from 0 to 23.5 kPa with a maximum 
flow rate of 419 ml/min (Fig. 3-38).  These flow rates are 5x greater than those exhibited 
by either the flexure or membrane suspended valves with the same voltage difference. 
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Fig. 3-37: Flow rates in a normal-flow starburst valve for actuations voltages ranging 
from -30 – 90 V with differential pressures up to 23.5 kPa and a maximum 
flow rate of 521 ml/min 
 
 
Fig. 3-38: Flow rates in a normal-flow starburst valve for actuations voltages ranging 
from -30 – 90 V with differential pressures up to 23.5 kPa and a maximum 
flow rate of 521 ml/min 
 
Both normal and high-flow valves were tested at 14 kPa of differential pressure with 
a wide range of differential actuation voltages.  The hysteresis due to piezoelectric 
actuation can be seen in the flow rate variations for various set voltages (Fig. 3-39).  The 
hysteresis curve direction is repeatable and dependent upon the polarity applied to the 
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actuator.  The flow rate ranged from 445 to 57 ml/min in the high flow valve and from 
336 to 64 ml/min in the normal flow valve. 
 
  Fig. 3-39: left: hysteresis of a high-flow starburst valve for increasing and decreasing 
actuation voltage with flow ranging from 445 to 57 ml/min; right: hysteresis 
of a normal-flow valve at 14 kPa with flow ranging from 336 to 64 ml/min 
 
The preferred voltages for use in a drug delivery system range from 0-80 V due to 
limitations of charge pumps and power regulation.  Normal-flow valves modulated gas 
flow from 100% when fully open to 64% of this flow within this preferred actuation 
range.  In contrast, high-flow valves provided a dynamic range of 100% to 12% of total 
flow with the same actuation (Fig. 3-40).  Further gas flow data and information on a 
capillary-driven sealant technique can be found in Appendix A. 
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Fig. 3-40: Normal and high-flow valve performance at 14 kPa of differential pressure.  
High-flow valves provide greater dynamic range using actuation voltages 
preferred by the drug delivery system design.  
 
For liquid modulation, experiments were conducted using regulated Ni gas to 
pressure a liquid reservoir.  Pressure driven IPA flow is regulated into the individual 
inlets of the manifold by external valves (Fig. 3-41).  Flow leaving the valve manifold (or 
single valve) is determined by recording the travel of air bubbles through a 1 m catheter 
at the outlet of the device.  The catheter is similar in length and size to those used in 
intrathecal drug delivery implants.  This mimics the output resistance experienced in the 
drug delivery system and allows for more accurate characterization of the liquid flow rate 
as it pertains to the targeted system application.  Liquid tests conducted on a normal-flow 
valve with pressurized IPA demonstrate flow modulation ranges necessary for intrathecal 
drug delivery.  A dynamic flow range regulation of 100% down to 8% is realized in the 
preferred 80 V actuation range (Fig. 3-42).   
 
 
Fig. 3-41:  Schematic of the liquid tests.  Nitrogen is used to pressure fluid in a large 
reservoir.  The pressurized fluid is independently routed to each side of the 
manifold, and a video camera records the travel of bubbles through a 1 m 
catheter tube to determine the flow rate through the valve. 
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Fig. 3-42: Normalized flow rate of one side of a normal-flow starburst manifold at 14 kPa 
differential pressure for varying actuation voltage.  The target dynamic range 
is realized in the preferred 80 volt operating range. The flow is regulated from 
100% down to below 10%. 
 
Further tests were conducted on a normal-flow manifold to determine mixing from 
the independently regulated flow channels.  Flow from valve A (one side of the manifold) 
varied from 1.77 mL/hr to 0.028 mL/hr and valve B varied from 2.12 mL/hr to 0.38 
mL/hr (Fig.3-43).  This flow range represents typical intrathecal drug delivery flow rates.  
When both valve A and B were open together, flow rates combined from each valve 
within two separate regimes.  At high flow rates, the catheter resistance dominated flow.  
At lower flow rates, valve resistance dominated, and the combined flow rates were close 
to the individual flow rates of each valve added together. 
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Fig. 3-43:  Flow rate of alcohol through individual and combined valves in a manifold at 
14 kPa.  Catheter resistance is greater than valve resistance at low voltages 
outside preferred operating region.  This results in reduced modulation.  
Mixing also functions as expected, and is particularly evident in the lower 
flow rate regimes. 
 
The pressure sensors are comprised of four boron doped piezoresistors on a silicon 
diaphragm.  T-Supreme 4 was used in conjunction with the data from the pressure sensor 
in the membrane suspended valve design to simulate and design the Boron piezoresistors.  
The results indicate that the resistors should have a sheet resistance of about 5.3×103 Ω/□ 
and a resistance of 112.6 kΩ.  Several resistors were tested at room temperature and 
resistance varied between 100 kΩ and 150 kΩ indicating close correspondence with 
simulation.  The resistors are arranged in a Wheatstone bridge configuration.  The 
pressure sensor was driven at 5 V as the differential output voltage was monitored.  
Multiple pressure sensors were monitored over 3 days to determine linearity and 
sensitivity (Fig. 3-44).   
At room temperature, the pressure sensors have a sensitivity of 698 ppm/kPa.  This is 
almost double the sensitivity of the sensors used in the membrane suspended valve design.  
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The device does exhibit a change in offset and sensitivity associated with temperature 
that needs to be accounted when it will be used in an implant.   
 
Fig. 3-44:  Characterization of pressure sensors with nitrogen gas.  Typical differential 
voltage from a piezoresitive pressure sensor Wheatstone bridge in a manifold 




Different types of valves were developed to address the design specifications for the 
throttle element in the implantable drug delivery architecture.  This work also addresses 
preliminary investigation into embedding sensors and using versatile assembly 
techniques and geometries.  The multiple valve designs and associated testing provide a 
robust background against which future regulatory designs can be compared and 
evaluated to meet specific drug dosing requirements. 
This work involved the design, fabrication, assembly, and early stage testing of three 
types of valves; one of which was designed as a manifold.  The first valve was suspended 
by flexure springs and was fabricated using an SOI wafer and a glass wafer.  The second 
valve design was a membrane suspended valve.  The third valve design utilized a 
starburst geometry and was fabricated in a manifold.  Membrane suspension allows for 
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easily embedded sensors, and also reduces the liquid channel dead volume when 
compared to flexure suspension.  The fabrication was modified from the flexure 
suspended valve process to include sensors and to increase device yield.  Further process 
modification was done for the starburst design to allow for greater pressure sensitivity 
and more accurate flow range regulation.  The valves were assembled with a PZT 
actuator in a ceramic encasing in a process that can set the gap to a predetermined un-
actuated height.      
All valves were tested for gas flow regulation across variable pressures.  Actuation 
voltage and respective valve seat displacement is very similar in all valves because they 
share a common actuation mechanism.  This allows for uniform control mechanisms to 
be developed regardless of the specific valve suspension or seat geometry.  Additionally, 
liquid flows have been characterized using both styles of valve and both sides of the 
manifold.  Results suggest that a membrane suspension is more suited for use to regulate 
delivery of a drug from a liquid reservoir in an implantable drug delivery device, and 
multiple pressure sensors are better for accurately monitoring system performance. 
Membrane suspended valves have positive and negative characteristics when 
compared to flexure suspended valves for use in delivery medication.  The membrane 
suspended valves are greater than twice the volume (2.25 cm3 compared to 1 cm3), 
deflect slightly less for a given voltage (due to the stiffer suspension), and have a lower 
maximum inlet pressure because of the bursting of the pressure sensor cavities.  This 
lower inlet burst pressure is due to a lower failure point of the pressure sensor membrane.  
This is further reduced when attempting to increase sensitivity by reducing the stiffness 
of the sensor membrane.  This lower pressure limit reduces the maximum pressure that 
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the reservoirs can generate, and ultimately reduces the maximum flow rates the drug 
delivery device can achieve.  Despite these relative drawbacks, membrane suspension is 
used in the preliminary system because of the use of embedded sensors, lower leakage 
levels, reduced channel volume, and higher fabrication and assembly yield. 
In summary, this piezoelectric design process allows for application specific 
microvalve variations while retaining a common assembly and actuation technique 
throughout.  Membrane suspended valves are easily integrated with embedded sensors to 
form throttles that are able to provide feedback for control algorithms to manage flow.  
Furthermore, a starburst geometry and manifold fabrication allow for membrane 
suspended valves to be integrated on the same substrate.  Valves were tested with gas and 
liquid flow across a variety of conditions to determine static and dynamic response over 
extended time periods.  These preliminary results provide the necessary components to 
design and fabricate the rest of an implantable drug delivery system.  
 





RESERVOIR SPRING DESIGN, FABRICATION, AND PERFORMANCE 
 
The compressive reservoirs that provide mechanical pressure to drive drug delivery 
from the system (Fig 2-1) can be designed in a variety of ways.  The two mechanical 
spring designs used in this work are very different in structure, material, and fabrication, 
but they both apply force to a polymer balloon to pressurize liquid.  More detail on the 
design, fabrication, operation and modeling of silicon torsion springs is in Section 4.1, 
metal compressive sleeves is in Section 4.2, and discussion on reservoir design is in 
Section 4.3. 
  
4.1 Silicon Torsion Springs 
4.1.1 Device Structure and Operation 
Using silicon bulk fabrication techniques to create z-axis mechanical springs is a 
relatively well developed technique.  An example of this technique is a valve that uses 
flexure springs to allow for deflection while creating the spring force necessary to return 
the membrane back to its initial position.  Traditional z-axis springs are designed with 
serpentine patterns in silicon to form “leaf” springs.  A 15 mL reservoir that operates by 
pressurizing polymer chambers with traditional leaf springs would require large, long 
devices.  This is due to springs generating force proportional to their length and 
displacement.  Our PET balloon reservoir is 4 mm in diameter.  In order to generate 
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reasonable force and achieve 4 mm of out-of-plane deflection, leaf springs would have to 
be approximately 10 cm long on each side of the balloon.  Torsion springs are a compact 
alternative because the torque (T) is dependent upon the spring constant (Kθ) and the 
angle of deflection (θ).  The tangential force at the end of an arm is the torque divided by 
the length of the arm (Eqn. 4-1) 
θθ ×=×= KlFT   (4-1) 
This means that the z-axis force from a torsion spring depends on the incident angle of 
the spring, the torsion spring constant, and torsion arm length (l) (Eqn. 4-2).    
lKFz /)()cos( θθ θ ××=  (4-2) 
Torsion springs are less dependent upon spring size for force generation than traditional 
leaf springs because the rotational spring constant and the arm length affect the final size.  
In order to increase the total force and, subsequently, the pressure generated by the PET 
reservoir, many parallel springs can used in conjunction.   
Torsion springs with the rotational plane set orthogonally to the spring arm would 
require wide spacing between parallel springs.  This limits the number of parallel springs 
that could apply force to a polymer balloon.  To increase the number of parallel springs, 
the torsion arms are set at 60˚ to the rotation plane.  This increases the overall width of 
the device, but it allows significantly more springs to generate pressure simultaneously.  
The torsion springs are designed to deliver the most torque in the smallest area while not 
exceeding the physical constraints of bulk silicon or the limits of fabrication technology.  
They were iteratively simulated using ANSYS.  The final serpentine torsion springs 
consist of bends that measure 40 µm deep, 60 µm wide, and 150 µm long.  The reservoir 
is pressurized by 50 springs in parallel.  The springs at the rear of the reservoir are stiffer 
 
-  - 
92
then the springs at the front.  This creates a force gradient that allows the reservoir to be 
emptied from the rear before the front like a tube of toothpaste.  The average total spring 
length is 3500 µm on either side of the reservoir. 
 
4.1.2 Device Fabrication 
The microspring fabrication process uses a silicon-on-insulator (SOI) wafer which 
has an epitaxial layer, a buried oxide layer, and bulk wafer thicknesses of 40 µm, 0.5 µm, 
and 400 µm, respectively (Fig. 4-1).  The use of the SOI wafer in the fabrication process 
permits the buried oxide layer to provide an etch stop for deep reactive ion etching 
(DRIE), while the epitaxial layer provides a well-controlled spring thickness and bulk Si 
properties.  PECVD oxide is deposited on the front side of the wafer.   
 
Fig. 4-1: Process for spring SOI wafer with DRIE etch to define springs and backside 
release DRIE etch and HF dip 
 
Photoresist is deposited on top of the oxide and lithographically patterned to define the 
torsion springs.  The oxide is then plasma etched.  Both the photoresist and oxide act as a 
mask while a DRIE etch down to the insulating layer from the top side of the wafer 
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defines the bulk silicon springs.  About 5 μm of PECVD oxide is deposited on the back 
side of the wafer.  Photoresist is deposited on top of this oxide layer and patterned into 
release windows.  The PECVD oxide is plasma etched.  Next, both the oxide and 
photoresist act as a mask for a 400 μm DRIE etch to the insulating layer.  Lastly, the 
device wafer is etched in HF to remove the insulating and oxide masking layers and 
release the springs.  To prevent stiction from destroying the springs, the wafer is rinsed 
with water and then immersed in methanol.  The methanol is evaporated to finish the 
spring release.   
The reservoir is assembled from the silicon bulk springs, a PET angioplasty balloon, 
and a bulk plastic substrate.  The PET balloon is secured to the plastic base using epoxy.  
The torsion springs are then aligned to the balloon, and the edges of the die are secured to 
the plastic base using epoxy.  The PET tubing for the inlet and the outlet of the reservoir 
are connected to nozzles that act as an interface between the balloon reservoir and the 
Tygon tubing (ID 1.52 mm) used to interconnect the entire system.  
 
 
Fig. 4-2:  SEM of the torsion springs showing twists of torsion beams 
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4.1.3 Modeling and Experimental Results 
Rotational spring deflection was achieved by inserting solid tubing into the springs 
(Fig. 4-2).   The springs rotated to achieve the necessary deflection.  Reservoirs can be 
characterized by monitoring resultant pressures as they are.  The experimental setup (Fig. 
4-3) used a gas to liquid pressure conversion method that was very similar to the valve 
flow rate tests.  The gas pressure was slowly increased and then held constant as the 
deflection of the valve was measured.   
 
 
Fig. 4-3:  Setup to measure deflection of springs using z-axis focal adjustment 
 
After the measurement, the pressure was again increased and the process was 
repeated until the balloon was completely filled.  The balloon was then allowed to empty.  
The process was repeated several times to verify functionality.  As the PET reservoir was 
inflated, the springs underwent z-axis deflection and lost focus.  This deflection was 
measured by setting the springs into focus on an optical microscope before applying 
pressure, and then lowering the entire device with a z-axis micrometer stage actuator after 
pressure was applied.  Once the image of the springs returned to focus, the distance the 
stage travelled was recorded as the deflection of the springs for a given inlet pressure.  To 
prevent measurement errors, the stage was only lowered, never raised.  Also, the entire 
measurement structure was reset for each empty-to-full reservoir test.  The optical 
 
-  - 
95
deflection measurement techniques have an error of ± 5 µm.  The torsion springs 
deflected up to 4 mm as the reservoir was inflated (Fig. 4-4).  The spring deflection for 




Fig. 4-4:  Photo of springs after balloon insertion showing 4 mm out of plane deflection 
  
ANSYS simulation data was used in a MatLab model of deflection and z-axis force.  
The spring force translates into reservoir pressure via the cross sectional area of the 
beams that are in contact with the PET balloon.  The predicted results from simulation are 
plotted against the actual measured results of spring pressure and deflection (Fig. 4-5).  
The simulated results are of the same order of magnitude, but the actual results show a 
deviation from simulation at both low and high pressures.   
 
 
Fig. 4-5:  Measured and predicted z-axis spring deflection and resultant force and 
pressure. 
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The variations can be due to differences in fabricated spring dimensions versus modeled 
dimensions.  They can also be the result of the mechanical properties of the PET balloon.  
It was modeled as contributing no effect, but it takes force to initially expand, and 
requires a high force to expand after it is filled to its nominal volume. 
 
4.2 Metal Compressive Sleeve Springs 
4.2.1 Device Structure and Operation 
Traditional methods for pressurizing reservoirs in drug delivery systems include using 
gas, mechanical springs, material elasticity, or osmotic pressures.  Most require 
significant volume when compared to the volume necessary for the fluid itself, which 
diminishes the VER of the final implantable system.  This problem is magnified if the 
system is scaled down in overall volume.  In contrast, elastic compression of the reservoir 
may have low dead volume if properly designed.  Compressive springs are used to 
pressurize the reservoir because they take little volume, generate necessary pressures, and 
plastically deform instead of break.   
The compression reservoir springs are fabricated in a mesh. The springs are batch 
fabricated in a sheet, and wrapped around the balloon to form the compressive sleeves 
(Fig. 4-6). 
 
Fig 4-6: The springs are designed as flat mesh sheets that are rolled around the balloon to 
compress the liquid inside and generate pressure  
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The liquid container is a PET balloon measuring 20 mm in diameter, and 60 mm in 
length.  This provides a total reservoir volume of 18.85 mL.  This is comparable to the 
volumes of the current intrathecal drug pumps made by either Medtronic or Codman 
(ranging from 15 mL to 50 mL). 
The material used to form the spring is 45% cold-reduced sheet Elgiloy.  Elgiloy is a 
Co-Cr-Ni alloy in 100 µm sheets.  Material information for Elgiloy was found for 40% 
and 50% cold-reduced, so the material properties used in spring design were taken as an 
average of the two.  This material was chosen for springs because of its high elasticity.  It 
also is ductile, so plastic deformation occurs before the springs physically break.  Actual 
and estimated material properties were taken from Matweb (www.matweb.com) and are 
summarized in Table 4-1.    
Table 4-1: Elgiloy Sheet Material Properties 
 40% Cold Reduction 50% Cold Reduction 
45% Cold Reduction 
(Estimated) 
Density 8.3g/cc 8.3g/cc 8.3g/cc 
Tensile Strength (ultimate) 1440 MPa 1620 MPa 1530 MPa 
Tensile Strength (yield) 1170 MPa 1310 MPa 1240 MPa 
Poisson’s Ratio 0.226 0.226 0.226 
Modulus of Elasticity 189.6 GPa 189.6 GPa 189.6 GPa 
Elongation at Break 4% 3% 3.5% 
 
 
Fig. 4-7:  Four Cells of a balloon mesh are shown.  Stiffer springs have dimensions (A: 6 
mm; B: 600 µm).  More expandable springs have dimensions (A: 10 mm; B: 
600 µm) 
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The springs were designed as a mesh that consists of a single cell that is continuously 
repeated to form a sheet that can be rolled into the compression sleeve.  Four cells with 
the direction of expansion are shown with relevant dimensions (Fig. 4-7). 
 
 
4.2.2 Device Fabrication 
Fabrication of the planar springs is done by photochemical machining (PCM) of a 
bulk metal sheet.  PCM, or chemical blanking, is a process that utilizes a laser-defined 
mask to lithographically pattern a photoresist (PR) layer covering the base metal layer 
[ASM89].  The PR is developed and the unprotected metal is etched with a heated spray 
of etchant.  In this way, intricately patterned flat metal parts can be produced, with 
thicknesses ranging from 10 µm to 1.6 mm.  The base metal sheet is typically 300 x 450 
mm, although larger sheets can easily be processed. 
PCM is derived from printed circuit board etching processes, so most common 
photoresists and etchants are geared towards processing copper.  However, with 
appropriate surface treatment (to promote photoresist adhesion) and modified etchants, 
many other metals can be processed. The photoresist is typically laminated onto both 
sides of the base metal layer, and both sides are exposed simultaneously.  Typical 
etchants include ferric chloride, cupric chloride, sodium hydroxide, hydrochloric acid, or 
even hydrofluoric acid for especially chemically resistant metals.  Among others, copper, 
aluminum, stainless steel, nickel alloys, platinum, tungsten, and even titanium can be 
processed with an appropriate etchant.  The etching is an isotropic process, so masks are 
adjusted for undercut based on the thickness of the part.  Feature sizes are constrained, 
and the minimum size is usually equal to the thickness of the work piece.  Tolerances of 
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+/- 10% of the part thickness are typical.  Material removal rates are approximately 10 - 
50 µm/min, although looser tolerances can allow for faster etching. 
One advantage of PCM includes burr-free processing of thin metal without distortion 
or other physical changes to the work piece.  Additionally, very hard and brittle metals 
are machined without difficulty.  Of importance to this work, Elgiloy can be processed 
with PCM.  Chief disadvantages of PCM include the limitations imposed by the 
chemistry of the work piece, as well as the fact that sharp radii cannot be produced due to 
the undercut involved in the isotropic process. 
 
                                                            A                                                 B 
 
C                                       D 
Fig. 4-8:  (a) The compressive sleeve and the polymer balloon used to form an 18.8 mL 
reservoir. (b) A reservoir filled with green water inside an expanded sleeve 
demonstrating the expansion of the diamond shape cells. (c) Relaxed Elgiloy® 
spring mesh showing the springs cells in an un-actuated rectangular shape. (d) 
Stretched springs in a diamond shape.  In all cases, the cell windows are each 
600 µm x 6 mm. 
 
Once the springs are fabricated, the planar sheets are rolled into sleeves and bonded at 
the seam with epoxy.  The reservoirs are assembled by inserting a 60 mm long 20 mm 
diameter PET angioplasty balloon into the metal springs (Fig. 4-8a).  Once the balloon 
has been inserted into the compressive sleeve, it is inflated with nitrogen gas to condition 
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the springs.  The first generation springs are 100 µm thick, the beams are 150 µm wide, 
and the mesh cell size is 600 µm by 6 mm.  An unrolled sleeve is 60 mm long by 10mm 
wide.  The reservoirs each hold 18.8 mL and have an un-pressurized volume of 4.7 mm.  
A fully inflated liquid reservoir (Fig. 4-8b) clearly demonstrates the uniform expansion of 
the mesh cells of the springs. 
 
4.2.3 Modeling and Experimental Results 
The spring mesh was modeled by simulating half of a cell with correct boundary 
conditions in ANSYS and extrapolating the results for application to the entire sheet.  
The cell was tested by deflecting the spring 600 µm.  The simulation software then 
partially relaxes the springs to ease extreme transitions that may cause simulation error.  
A final step is conducted in which the springs are released entirely and are allowed to 
relax to a default state.  This is different then the initial state to due to plastic deformation 
that occurs during the initial expansion.  This simulation uses in-plane forces and stresses 
to predict the forces the compressive springs will provide when curled around a balloon.  
The assumption is that the out of plane deflections (total bend angle of a cell is about 4 
degrees) will not have a dramatic impact on the final device performance.  This 
simulation mechanism was tested by simulating both a single half-cell (with the correct 
simulation parameters), and simulating an entire sheet.  The results were the same.   
Two different mesh sizes were chosen for the trade-off between total deflection and 
total pressure.  Spring type A is designed with a higher spring constant.  It delivers higher 
forces, but deflects a smaller amount before plastic deformation occurs.  The second 
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spring is designed to deflect much more (this reduces “dead” volume) but it has a lower 
spring constant and generates smaller forces. 
The volume change of reservoirs designed from two spring types are compared in Fig. 
4-9.  The stiffer springs expand from an initial diameter of 10 mm to a final diameter of 
20 mm.  This leaves a 25% unpressurized reservoir volume when they are un-stressed.  
The second spring geometry has an initial diameter of 6.66 mm.  These springs have only 
an 11% unused volume. 
 
Fig 4-9:   Comparison of initial and fully actuated spring sizes and reservoir volumes 
 
 
The spring model parameters were determined by using the forces and stresses from 
ANSYS coupled with calculations based on hoop-stress equations.  The stiffer springs are 
designed to generate about 18 kPa of pressure when the reservoir is full.  The softer, 
larger deflection springs generate about 5.3 kPa when full.  An interesting option with 
these types of springs is the ability to apply them in parallel.  Two or more sleeve springs 
can be wrapped around the same balloon to double (or triple etc) the pressure generated 
from a single reservoir.  This allows many different configurations with very limited 
changes to fabrication.   
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The planar metal springs are tested by stretching and measuring force generation for 
varying displacements.  Each side of an unrolled spring sheet is affixed to a metal rod.  
This acts as a simulacrum for pressurized expansion because it distributes the force 
applied to the mid-point of the rod along the sheet evenly.  Fixing one side of the sheet 
and attaching the other side of the spring sheet to a force transducer on a micrometer 
stage distributes forces along the bonding edge of the spring uniformly.  The micrometer 
stage slowly deflects the springs while the force is measured (Fig. 4-10).  The springs are 
measured after fabrication and again after they are stretched 20 mm to condition them 
with plastic deformation similar to that which occurs when they are used in a fully 
inflated reservoir.  Conditioned springs have a spring constant of 305.7 N/m.  The 
measured spring constant and plastic deformation closely match the finite element 
analysis (FEA) simulation results from ANSYS software during the design phase 






Fig. 4-10: (a) Measured load characteristics of the mesh springs as a function of linear 
conditioning (stretching). The unconditioned spring constant is 407.3 N/m and 
the pre-conditioned spring constant is 305.7 N/m. (b) Measured reservoir 
pressure generated for various balloon/sleeve distension.  From 12 mm to 19 
mm, the pressure is generated by the springs. Beyond 19 mm, the balloon 
elasticity changes the profile. Fully inflated, the reservoir is 20 mm in 
diameter and generates almost 15 kPa. 
 





Reservoir development addresses the need to store and pressurize medication in an 
IDDD with a valve regulated architecture.  This work investigates multiple balloon 
pressurization methods by using two different spring types.  In one type, silicon was 
etched into planar torsion springs, and in the second type, Elgiloy was fabricated in 
planar mesh sheets and rolled into compressive sleeves.  The torsion springs and the 
compressive sleeves are combined with a PET angioplasty balloon to transfer the spring 
force into pressure.  Both methods generate pressures for most of the liquid volume of the 
reservoir, and the mechanisms themselves take relatively little volume.   
Pressure was applied using nitrogen gas, and the displacement of the springs was 
measured.  The experimental results agreed with design simulations reasonably well.  
Additionally, both reservoir types have been filled with liquid and exhibit similar 
decreasing volume with decreasing pressure tendencies.  Results suggest that spring 
pressure can be used to regulate delivery of a drug from a liquid reservoir in an 
implantable drug delivery device.  The multiple reservoirs and associated testing provide 
a robust background that allows for similar development methods to be used in designing 
future devices for other target applications.   
Compressive Elgiloy springs have both positive and negative characteristics when 
compared to silicon torsion springs for use as the mechanical force transducer in a 
pressurized reservoir.  The metal springs have less device volume, are cylindrical in 
shape, are liable to plastic deformation instead of breaking, and are easier to fabricate and 
assemble.  The principal drawbacks of the metal springs are lower pressure generation 
when fully inflated (15 kPa compared to almost 80 kPa), the use of a metal instead of 
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silicon (making integration of sensors more difficult), and greater unused liquid volumes.  
This lower pressure limit reduces the maximum flow rates the drug delivery device can 
achieve.  Despite these relative drawbacks, the metal sleeves are used in the preliminary 
system because of robustness, reusability, smaller dead volumes, and ease of fabrication. 
In summary, reservoirs have been designed that meet system requirements.  
Compressive sleeve springs are easily designed and assembled with PET balloons into 
reservoirs that have title total dead volume.  Reservoirs were characterized with gas and 
liquid to determine their properties for use with the PZT throttle valve.  These 
preliminary results provide the necessary reservoirs to use in conjunction with membrane 
suspended valves for the design and fabrication of a complete drug delivery system.  
 





PRELIMINARY SYSTEM RESULTS 
 
This work describes the development of a preliminary drug delivery system using a 
less complicated architecture than the design suggested in Chapter 2 (Fig 5-1).  A single 
valve and reservoir are used to regulate flow from the implantable device while 
maintaining a relatively high volume efficiency.  More details on partial assemblies, 
demonstrated diffusion, control algorithms, electronic circuit implementation, and 
complete system results are in the following sections.     
 
Fig.5-1:  System overview: A large reservoir is pressurized with compressive sleeves and 
regulated by a microvalve to control drug delivery rates.  Control is regulated by 
onboard electronics that allow for pressure monitoring and reprogramming. 
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5.1 Control Algorithms and Electronics 
5.1.1 Circuitry and Power Consumption 
Drug delivery system lifetimes are typically dependent upon battery life.  Battery life 
can be extended by enlarging the battery, or by reducing the power consumption.  The 
reservoir uses no electrical power, and the PZT valves only consume significant amounts 
of power when they are adjusted.  The primary source of power consumption is the 
electronic circuit board.  This requires board design, component selection, system 
functionality, and programming to be optimized for power consumption.  The electronics 
should be powered from a single battery.  The system should include multiple sensor 
inputs, storage of complex delivery programs, drive the valves across operating voltages, 
and wirelessly communicate with an external programmer used by a medical professional.  
This functionality should be implemented with the smallest battery possible that allows 
the entire system to run for 5 years. 
The circuit has several functions, the most important of which is control of the 
delivery rate.  Control is achieved as follows: the input from the differential pressure 
sensor is amplified and read into the microcontroller.  This sensor data is processed, used 
in control algorithms, and the valve actuation voltage needed to realize the desired flow is 
generated by the charge pump amplifier.  Minimally, the control system includes multiple 
sensor inputs, storage of complex delivery programs, and capacity to drive the valves 
across operating voltages.  Circuit board design, component selection, system 
functionality, and programming optimization for power consumption may yield 
substantial reductions in battery requirements.  The system electronics are designed with 
the long term goal of a 5 year system lifetime. 
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The prototype control PCB (Fig. 5-2) is designed to use feedback from the embedded 
sensors to operate the system.  The circuit is designed to operate from a battery providing 
3-4 volts.  The battery regulator is selected for power efficiency and is the LT 1761 from 
Linear Technologies.  The microprocessor selected to control the chip is the 
MSP430F169 made by Texas Instruments.  It is well suited to this application because it 
has the necessary peripherals (ADC and DAC), a low power sleep mode in which it 
consumes 2 μW, and power consumption of 600 μW when active.  Capacitive boost-
boost amplifiers (LT3482, Linear Technologies, California) are used to amplify the 
output signals from the microprocessor to power the PZT actuators.  The differential 
input from the piezoresistive Wheatstone bridge pressure sensors are amplified and 
converted to a single-ended output voltage by AD623 instrumentation amplifiers from 
Analog Devices.  These amplifiers are shut-down when they are not reading pressure, 
greatly reducing their power draw.  The preliminary circuit board is a double-sided, two 
metal layer board that measures 4 cm x 6 cm.  The CC1100 from Texas Instruments is the 
chip used for wireless communications in the ISM band.  The preliminary circuit board is 
a double-sided, two metal layer board that measures 4 cm X 6 cm. 
Different control algorithms can both be implemented using the embedded pressure 
sensors, the compressive spring pressurized reservoir, and PZT microvalves.  The sensors 
can be used in multiple ways to determine the flow rate.  Given this flow information, 
continuous delivery can be regulated by slowly adjusting the aperture of the valve to 
compensate for decreasing pressure.  It could also be regulated by using duty cycle 
control that appears continuous to the patient at the catheter/CSF interface because of 
fluidic capacitance effects.    
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Fig. 5-2: A block diagram outline of the electronics is overlaid on an image of the actual 
control PCB that is 4 cm X 6 cm and powered from a 3V battery.  The pressure 
sensor input is amplified and read by an ADC.  This data is used in the closed 
loop control algorithms implemented in the microcontroller.  The PCB is 
capable of independently controlling two valves and has the circuitry necessary 
to enable wireless communication for data readout and reprogramming.   
 
Additionally, a bolus dose can be delivered by fully opening the valve until the 
desired volume is delivered.  These continuous and bolus control algorithms can be 
combined to generate unique delivery profiles or respond to environmental stimuli.  The 
implementation of the control algorithms and other circuit functions will dominate the 
power consumption of the device, but there are several trade-offs between power 
consumption and delivery accuracy that can be used to reduce the battery drain.   
 
5.1.2 Control Algorithms and Valve Power Consumption.    
In analyzing the power consumption of continuous flow, it is necessary to consider 
the reservoirs and the actuation of the valves.  The reservoirs generate pressure as a 
continuous function of stored volume (V) (Eqn. 5-1).  
)(VfP =  (5-1) 
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The flow rate (Q) is related to the differential pressure (P) between the reservoir and 
the delivery load through the hydraulic resistance of the serial combination of the valve 
and catheter.  For an unactuated open valve, the minimum hydraulic resistance is 7.32 x 
1012 Pa/m3, which is 10 times the resistance for a 1 m long catheter (6.519 x 1011 Pa/m3).  
Therefore, the valve approximately defines the resistance of the system, and regulates 













Fig. 5-3: (top) Calculated voltage needed to actuate the valve to maintain a set flow rate 
for various reservoir pressures (middle and bottom) Calculated change in flow 
rate over time due to changes in valve constriction at various error rates.  The 
frequency of valve adjustments decreases over time due to non-linearity in the 
reservoir. 
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The delivery rate can be determined by monitoring the change in reservoir pressure 
(Figure 5-3).  This mechanism requires no information about the valve for accurate 
continuous and bolus flow regulation. 
Another regulation mechanism involves setting an initial flow rate and 
maintaining it by periodically increasing the throttle aperture to compensate for the 
decrease in the reservoir pressure as the reservoir is emptied.  Assuming the valve is at a 
particular set aperture, the flow rate is determined by the differential pressure across the 
valve divided by the flow resistance.  The reservoir pressure changes as material flows 
from it, so the flow rate for a specific aperture is a function of volume and consequently, 
time (Eqn. 5-3).  The highest possible actuation voltage is 120 V, and at this voltage, a 





errset ==+=  (5-3) 
For a constant set point, there is a set flow (Qset) and an acceptable deviation from this set 
point (Qerr) such that the flow rate remains within an acceptable error range.  The flow 
rate function h(t) will slowly decay because the reservoir pressure drops as material flows 
out of it.  The initial time (ta) and the final time (tb) that the flow rate will be within the 
error bounds for a particular set point can be determined (Eqn. 5-4).   
)(1 errseta QQht +=
− ; )(1 errsetb QQht −=
−    (5-4) 
The power consumption (U) of the valve is a combination of the continuous power 
draw and the valve transition energy multiplied by the switching frequency (Eqn. 5-5).  
The transient energy consumption (Echange) is estimated at 376.8 µJ per switch based on 
experimental observations for a valve assembled with three PZT actuators (PLO55.31, 
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Physik Instrumente, Germany).  The transient power consumption is much greater than 
the leakage for actuation frequencies that are greater than one stroke every 5 minutes. 
 










×=×≈ −−  (5-6) 
 
The stroke frequency for a specific error rate is the inverse of the error period and is 
used to determine the power consumption.  The result (Eqn. 5-6) is an analytical formula 
that allows the error rate, set point, and power consumption levels to be adjusted with 
respect to each other for any chosen application.  
The typical range of delivery for intrathecal medication varies from 0.2-5.0 mL/day.  
Analytical models were built from empirical data taken from the PZT microvalve and the 
compressive spring reservoir.  These models were used to simulate drug delivery from 
the system at various constant flow rates.  Figure 5-3 represents the regulation of delivery 
from a typical reservoir with varying error (5%, 1%, .02%) over one day.  The stroke 
frequency for delivering 0.2 mL/day with a 5% error is 2.1 adjustments/day.  The primary 
power consumption at this switching rate is due to current leakage through the 
piezoelectric actuator.  Conversely, the worst case power consumption scenario requires 
one adjustment every four minutes to regulate 5.0 mL/day with 0.2% accuracy.  Using a 
maximum accuracy of 0.2%, the average power consumption of the throttle is 1.68 µW.  
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5.1.3 System Power Consumption and Noise of First Generation Systems 
A worst case power consumption of the valve for any possible operation was 
determined to be 1.6 μW.  Additionally, a preliminary circuit design consumes less than 
10 mW of power when not communicating via the wireless interface.  The current power 
consumption is due to added features not necessary for operation, and should be reduced 
to at most 1 mW with the implementation of power management features.  Further power 
optimization techniques (software implementation) could reduce the non-communicating 
power to approximately 100 μW without any hardware restructuring.  Communications 
only occur once every 3 months and currently consume approximately 30 mW of power; 
so they can be ignored.  Circuit consumption of 1 mW will yield a battery life of 120 
days with a standard rechargeable AA battery.  After fluid flow and medical issues are 
addressed, power consumption can be reduced.  This should yield a system with a battery 
life of 3-5 years powered from a single AA Li-on cell.  
The circuitry is very important in accurately reading the pressure from the embedded 
sensors.  Sensitivity of the circuit, drift, and repeatability are the parameters that 
determine the ability to regulate delivery within tolerance and need to be addressed in the 
readout circuitry. 
The pressure of the reservoir is linearly related to the flow rate through the reservoir.  
A medically viable flow rate can be achieved above 500 Pa.  The maximum error in 
delivery due to sensor properties will occur at this minimum pressure, and it needs to be 
less than 2.5% of the delivery rate.  The minimum resolvable pressure difference needs to 
be 12.5 Pa to achieve this.  The embedded pressure sensors are piezoresistive Wheatstone 
bridges that provide a linear (within 2%) differential voltage.  The pressure sensors 
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exhibit slightly different initial offset voltages (within +/- 2% of the supply), and have a 
sensitivity of 250 ppm/kPa.  The pressure sensors are calibrated before and after 
assembly of the device, and a polynomial linearization is used to create a memory model 
that the microcontroller uses to determine the actual pressure.  The full scale pressure 
range the sensor needs to realize is 0-20 kPa with a 3.3 V power source.  The sensor 
output enters a differential amplifier.  From there the amplified signal is converted by a 
12-bit analog-to-digital converter (ADC).  The minimum pressure step the electronics can 
resolve is 4.886 Pa.  This corresponds to an ADC input of 0.8 mV.  The electronic 
sensitivity is well below the 4.886 Pa threshold required.  The pressure sensor is not 
limited by the DAC, but it may be limited by noise. 
Noise in piezoresitive diaphragm circuits come from three sources: mechanical 
vibrations, electrical noise in the piezoresistors, and electrical noise in the interface 
circuit.  The mechanical noise is dominated by viscous forces.  The second noise source 
is electrical noise from the piezoresistors and is Brownian in origin.  These noise sources 
are usually dominated by interface circuit.  The noise from these three components, 
respectively, is provided in pressure-equivalent units by Eqn. 5-7: 






   (5-7) 
Here, Ra is the mechanical resistance coefficient per unit area; B is the system bandwidth; 
Vs is the source voltage; and S is the sensitivity. In this case, the interface circuit is an 
AD623 with a minimum resolvable voltage difference (ΔVmin) of 200 µV.  The pressure 
resolution limit due to this is 0.24 Pa.  The noise generated from the interface circuit is at 
least an order of magnitude less then the minimum resolvable unit of the ADC, and is 
well with the specifications of the pressure sensor. 
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Another source of pressure sensor error can occur from drift.  Long term drift needs 
to be studied to verify that it is within tolerable limits.  If necessary, the pressure sensor 
can be re-calibrated every time the reservoirs are refilled.  Temperature can also cause 
sensor drift, and this can be calibrated out when used in conjunction with the internal 
temperature sensor. 
Additional flow rate errors can arise from hysteresis in the PZT valve.  The effect of 
hysteresis varies on the method of control being employed.  If continuous flow regulation 
is the only technique employed, hysteresis can be accounted for by following one side of 
the actuation vs. deflection curve.  This is accomplished by slowly opening the valve and 
never closing it until there is a refill.  If bolus or mixed regulation methods are employed, 
the hysteresis needs to be calibrated and an internal model that accounts for increasing or 
decreasing voltage needs to be coupled with the pressure sensor linearization to derive 
the flow rate. 
 
5.2 Diffusion Regulation 
5.2.1 Experimental Results 
Intrathecal drug pumps deliver medication into cerebral fluid in the spine by pressure-
driven diffusion.  Tests to confirm diffusion regulation were conducted using integrated 
valves and reservoirs filled with fluorescent dye for regulating delivery into agar gel.  
These tests were conducted with normally closed valves that were actuated at 30 V 
during assembly.  A silicon spring reservoir was completely filled before each diffusion 
experiment was conducted.  Fluorescent images of dye diffusion were taken every 30 s 
for 5 min for various actuation voltages.  This test demonstrates control over a wide range 
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of diffusion rates with varying voltage (Figure 5-4).  A beveled needle tip resulted in the 
noticeable non-circular diffusion patterns.  The results indicate that the mechanism of 
diffusion does not present a barrier to this delivery architecture. 
 
Fig. 5-4: Microvalve regulated fluorescent dye diffusion from a spring pump into agar gel.  
The setup is on top and typical fluorescent images taken for different valve 
actuation voltages are shown over time.   
 
5.2.2 Analysis  
In order to verify that valve regulation is the only element responsible for the changes 
in diffusion rate, analysis of the experimental data has been done.  Constant-source 
diffusion models based on Fick’s law (Eqn. 5-8) were mapped to fluorescent intensity at 
various modulation levels presented by the valve (Fig. 5-5) using specialized Matlab® 




xerfcNtxN ×=   (5-8) 
The model assumes spherical diffusion from the needle that acts like a constant 
source.  The software was used to determine constants for every point independently.  
 




Fig. 5-5:  The normalized output of total fluorescent intensity of diffusion into agar gel for 
actuation voltages over time. 
 
 The Dt product for every point was determined using the constant source diffusion 
model and a least squares fit (Fig. 5-6).  The slope of the Dt products is the time 
independent diffusion constant for a given modulation voltage applied to the valve.  The 
very close linear fit of these independently determined diffusion constants is expected, 
and it lends credence to the model.   
 
 
Fig. 5-6: Extracted Dt values for infinite source diffusion plotted with modeled diffusion 
Dt values showing close fit validating the model  
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The determined diffusion constants were inserted in the constant source model, and it 
was then used to predict time-based diffusion distances for particular fluorescent 
concentrations across actuation voltages (Fig. 5-7).  This model makes several 
assumptions for simplification, but accuracy suggests that valves can be used to achieve 




Fig. 5-7: Observed distance of a set intensity compared to the expected distance based on 
the diffusion model of the system. 
 
5.3 Housing and Assembly 
A complete system requires the development of a long-term biologically compatible 
housing containing the components necessary for drug delivery.  The preliminary 
prototype is made from aluminum; the final device for implants will likely be made from 
biocompatible titanium.  The metal encasement contains a microvalve, a large reservoir, 
the control circuitry, a battery, and has two ports for refilling the reservoir and accessing 
the catheter.  The prototype housing measures 4.5 cm X 8.5 cm X 3.4 cm with 1 cm 
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beveled edges.  The housing has a total volume of 113 cm3 with a total reservoir volume 
of 37 cm3.  This prototype has a relatively high VER, but it can be further increased by 
improving the component form factors and the assembly procedure.   
Table 5-1: Comparison prototype device with current commercial intrathecal implantable pumps. 
 SynchroMed EL SynchroMed II IsoMed Proposed Device 
Manufacturer Medtronic Medtronic Medtronic U. Michigan 
Volume (cm3) 123 cm
3, 156.7 
cm3 91 cm
3, 121 cm3 111.7 cm
3, 135 
cm3,172.2 cm3 73.9 cm
3 
Weight (empty) 185, 205 g 165, 175 g 113, 116, 120 g 80g 
Reservoir Size 10, 18 ml 20, 40 ml 20, 35, 60 ml 37 ml 
Battery Life 6.5 years at 0.5 ml /day 
7 years at 0.5 ml 
/day No battery 15+ years 
Flow Rate 
(ml/day) 




0.3, 0.5, 1.0, 1.5, 
4.0 
(constant flow) 
0.1 – 30  
 (programmable) 
 
The current ports attached to the prototype are micro vascular access ports made by 
Instech Laboratories.  The access ports are designed for long term subcutaneous 
implantation and are designed to sustain hundreds of needle punctures and up to 690 kPa 
back pressure.  The assembled prototype in the housing can be seen in Figure 5-8.  
 
 
Fig. 5-8:  A drug delivery prototype pictured during assembly.  A polymer reservoir is 
pressurized with Elgiloy compressive sleeve springs and regulated by the PZT 
microvalve to control drug delivery rates.  The entire device takes up about 130 
cm3.  The inset is a photograph of the closed device with the refill and catheter 
access ports prominently displayed.  
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5.4 System Results 
5.4.1 Pressure Sensor Control and Delivery 
Continuous flow delivery requiring differential pressure and duty cycle based 
regulation both require characterization of the valve to be properly implemented.  In 
contrast, bolus flow regulation requires a pressure sensor and characterization of the 
reservoir.  With proper sensor arrangement, both techniques are combined to provide 
information about the delivery rate, reservoir volume, and increase delivery accuracy.   
Pressure sensor errors may be caused by non-linearity in the piezoresistors, the 
resolution of the digital-to-analog converter, and unaccounted differences between the 
operating temperature and the calibration temperature.  During laboratory testing and 
calibration, photocurrents induced in the wires connecting the valve to the circuit may 
also contribute to errors.  Since the pressure sensor readings are used to determine valve 
settings in this architecture, errors in pressure measurement will translate into flow 
inaccuracies.  Additional flow inaccuracies may result from approximations used for the 
valve response, unforeseen drift in piezoelectric actuation, or changes in the mechanical 
loading along the length of the catheter.  The compounding effects of these errors may be 
reduced by simultaneously characterizing the system for pressure and flow in two-
dimensions.  
Pressure and flow properties were characterized by flowing nitrogen gas through 
valves at several actuation voltages.  The inlet pressure was monitored with the 
embedded PZT pressure sensor as well as a capacitance manometer (727A Baratron®, 
MKS Instruments, Massachusetts) that provided an accurate reference pressure.  Sensor 
error was recorded as the discrepancy between the embedded sensor and the reference.  
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Averaging 128 pressure sensor measurements over a time period of one second reduced 
the error in the system.  Pressure sensor and flow rate results for a typical valve are 
partially displayed in a two-dimensional error map in Figure 5-9.  The flow rates that 
were evaluated were typical of intrathecal delivery ranges.  The average pressure sensor 
error was less than 1.04 kPa, and the average deviation from the target flow rate at any 
pressure was less than 6.4% of the maximum flow rate for that pressure.  Well 
characterized valve mappings may be interpolated to create continuous functions or look-
up tables to control the system with acceptable delivery error. 
 
Fig. 5-9:  A two dimensional mapping of continuous flow regulation measuring the 
average pressure sensor error and the corresponding actual flow versus the 
target flow rate.  The pressure sensor average error is less than 1.04 kPa and the 
average deviation from target flow is less than 6.4% of the maximum flow for a 
particular pressure. 
 
Tests were conducted for both continuous and bolus delivery.  Third order 
polynomial models were built from empirical data taken from the PZT microvalve and 
the spring pressurized reservoir and incorporated into a microprocessor program to 
regulate continuous flow,  Flow measurement was performed by observing the distance 
travelled by an air bubble in a delivery catheter.  Tests typically ran from 8 hrs to as long 
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as a week.  One typical test (Figure 5-10a), demonstrated average delivery accuracies of 
3.22% with no deviation from the flow rate worse than 9.09% at delivery rates of less 
than 0.2 mL/day.  Additionally, the total delivered volume over the 6 day period was 
3.003 mL with the expected total volume being 3.015 mL.  This represents a long term 





Fig. 5-10:(a) Controlled long term flow from the assembled system in a typical reliability 
test.  In these tests, reservoirs were refilled through the insertion port and were 
programmed with specific delivery schedules.  In this instance, a system was 
programmed to deliver 155 μL/day for three days followed by 180 μL/day for 
the next three days.  Actual flow rates are recorded by monitoring the distance 
an air bubble traveled along a catheter.  The flow rates for each set-point have a 
maximum deviation from the target flow rate of 9.09% and an average deviation 
of 3.22%.  The total volume delivered was within 0.39% of the target volume 
for the time period.  (b) Programmed delivery of 6 mL in four boluses of 1.5 mL.  
The volume delivered was 5.971 mL. 
  
Bolus delivery was conducted with a microvalve and reservoir model using a 
calibrated pressure-volume relationship.  A program was implemented to deliver a total 
volume of 6 mL in four 1.5 mL bolus doses.  The throttle valves were actuated at 40 V 
according to the pressure-volume relationship of the reservoir that had been previously 
determined (Figure 11b).  These results suggest the methodology used to regulate flow 
can achieve high accuracies. 
 
 




This effort has resulted in the successful design and realization of a prototype system 
for eventual use in intrathecal drug delivery.  Piezoelectric microvalves were assembled 
and used as the throttle mechanism to regulate flow.  Compressive springs made from 
rolled Elgiloy sheets generate fully inflated reservoir pressures of almost 15 kPa and were 
pre-conditioned to increase repeatability.  Control electronics were designed to regulate 
flow using embedded pressure sensors within the valve.  The valves, reservoirs, 
electronics, and access ports were integrated with a metal casing to form a complete 
prototype with a total volume of 113 cm3 and a reservoir volume of 37 cm3.  With 
appropriate refinements to the component form factors and assembly procedures, the 
reservoir volume can be doubled leading to a VER of approximately 60%.  Several 
delivery tests were conducted for both bolus and continuous flow delivery.  Four bolus 
units were delivered with a total error of 0.48%.  Continuous flow programs were also 
implemented in one of two ways.  Either the valve was slowly adjusted (opened) to 
maintain a set flow rate, or a changing duty cycle was used to maintain a set flow rate.  In 
six day tests conducted at low flow rates (0.1-0.2 mL/day), delivery was regulated with 
average accuracies of 3.22% and a total delivered volume that was within 0.4% of the 
target. 
Drug delivery systems utilizing this architecture can be scaled up or down for various 
applications; this can be done by changing the reservoir size, shape, or the valve 
modulation range.  Additionally, specific un-powered flow rates can be set by assembling 
the throttle valves with a nominal gap that meets delivery needs.  This can be used to 
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create a failsafe delivery (in cases of power loss) that can prevent hazardous withdrawal 
or overdose effects.  The valve can be easily altered to include embedded sensors that 
measure other physical properties to increase the information available to the clinician.  
Additionally, the current sensors can be used to improve the accuracy and the safety of 
the device.   In summary, valve regulated drug delivery holds promise as a volume 
efficient, versatile, and safe architecture for an intrathecal system.  
 





SECOND PROTOTYPE SYSTEM RESULTS 
 
This chapter describes the development of a second generation preliminary drug 
delivery system using a different architecture than the design in Chapter 2 (Fig 6-1).  A 
two-valve manifold and two reservoirs are used to regulate flow from the implantable 
device.  Section 6.1 details the housing assembly and component; section 6.2 reviews 
system testing, and section 6.3 is a summary discussion. 
 
Fig.6-1:  System overview: Two polymer reservoirs are pressed by a plate attached to 
compressive springs to generate pressure.  Two valves in a manifold are used to 
regulate drug delivery rates.  Control is regulated by onboard electronics that 
allow for pressure monitoring and reprogramming. 
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6.1 Housing Assembly, and Components 
The complete system requires the development of a long-term biologically 
compatible housing with integrated components necessary for delivery monitoring and 
regulation.  This prototype is made from stainless steel using traditional machining 
processes.  An actual realization of the implant would likely be made of biocompatible 
titanium.  The stainless steel housing contains a two-valve manifold, control circuitry, 
two PE reservoirs, a steel pressure plate, traditional springs, three access ports, and a 
battery.  The system housing measures 5.08 cm X 9 cm X 3 cm with 5 mm beveled edges.  
The housing has a total volume of 130 cm3 with a total reservoir volume of 40 cm3.  This 
prototype has a VER of 30.7 % but it can be increased by integrating system components 
into the housing more efficiently.  The assembled prototype in the housing can be seen in 
Figure 6-2.  
 
 
Fig. 6-2:  A second generation drug delivery prototype pictured during assembly.  Two 
polymer reservoirs are pressurized using a spring-loaded plate.  Flow is 
monitored and regulated by a PZT actuated valve manifold with embedded 
pressure sensors.  The entire system takes up about 130 cm3.  Inset is a 
photograph of the closed system with the refill and catheter access ports.  
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The reservoirs in this prototype are made from Polyethylene (PE) and are pressurized 
through compression by a metal plate (Fig. 6-3).  The reservoirs have an inlet tube from 
the refill port and exit tubing to the manifold and inlet pressure sensor.  The reservoirs are 
fabricated by heat sealing sheet polyethylene into the desired shape to fit within the 
housing cavity designed for the pressure plate.  The reservoirs are stacked on top of one 
another and compressed traditional springs drive the pressure plate against the top 
reservoir, which, in turn, presses against the bottom reservoir.  There are tracks in the 
plate and in the casing to maintain alignment of the plate, springs, and reservoirs.  The 
pressure response of the reservoir is adapted to specific system needs by altering the 
compressive springs used to drive the pressure plate 
    
Fig. 6-3:  A photograph of a reservoir before it is inserted into the system.  There reservoir 
is connected to the refill port and interconnect tubing that leads to the manifold 
and a pressure sensor. 
 
A prototype was developed using two centralized compressive springs designed to 
generate forces necessary to drive flow at intrathecal drug delivery rates.  The reservoirs 
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were characterized inside of the housing by filling each one with 1 mL of isopropyl 
alcohol and measuring the resultant pressure using the internal pressure sensors (Fig. 6-4).  
The outlet tubes were sealed closed to prevent outflow and subsequent transient pressure 
measurement variation.  The most sensitive pressures occur when the reservoirs are 
significantly depleted.  Reservoirs generated pressures from 0 kPa when completely 
empty up to 5.17 kPa at 10 mL of total volume.  This represents a typical increase of 0.52 
kPa/mL which is an acceptable pressure profile for system functionality.      
 
Fig. 6-4:  Results from one reservoir filling test where each reservoir was filled with IPA 
in 1 mL increments.  Results for fill volumes up to 10 mL suggest a linear 
pressure profile of 0.52 kPa/mL. 
 
 
6.2 System Tests 
6.2.1 Testing Methods 
The changes in implementation from the first prototype to the second allow for a 
series of testing that is more analogous to the use of the final system in multi-drug 
delivery protocols.  This is principally enabled by the use of multiple reservoirs and the 
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use of inlet and outlet pressure sensors.  An experimental method was developed to allow 
for both the testing of the regulation of multiple flow paths and preliminary testing of 
medically relevant techniques. 
 
Fig. 6-5:  A schematic of the entire system under test.  A cylinder at the outlet of the 
device is used to simulate intrathecal pressure.  The schematic is labeled to 
signify important nodes at which partial system test results may be monitored. 
 
A complete schematic of the experimental set-up includes refilling the reservoirs 
from the refill port through delivering medication into a pressurized cylinder to mimic 
pressures in the intrathecal space (Fig 6-5).  The schematic is labeled at the major 
branches for reference; for example, the outlet of the manifold is labeled as O1.  The 
structures for individual tests are described in relation to this schematic.  For example, the 
reservoir characterization discussed previously could be referred to as a test where IPA 
was driven into the inlet ports (I1 and I2) and the reservoir outlets (P1 and P2) were 
sealed while the pressure was monitored. 
During testing, three variants were most commonly used.  The complete system tests 
used absolute pressure sensors at the inlet and outlet ports.  The inlet pressure sensors are 
MEMS absolute pressure sensors from Freescale with a range of 0-200 kPa (MPXA4250) 
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and the outlet pressure sensor was a MPXA6115 from Freescale (range of 0-115 kPa).  A 
one channel variant replaces the polymer reservoirs with gas pressurized liquid from an 
N2 canister using feedback and set-point control.  In this scheme, only one side of the 
manifold is used for testing.  The second valve in the manifold was flooded with IPA (to 
remove all air bubbles from the device) and was sealed at the inlet to allow no air in or 
alcohol out.  The inlet pressure sensor was a Baratron absolute pressure sensor from 
MKS.  A second one sided variant uses the complete system schematic, except, instead of 
using two pressurized reservoirs, on channel was sealed and only one reservoir was used.  
This variant was used to test individual channels via superposition before testing the 
finished system. 
 
6.2.2 Catheter Kinks, Catheter Disconnects, and MRI Compatibility 
There are several failure and compatibility issues with implantable intrathecal drug 
pumps that are of medical interest.  Three of these issues are delivery catheter kinks (or 
tip occlusions), catheter disconnects from the pump or displacement from the intrathecal 
space, and functionality of the device during an MRI.  Addressing catheter changes and 
MRI compatibility allows for a high level of patient safety when using an implant.    
Traditionally, changes in the state of the catheter are detected by symptoms related to 
alterations in medication rates due to the state change.  Basically, the patient receives a 
change in dosing due to an occluded or disconnected catheter, realizes it, and informs a 
physician.  The physician may then use one of several techniques to determine the actual 
alterations in the catheters; from tracing radioactive dye through the delivery chain to 
surgery to physically investigate.  The use of embedded sensors within the device may 
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allow for the system to detect potential catheter state changes before a patient may notice 
them.  This rapid information dissemination could reduce the time or effects of an acute 
withdrawal of the medication being delivered by the drug pump. 
 
Fig. 6-6:  The outlet pressure sensor before, during, and after the catheter is blocked.  The 
sensor detects a pressure ramp of about 90 Pa/s when the catheter is occluded. 
 
The sensor response for catheter kinks was tested by flowing IPA at a constant rate 
through the manifold, and out the catheter into an air ambient environment.  In an effort 
to simulate the effects of a kink or occlusion, the tip of the catheter was completely 
blocked (C1) and the response was measured on an oscilloscope.  The length of the block 
was varied to determine the sensor response to temporary blocks or severe kinks (Fig 6-6).  
The outlet pressure sensor measured 100.3 kPa of absolute pressure while IPA was 
flowing from an unrestricted catheter.  Once the catheter was occluded, the output sensor 
detected an average pressure ramp of 90 Pa/s while the catheter remained blocked.  This 
consistent pressure change for a blocked catheter was repeatable and occurred at a much 
faster rate than pressure changes occur during normal operation of an implantable drug 
delivery device.  This test represents a preliminary investigation into acute catheter 
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occlusion and suggest that detection of a significant pressure ramp can occur within 
several seconds; at which time the delivery system could beep or otherwise notify the 
user of the situation.   
 
Fig. 6-7:  Oscilloscope traces of the outlet pressure sensor when the catheter is acutely 
disconnected and later reattached to the drug delivery device.  The tests were 
conducted in air ambient; some artifacts of the sensor response may be due to 
test conditions. 
 
The sensor response for catheter disconnects was tested in a manner similar to the 
tests for catheter occlusions.  Instead of blocking the catheter at the delivery point, the 
catheter was manually disconnected from the system at connection point (O1).  The 
sensor output was measured before the disconnect, during the disconnect, and after re-
attachment of the catheter to investigate the capacity of the outlet sensor to determine 
disconnects (Fig 6-7).  Initial tests indicate a significant initial drop in pressure at the time 
of the disconnect.  The sensor then settles at a new output.  This tendency is repeatable in 
the air ambient tests with an acute disconnect.  Some elements of the disconnect pattern 
may be artifacts of the test procedure.  In particular, the magnitude of the pressure drop 
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that is observed at the disconnection of the catheter might be diminished in a pressurized 
liquid ambient.  Further tests to confirm these disconnect results should be conducted 
with various conditions; such as submerged in saline, in tissue, or with an alternative 
disconnection means.  If such tests confirm the capacity for the outlet sensor to almost 
immediately detect acute disconnects,  the delivery system could notify the patient and 
reduce the effects of acute drug withdrawal. 
Magnetic Resonance Imaging (MRI) is a relatively common medical diagnostic 
technique in which the patient is exposed to very strong magnetic fields (~3 tesla).  The 
long-term implantation of an intrathecal drug delivery device makes it likely that some 
patients with implants will experience an MRI.  It is important that the effects of the 
strong magnetic field on the delivery profile are understood so patients undergoing an 
MRI do not experience unexpected changes in dosing.  
 
 
Fig. 6-8:  A diagram of the two radial magnets used for the MRI compatibility test and the 
location of the hall sensor for field strength testing.  The minimum measured 
field strength the manifold experienced was 453 gauss.   
 
Preliminary magnetic compatibility tests for the system were conducted on the 
manifold to determine changes that occur due to the presence and orientation of a 
magnetic field.  Test fields were generated by separating two radial magnets by 3.5 cm 
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with an aluminum spacer that kept the plates parallel and maintained a constant 
separation (Fig. 6-8).   
The manifold was placed between the disc magnets in various orientations to test the 
effects of different magnetic field directions.  A hall sensor was placed in the center of 
the radial discs to determine that 453 gauss was the minimum field strength the manifold 
would experience.  This field was significantly weaker than the strongest fields generated 
by MRI machines, but it was still strong enough to displace ferromagnetic material and 
suffices for a preliminary magnetic compatibility test.    
 
Fig. 6-9:  Magnetic field compatibility tests at two target flow rates.  Magnetic field 
orientation and strength caused no significant alteration in flow profiles through 
the manifold. 
 
Compatibility tests were conducted by constantly flowing IPA through one inlet at 
two different flow rates while blocking the second inlet (Fig 6-9).  Tests were conducted 
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with no magnetic field, with a field going from bottom to the top of the manifold 
(Direction A), with a field going from the inlets to the outlet (Direction B), and with a 
field going across the width of the valve (Direction C).  For set flow rates of both 1 
mL/hr and 0.67 mL/hr, there was no significant variation due to the presence or 
orientation of magnetic fields.  These initial tests suggest that PZT actuators in a valve 
manifold are unaffected by magnetic fields.  Further testing is necessary to determine if a 
regulatory system based on this component is MRI compatible, or if magnetic effects 
cause changes in other features of the system that are not detected in this preliminary test. 
 
6.2.3 System Level Delivery 
In the first preliminary device, successful valve regulation of fluid flow was 
demonstrated using both continuous and duty cycle regulation techniques.  The manifold 
regulated two-reservoir system provides the means for more pertinent tests as they relate 
to intrathecal delivery of mixed drug protocols.  This occurs in two ways; first, having 
inlet and outlet sensors allows the system to regulate flow with varying CSF pressure.  
Second, a two-valve manifold allows the regulation of multiple flow streams to occur 
within a single device. 
Intrathecal drug delivery devices have to drive against the CSF pressure to deliver 
medication.  This pressure varies from person to person, and varies within the same 
person over time based.  Typically, intrathecal pressure varies from 0.7 kPa to 1.8 kPa in 
healthy adults.  Detection and compensation for this pressure variation can be achieved 
by using the outlet pressure sensor. 
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Fig. 6-10: Tests to assess system capability for outlet pressure variation detection in 
which the sensor voltage at the outlet of the manifold compared varied 35.8 
mV/kPa to the actual changes in pressure at the outlet of the catheter 
 
To test the outlet pressure sensor for the capacity to detect intrathecal pressure 
changes, the outlet catheter was inserted into the bottom of a column of water.  The level 
in the column was varied to reflect the ranges of pressure differences that can occur in the 
human body.  A graph of the pressure sensor characterization for varying flow with a 
fixed valve width indicates a linear relationship between the sensor pressure and the 
cylinder pressure with a sensitivity of 35.8 mV/ kPa (Fig 6-10). 
The pressure sensor calibration was then used with flow characterizations of the 
manifold to create a program compensated the aperture to maintain a set flow rate.  In a 
second test, the pressure in the water column was varied while flow rates for 
uncompensated and compensated delivery were monitored (Fig. 6-11).  For valves that 
remained unadjusted by the compensation program, the flow rate behaved as expected 
and decreased from 0.58 mL/hr down to 0.21 mL/hr.  In contrast, the compensated flow 
program adjusted the manifold to maintain a flow rate of 0.58 mL/hr while remaining 
within 0.5 % across outlet pressures.       
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Fig. 6-11: Flow and actuation voltages for changing heights of cylinder pressures to 
represent unregulated and regulated flow using the internal pressure sensor.  
Unregulated flow varied from 0.58 mL/hr to 0.21 mL/hr while regulated flow 
remained within 0.5 % of the target flow rate.  
 
The system was designed to independently regulate delivery from each reservoir.  
Complete system tests were conducted using previously characterized reservoirs and 
manifolds in a system assembled with the same control electronics used for the first 
prototype.  Each inlet was driven from a reservoir that was at the same pressure due to the 
nature of the plate pressurization mechanism.  The inlet pressure was recorded and was 
held constant at 18 kPa.  Flow mixed inside the manifold, and was delivered through a 1 
m long, 500 µm diameter catheter into an air ambient.  One side of the manifold was 
varied from -30 to 90 V of actuation while the second side was held constant at either -30 
or +30 V (Fig. 6-12).  The resultant flow rates represented independent regulation of each 
channel in a manner that is consistent with changing flow resistances along a delivery 
chain.  This is particularly prevalent when Side 1 was either fully open or fully closed.  
When it was fully open, it had a very low resistance and dominated the flow profile.  
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When it was fully closed, it had a very high flow resistance and the set state of Side 2 
dominated the flow profile.   
 
Fig. 6-12: Both sides of the manifold independently regulate flow.  Flow rates typically 
fall within two regimes.  In one regime, one side is significantly more open 
then the other and dominates flow (side of the graph).  In the second regime, 
both valves have similar apertures and contribute to the flow rate (middle). 
 
In controlled flow tests, both reservoirs were pressurized by the spring driven plate, 
filled via the refill ports, and controlled using a 0-60 V duty cycle powering each side of 
the manifold from the control PCB.  A program was instituted to control the flow at 
various target flow rates that were altered during the tests.  The average supply voltage to 
the system was 3.3025 V and the average current draw was 18 mA.  This resulted in an 
un-optimized power draw of 57.6 mWhr for the entire system during operation.  The 
device in its current state could only run 100 hrs from a single NiMH AA battery.  
Additionally, flow rates were well within medical limits of less than 15 % deviation from 
the target delivery rate.  One typical test of this regulation technique is illustrated in Fig. 
6-13.  In this test, three target flow rates were programmed over a 200 minute period, and 
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the resultant flow rates were measured with an instantaneous deviated from the set flow 
rate of no more than 0.01 mL/hr.   
 
Fig. 6-13: A typical duty cycle regulation of flow through the manifold with multiple set 
points.  In this instance, the duty cycle of a 60 V square wave at 0.02 Hz is 
altered to achieve mixed flow at the target delivery rates.   
 
6.3 Discussion 
This effort has resulted in the successful design and realization of a second prototype 
system for use in testing aspects of multi-drug protocols with a valve regulated 
architecture.  Piezoelectric valve manifolds with embedded inlet and outlets sensors were 
assembled and used to regulate flow.  A pressurized plate was driven against two PE 
reservoirs to generate pressures that linearly increased 0.52 kPa per milliliter of volume 
added.  The components were integrated into a stainless steel housing with a total volume 
of 130 cm3 and a reservoir volume of 40 cm3.  Several delivery tests were conducted as 
preliminary investigations into various aspects of intrathecal delivery.  Power 
consumption was 57.6 mWhr, but shows promise for reduction to 100 μWhr with 
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software optimization.  Further reduction to 10 μWhr could be achieved with an 
alternative low-power microcontroller [Han08].  Initial results suggest possible detection 
of catheter occlusions and disconnects.  Testing also indicates that a system based on this 
preliminary design should be unaffected by during an MRI and can compensate for 
changes in spinal fluid pressure.  Several delivery tests were conducted for both bolus 
and continuous flow delivery using flow from two reservoirs.  In summary, valve 
regulated drug delivery holds promise as a volume efficient, versatile, and safe 
architecture for an multi-drug protocol system.  
 
 





TRANSDERMAL POWER TRANSFER MECHANISM 
 
The power transfer mechanism used to recharge the battery in the implantable system 
(Fig. 2-1) can be designed using several techniques.  This chapter describes a power 
transfer mechanism that was designed to allow for direct contact between the recharging 
source and the implanted device.  Further details on the needle and port pairing are in 
Section 7.1.  The device design is discussed in Section 7.2.  Details on the fabrication and 
assembly are in Section 7.3.  Experimental results are reviewed in Section 7.4, and 
Section 7.5 provides are summary discussion. 
   
7.1 Needle and Refill Port Pairing 
7.1.1 Device Overview 
Recharging the battery of an implantable device provides efficiency and convenience.  
It allows designs that require a much smaller battery.  Architectures taking advantage of 
this reduced battery size are able to achieve a greater volume efficiency than traditional 
devices.  This is particularly true for devices that have long implant lifetimes and 
relatively high rates of power consumption like intrathecal drug pumps [Car07].    
Implantable batteries can be recharged through either a direct physical connection, 
through a wireless radio frequency, or an inductive link.  While wireless power transfer is 
possible for very low-power applications [Bov08], DC recharge capability offers higher 
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current levels and may be more suitable for implantable drug delivery devices [Vip07].  
The only connection made between the external environment and the implanted drug 
delivery device occurs while a needle is inserted into the access port during a reservoir 
refill session.  Refill ports typically consist of an external biocompatible housing, a re-
sealing silicone septum, a metal base plate that limits needle penetration, and a gap 
between the septum and the base plate with an exit channel through which the fluid enters 
the reservoir [And90, Str86].  The refill port is typically inset within the drug pump 
housing in a position in which the rounded rim protrudes just above the wall of the 
housing [Rey96].  A normal refill session begins with the puncturing of the septum using 
a non-coring Huber needle until the needle tip presses against the base plate.  Medication 
is then driven into the device from an external syringe [Mor92].  Refills generally require 
10-20 minutes and occur every 8-10 weeks. 
 
Fig. 7-1: The system view:  A two-pole needle is inserted into the refill port of a drug 
delivery device.  Inset:  A close view of the two needle halves making electrical 
contact with springs inside the septum. 
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A method for power transfer through a customized conductive needle designed to 
interface with metal spring electrodes embedded in a refill port was developed for 
implantable drug pumps (Fig. 7-1).   
The needle adapts a current model to allow for two isolated conductive pathways.  
The refill port is designed with embedded metal springs to mate electrically with the 
modified needle.  The system is designed to mate successfully regardless of the rotational 
orientation or insertion angle of the needle.  This prevents the need for the physician to 
rotate or reinsert the needle to make proper contact, which may otherwise create an 
additional risk of infection or patient discomfort beyond that which is already experience 
in the refill process.  
 
7.2 Device Design 
The most important aspects of the design are power handling capability, isolation of 
the drug and tissue from electrical current, and ease of alignment between the needle and 
the port.  In order to transfer DC power, the needle should be composed of at least two 
conductors, or poles, which must mate with corresponding poles in the refill port.  The 
conductive path should also be electrically isolated.  (The isolation is particularly 
important if the needle is being used to refill the drug reservoir at the same time the 
battery is being recharged.  While this capability is not fundamentally required, it can 
improve efficiency and convenience.)  Structural options for providing multiple 
conductive paths in a single needle include the use of multiple conductors within the 
lumen, the use of concentric isolated conductors, or splitting the needle longitudinally 
 
-  - 
143
and isolating the halves.  The split needle allows for simple alignment because it provides 
access to both conductors on the exterior of the needle.    
 
7.2.1 Power Transfer and Needle Design 
While it is relatively easy to transfer data across most electrical connections, it is 
more difficult to transfer current at levels of hundreds of milliamps as required to 
recharge a battery [Sor01].  One challenge is resistive heating in the conductors.  For a 
given conductor, this requires the use of a conductive path with the largest possible cross 
sectional area.  The two methods of creating conductors with the largest cross sectional 
area are either using the needle itself or filling the needle with a conductor.  Using the 
needle itself is preferable to other methods because the lumen remains unobstructed.  
Typical refill needles used in implantable drug delivery devices range in size from 22 
gauge to as narrow as 28 gauge.  The ratio of the inner diameter (r) to outer diameter (R) 
ranges from 0.55 to 0.6 across this needle range.   
  
7.2.2 Refill Port Design 
The refill ports of most implantable drug delivery devices are composed of a polymer 
septum through which the needle enters the device.  The polymer is relatively thick (2-5 
mm), and is designed to reseal itself after the refill needle is removed from the device.  
Below the septum is a small open volume that is connected to the reservoir of the implant.  
The thickness and insulating properties of the septum make it an appealing candidate for 
modifications that would allow power transfer. 
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Fluid ports in conventional implants are typically accessed by non-coring Huber 
needles.  In our design, the power transfer system mates when a multi-pole, non-coring 
needle punctures the PDMS septum of the refill port and is advanced until the tip of the 
needle reaches the metal base plate at the bottom of the port.  (This metal base plate is 
electrically floating.)  Each longitudinal half of the needle is exposed at a “window” on 
its exterior; the “window” for each half is at a different point along its length.  The 
location of metal contact springs that are embedded within the septum and the exposed 
“windows” in the insulation of the needle are designed so the windows align with the 
mating regions when the needle is fully inserted.  This occurs upon every insertion 
because the tip of the needle presses against the bottom base plate of the refill port.  Since 
two separate springs are located at different heights, rotational alignment of the needle is 
not necessary to make electrical contact.  This prevents the need to twist the needle upon 
insertion, and it also prevents mating the incorrect conductors to the springs.  It should be 
noted that the needle and the metal springs in the septum are electrically isolated from the 
casing of the port, the surrounding tissue, and the drug being refilled.  The metal contact 
springs could potentially be replaced by conductive layers that are composed of 
specialized polymers [Ger02] or conductive fibers in a weave [Taj02].  The most 
important criteria for determining the structure of the mating springs are the formation of 
a low resistance contact and the ability to maintain functionality after repeated insertions. 
   
7.3 Fabrication and Assembly 
The two system components requiring custom fabrication are the non-coring needle 
and the refill port.  Two-pole Huber needles (700 µm ø, 26 gauge) for use with a smart 
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refill port are fabricated by lapping two stainless steel needles in half using an oil-based 
diamond slurry (Fig. 7-2).  The needle halves are completely coated in 2.8 µm thick 
Parylene to electrically isolate the halves from each other and from the environment.  
Parylene is selectively removed from areas near the needle tip to create the contact 
windows that mate in the refill port and from the back of the needle to allow contact with 
the power source.  The needle halves are then aligned and bonded [Kim05], with further 
insulation and sealing strength provided by inserting the needle into a 50 µm thick 
Kapton tube.  Stainless steel needles and Parylene are used to create the two-pole needle 
because they are biologically compatible materials.  Additionally, the thin Parylene 
coating does not significantly change the inner or outer diameter of the needle.   
 
Fig. 7-2: The needle is fabricated from biologically compatible materials.  The fabrication 
process creates open conduction paths or “windows” that are self-aligning once 
inserted into the port. 
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The refill port requires a septum designed with contact springs at specific heights to allow 
for self-aligned mating.  The electrical contact springs are fabricated from 100 µm thick 
stainless steel by micro-electro-discharge machining (µEDM) [Tak02, Ric08].  The 
contact springs are 5.2 mm in diameter with four quadrants separated by 300 µm wide 
slots (Fig. 7-3).   
The septum is fabricated by inserting two 100 µm thick stainless steel contact springs 
within the septum at the positions of 4.5 and 5.5 mm above the base plate.  The PDMS 
itself begins at 3.5 mm above the base plate extends to 6.5 mm above the base plate.  The 
septum is 5.88 mm in diameter and is held in place on a shelf in the refill port by 
compression.  A fabricated needle and port are show in Figure 7-4.   
   
 
Fig. 7-3: The septum is fabricated from biologically compatible materials.  Contact 
springs of various heights are created to form contact with the openings in the 
needle coating the conductive needle to allow power transfer. 
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Fig. 7-4:  (a) Photographs of 26 gauge coated needle halves before and (b) after assembly 
taken on a white ruler. (c) A photograph of an assembled refill port in which the 
top contact spring of the septum is clearly visible.  The port is pictured here 
with a US Penny. (d) An implantable drug delivery device with the refill port 
and a similar catheter access port. 
 
The springs press against the needle as it is inserted.  The pressure forces the needle 
toward the middle of the refill port, and it also improves the lead transfer conductance by 
maintaining pressure at the spring/needle junction.  The symmetrical nature of the contact 
springs prevents the need for rotational needle alignment.  Additionally, the springs are 
supported by the PDMS used as the septum polymer and return to their initial positions 
after the needle is removed.  This allows for multiple recharging sessions to occur using a 
single port. 
7.4 Experimental Results 
 
Contact resistance, in both dry and wet ambients, can provide an indication of the 
integrity and power handling capability between the needle and the port.  Higher transfer 
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currents can alter the contact properties of the mating pair, and these changes can be 
monitored while recharging batteries.  Long term viability can be determined by 
puncturing the septum multiple times and monitoring the transient changes in resistance 
and septum deformation.  Proper testing allows for determination of both short term and 
long term properties of the mating pair. 
In mating both conventional Huber needles and two-pole needles with assembled 
refill ports, continuity tests can identify if electrical connections are made as expected 
(Fig. 7-5).  Resistances between the two poles of the needle (A and B), the two septum 
springs (C and D), and the electrically floating metal base plate (E) were measured as 
both types of needles were advanced into the septum.     
 
 
 Not Inserted Partially In Disconnect In Inserted Saline
Conventional Expected Actual Expected Actual Expected Actual Expected Actual Actual (wet) 
A to C Open >10M Short 0.328 Short 0.374 Short 0.367  
A to D Open >10M Short 0.528 Short 0.528 Short 0.532  
A to E Open >10M Open >10M Open >10M Short 1.09  
Two-pole          
A to C Open >10M Open >10M Open >10M Short 0.64 - 1.22 
B to D Open >10M Open >10M Open >10M Short 0.83 - 1.65 
B to C Open >10M Short 1.4 Open >10M Open >10M 2.3M 




Fig. 7-5:  Stages of insertion with resistances color coded to expected states for normal 
and split needles both dry and completely filled with saline after insertion. (All 
resistances are in Ω) 
In a dry ambient, typical resistances for a fully inserted normal needle were about 0.5 
Ω from A to C and D; and 1 Ω between A and E.  The two-pole needles had slightly 
higher resistances from A to C and B to D (~0.7 Ω) but maintained isolation from A to B 
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(1.6 MΩ) and from A to E (greater than 10 MΩ).  The resistance tests also confirmed that 
C and D were electrically insulated from each other and from E.  The slightly higher 
resistances attributed to the two-pole needles were likely due to the decreased cross 
sectional area of the needle, and the decreased contact area between the conductors of the 
split needle and the metallic contact springs.  These tests indicated that both the modified 
and original needles made good electrical contact with the springs.  Additionally, the 
isolation mechanisms of the split needle and the septum functioned as expected.  This 
was verified in the fully inserted state because a normal needle short circuited with both 
springs and the base plate while the split needle functioned as expected. 
Saline is often used as the carrier agent for medication.  Saline can also be used to 
approximate the in vivo electrical conditions experienced by implantable devices.  In a 
separate set of tests, saline was introduced into the needle lumen and the port cavity.  The 
exterior of the port was also immersed in saline.  Insertion tests, similar to those done in a 
dry environment, were conducted in this wet ambient.  As shown in Figure 7-5, 
resistances from A to C and B to D were low (less than 2 Ω), and electrical isolation was 
maintained from B to C and A to E (greater than 2 MΩ).  This suggests that the isolation 
techniques used in the system are effective at isolating the conductive paths from both the 
medication and the surrounding environment.  Additionally, no electrolysis was observed 
in either the needle or in the mated port during characterization. 
One potential limitation on the current levels that can be sustained during a 
recharging operation is imposed by the parasitic resistive heating of the implantable 
device, medication, and surrounding tissue.  In order to determine the resistive heating in 
the needle and at the interface between the needle and the contact springs, the change in 
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temperature was monitored as batteries were recharged.  Two 1.2 V NiMH AA batteries 
were recharged using various current levels at room temperature in a dry environment.  
The air environment restricts the thermal conductance of heat away from the refill port as 
compared to a refill port located subcutaneously in vivo or in an aqueous medium.  
Additionally, a lack of liquid located within, or flowing through, the lumen reduces the 
thermal capacitance of the system and increases the heating of the device for any 
particular power transfer rate.  Typical room temperature recharging with power transfer 
rates ranging from 10-500 mA demonstrated the expected temperature rises at needle-
septum interface (Fig. 7-6) and out on the port housing (Fig. 7-7) of the refill port.  
  
  
Fig. 7-6:  Temperature change at the septum entry point over time for recharging currents 
from 10-500 mA.  The circle in the inset denotes the temperature sampling 
location.  The test was conducted in an air ambient environment with a baseline 
temperature of 22.4 °C. 
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Fig. 7-7:  The temperature change of the exterior of the port housing for battery charging 
currents ranging from 10-500 mA. The temperature increase has resolution of 
0.1°C and was conducted in ambient air with a temperature of 22.4 °C.  The 
circle in the inset denotes the temperature sampling location.   
 
The temperature changes at the needle septum entry point exhibited much higher 
swings because the PDMS septum is not thermally conductive.  This is a location in the 
system that will experience one of the largest temperature increases.  The battery voltage 
was monitored (Fig. 7-8) along with temperature for varying current to confirm the 
batteries were recharging at rates relative to the transfer current.  Typical starting voltages 
ranged from 1.1 V to 1.4 V.  No measureable heating was observed for charging currents 
of 100 mA or less.  At higher current levels (above about 500 mA), modest heating 
occurred: temperature increases were less than 15°C at the septum and 2°C at the casing.  
Overall, these results indicate that this type of port is suitable for rapidly recharging a 
small battery in an implantable drug delivery device. 
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Fig. 7-8:  The voltage increase of a NiMH 1.2 V AA battery as it is being recharged 
across a refill port with various charging currents.  Typical starting voltages 
range from 1.1 V to 1.4 V.  Charging profiles match expected values, and 
demonstrate power transmission with acceptable heating rates for a smart needle 
and port to be used in implantable drug delivery devices. 
 
In addition to forming good electrical connections and limiting heat generation during 
battery recharging, this type of power transfer system needs to be reliable over many 
refill sessions.  This is particularly true for mechanical springs because of potential 
plastic deformation.  Typically refill sessions occur once every 6-8 weeks, and device 
lifetimes range from 5-8 years.  Assuming the device is refilled every 6 weeks for 8 years, 
the refill port could be punctured as many as 70 times.  Puncturing the septum many 
times acts as an approximate simulation of the effect of accumulated refills on the springs, 
silicone, and device connectivity. 
Puncture tests were conducted in an air environment using a refill port and a standard 
Huber needle.  A refill port was punctured one hundred times, and both the resistance and 
images of the septum were captured.  The resistance measurements (Fig. 7-9) varied over 
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0.27-1.4 Ω and exhibited a roughly logarithmic increase with the number of needle 
insertions.   
 
Fig. 7-9:  The resistance of the needle and spring contact resistance across many 
insertions with a logarithmic fit.  The resistance varies from 0.27-1.4 Ω over 
100 punctures.  The logarithmic nature of the resistance indicates that the 
principal changes to the connection occur early in the life cycle of the refill port. 
 
The image data (Fig. 7-10) clearly displays the plastic deformation that occurs to the 
septum springs during the initial insertions.  Additional punctures caused no apparent 
changes to the springs, and only slightly altered the PDMS.  The image analysis indicates 
that plastic deformation in the springs and additional mechanical failures in the septum 
are only likely to manifest themselves during the first few insertions.  This logarithmic 
resistance tendency agrees with the image analysis and further suggests that changes to 
the mechanical properties of the system occur early on in the lifecycle of the device.  The 
long term tendency to approach a stable operating point, in addition to acceptable 
electrical and thermal performance from the complete system, indicates that it could be 
used to recharge batteries in an implantable drug delivery device. 
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Fig. 7-10:  Photographs of the needle septum after a set number of punctures taken under 
a microscope.  The photographs reveal that almost all of the spring 
deformation occurs during the first needle insertion, and subsequent punctures 




Power transfer development addresses the design and specifications for a potential 
method of recharging the battery in the implantable drug delivery architecture.  This work 
focuses on recharging the implanted battery during a refill session every 8-12 weeks with 
enough power to replace what is used between visits.  Transferring electrical power 
through the refill port allows high enough energy densities to be transferred during a refill 
while minimizing impact to system size and complexity. 
This work explored a method for transferring electrical power across a bifurcated 
needle through the refill port of an implantable drug delivery device.  The method is 
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intended for current levels up to 500 mA and voltage levels up to 3.3 V, as needed to 
rapidly charge implant batteries.  The approach utilized a longitudinally split, two pole 
Huber needle and a mating port with spring-loaded connections.  The refill port 
connection self-aligns with the needle and makes ohmic contact when the needle is fully 
inserted.  This required no additional alignment.  The electrical contact and insulation 
performed well in both wet and dry ambient environments.  The mechanical properties of 
the refill port remained functional for repeated needle insertions.  The modest increases in 
temperature for even the highest current levels demonstrated that a physical recharging 
mechanism can work for an implant.  The possibility of recharging the battery of an 
implantable drug delivery device during a drug refill session could result in an 
implantable drug delivery device size reduction of up to 40%.  The recharging capability 
allows greater system versatility because more energy intensive functions can be 
implementer.  A power transfer connection across the refill port of an implanted device 
could greatly improve both volume efficiency and system functionality. 
 





SUMMARY AND FUTURE WORK 
A valve regulated active architecture was developed for intrathecal drug delivery 
devices.  The architecture allows for new functionality and high volume efficiency.  
MEMS components for two prototype systems were developed and tested.  Prototypes 
were assembled and valve regulated delivery was demonstrated.  Additionally, a 
transdermal power transfer mechanism was developed to further reduce device size by 
allowing the battery to be recharged.  
 
8.1 Dissertation Summary 
Chapter 2 outlines the architecture of the final integrated system and component 
specific parameters.  The system is designed with multiple independently regulated 
microvalves that throttle drug flow from mechanically pressurized reservoirs.  The use of 
regulatory valves allow for high volume efficiency, therapeutic returns from mixed 
medication, and low power consumption.  Additionally, power transfer mechanisms 
allow for battery recharging and communications.   
Potential valve actuation mechanisms were explored to determine a suitable candidate 
for the system architecture.  Piezoelectric actuation was found to be appealing because it 
can overcome high reservoir pressure and has low power consumption.  Metrics for 
microvalve performance were set at regulation of saline flow from 0.1 – 5 mL/day.  
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Addionally, the valves should consume less than 1 mW and be smaller then 3 cm3.  The 
reservoirs were defined as needing volumes between 10-30 mL with dead volumes of 1-3 
mL.  Compressive pressure mechanisms should pressurize 80% of the reservoir volume 
at 600 Pa or greater.  Also, it was determined that reservoir pressure should not exceed 
200 kPa.  The system should have linear pressure sensors in the flow path for feedback 
control of the valves to adjust the delivery rate.  An embedded processor is necessary to 
process the sensor data for the control algorithms, device communication, and error 
detection.  Every element of the circuit must conform to a single supply voltage.  A 
recharging mechanism is necessary to minimize battery size.  The circuit needs to provide 
the full range of clinical functionality while being as power efficient as possible in an 
effort to further reduce battery volume.  These system component definitions should 
allow an itrathecal drug delivery device the advantages of a valve regulated architecture. 
Chapter 3 outlined the PZT microvalves used in the drug delivery system.  Three 
different types of valves were discussed.  The first type uses a rectangular serpentine 
valve seat and flexure suspension.  The second type uses a curved valve seat and 
membrane suspension.  It also has an embedded pressure sensor.  The third type is a 
manifold with two starburst valve seats and multiple pressure sensors to determine the 
differential pressure across the valve.  
Flexure suspended valves were assembled with PZT stacks in a ceramic header for a 
total device size of 1 cm3.  The valves were tested with gas flow at a gauge pressure of 55 
kPa and the flow rate could be modulated from 0 to 980 mL/min. At 60 V, valve leakage 
was below the measurement limit (< 0.1 mL/min.).  Preliminary liquid flow tests were 
performed at room temperature using oil (viscosity 4.5 cP) and the flow rate varied 
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linearly with the differential pressure over a range of 250-460 μl/min; the corresponding 
differential pressure drop was 16 - 47 kPa. 
Membrane suspended valves were assembled into devices with a total size of 2.25 
cm3 but with a fluid path dead volume of only 0.021 cm3.  The valves were fabricated a 
boron piezoresistve Wheatstone bridge pressure sensor at the inlet.   A normally-open and 
a normally-closed valve were tested at room temperature with N2 gas flow at the gage 
pressure of 52 kPa.  The valves were actuated from 0−40 V and the flow rate varied from 
below the measurement limit (< 1 mL/min) to above 200 mL/min in the normally open 
valve and above 100 mL/min in the normally-closed valve.  Several resistors were tested 
at room temperature and they averaged around 23.5 kΩ with an average pressure 
sensitivity of 356 ppm/kPa at room temperature. 
Valve manifolds with starburst valve seats were assembled with Macor into devices 
with a total size of 4.5 cm3.  The manifolds had three Wheatstone bridge pressure sensors 
to monitor both inlets and the common outlet.  Gas flow tests in standard flow valves 
used actuation voltages ranging from -30 to 90V with inlet pressures from 0 to 23.5 kPa 
and a maximum flow rate of 521 ml/min.  High-flow used lower valve actuation voltages 
(-20 to 40V) across inlet pressures from 0 to 23.5 kPa with a maximum flow rate of 419 
ml/min.  Tests were conducted with pressurized IPA on a standard manifold to determine 
mixing from each channel.  Flow from one side of the manifold varied from 1.77 mL/hr 
to 0.028 mL/hr and the other varied from 2.12 mL/hr to 0.38 mL/hr.  Several pressure 
sensors were tested at room temperature with average resistances between 100-150 kΩ 
and an average sensitivity of 698 ppm/kPa.      
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Chapter 4 outlined the design and testing of two types of compression mechanisms 
that provided mechanical pressure necessary to drive drug delivery.  One mechanism 
utilized compressive metal springs wrapped in a sleeve around a polymer chamber.  The 
alternative mechanism used silicon torsion springs to press against a PET balloon to 
generate pressure.  
Fifty-element springs were fabricated to pressurize a 4 mm thick balloon.  The 
springs consisted of bends that measure 40 µm deep, 60 µm wide, and 150 µm long with 
a total length of 3.5 mm.  Optical techniques were used to measure the spring deflection 
for various pressures.  The torsion springs deflected up to 4 mm as the reservoir was 
inflated for nonlinearly increasing pressure that reached 80 kPa for a fully filled reservoir.  
The silicon springs were brittle and difficult to handle. 
Planar Elgiloy springs were designed to be used in compressive sleeves that 
pressurize a PET chamber measuing 20 mm in diameter and 60 mm in length.  The 
springs were fabricated from 100 µm thick sheets with a pattern in which the beams were 
150 µm wide, and the mesh cell size was 600 µm by 6 mm.  Conditioned springs were 
found to have a spring constant of 307.5 N/m and generated reservoir pressures up to 
almost 15 kPa when fully inflated.  Compressive sleeve springs were used to pressurize 
the reservoir in the initial system because they take little volume, offer comparable 
pressures to traditional springs, and plastically deform instead of break.   
Chapter 5 outlined the results of a preliminary drug delivery system using a valve 
regulated architecture.  A single valve was used to regulate fluid flow from a single 
spring pressurized reservoir.  Control circuitry was designed and assembled to operate the 
system.  A housing was developed to encase the system components for testing. 
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A control PCB was designed that measures 4 cm x 6 cm and powered from a 3 V 
battery.  The pressure sensor input was amplified and read by an ADC.  This data can be 
used in the closed loop control algorithms implemented in the microcontroller.  The 
circuit can actuate the throttle valve with 0-90 V.  The maximum power consumption of 
the valve was 1.68 µW when it was controlled with the PCB.  Controlled diffusion into 
agar gel was demonstrated.  Analysis of the images strongly suggested valve regulation is 
the only element responsible for diffusion rate changes.  A preliminary aluminum 
encasement was developed for the system.  It held a microvalve, a large compressive 
sleeve reservoir, the control circuitry, a battery, and had two ports for refilling the 
reservoir and accessing the catheter.  The housing has a total volume of 113 ccm with a 
total reservoir volume of 37 ccm giving it a high VER. 
The system was tested for both bolus and continuous flow regulation.  In one typical 
test, four boluses of 1.5 mL were delivered using a program targeting 6 mL by actuating a 
valve with 40 V to open it and 0 V to close it.  The actual delivered volume was 5.971 
mL.  The pressure sensors averaged errors of less than 1.04 kPa.  Deviation from target 
flow for one control algorithm averaged less than 6.4% of the maximum flow for a 
particular pressure.  Testing of the complete system for continuous flow was conducted 
by re-filling the reservoirs, programming a delivery schedule, and measuring the distance 
travelled by an air bubble through a catheter.  Tests typically ran from 8 hrs to as long as 
a week.  One such long term test (Fig. 5-10a), demonstrated average delivery accuracies 
of 3.22% with no deviation from the flow rate worse than 9.09% at delivery volumes of 
less than 0.2 mL/day. 
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Chapter 6 outlined the results of a second preliminary drug delivery system using a 
two-valve manifold.  The manifold was used to regulate fluid flow from multiple polymer 
reservoirs pressurized by a spring loaded plate.  A stainless steel housing was developed 
to encase the system components for testing. 
Embedded pressure sensors at the outlet of the device were used to determine the 
potential of the system to detect catheter occlusions.  The outlet sensor also demonstrated 
the potential to detect acute catheter disconnects from the delivery device.  Oscilloscope 
traces of the pressure sensor response provide good preliminary to justify further 
investigations into the capacity of the outlet sensor to determine the state of the delivery 
catheter.  Magnetic compatibility tests were conducted and no evidence of device 
alteration was found with magnetic fields of at least 453 gauss is various orientations.  A 
preliminary stainless steel encasement was developed for the system with a total volume 
of 130 cm3 and a total reservoir volume of 40 cm3. 
The system was tested for various aspects of flow regulation.  A control program was 
designed to compensate valve apertures to adjust for changes in output pressure that 
reflect the range of typical intrathecal pressures.  The regulated program maintained a 
steady flow of 0.58 mL/hr across pressures while flow from an unregulated valve 
diminished from 0.58 mL/hr to 0.21 mL/hr.  Various actuation voltages were applied to 
both sides of a manifold, and resultant flow operated in one of two regimes.  Either one 
valve was significantly more open then the other, in which case it dominated the flow 
profile, or both valves apertures were comparable and flow was relatively evenly 
distributed.  Regulation tests were conducted by adjusting the duty cycle of a 0-60 V 
actuation to each side of the manifold.  In on such test, three different flow rates were 
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preprogrammed, and measured flow deviated less than 0.01 mL/hr from the target flow 
rate. 
Chapter 7 outlined a method for power transfer through a customized conductive 
needle designed to interface with metal spring electrodes embedded in a refill port.  The 
needle adapted a current model to allow for two isolated conductive pathways.  The refill 
port was designed with embedded metal springs to mate electrically with the modified 
needle.  The system was designed to mate successfully regardless of the rotational 
orientation or insertion angle of the needle.   
Two-pole Huber needles (700 µm ø, 26 gauge) for use with a smart refill port were 
fabricated by lapping two stainless steel needles in half.  The needle halves were coated 
in 2.8 µm thick Parylene for electrical isolation, and further insulation and sealing 
strength was provided by inserting the needle into a 50 µm thick Kapton tube.  The refill 
port electrical contact springs were fabricated from 100 µm thick stainless steel by 
µEDM.  The contact springs are 5.2 mm in diameter with four quadrants separated by 
300 µm wide slots.  The septum was fabricated by inserting two contact springs in the 
septum at 4.5 and 5.5 mm above the base plate.  Resistance was tested in both wet and 
dry ambients and results conformed to expectations.  Two 1.2 V NiMH AA batteries 
were recharged using various current levels at room temperature in a dry environment.  
Power transfer rates ranging from 10-500 mA demonstrated the expected temperature 
rises at locations along the refill port.  Typical starting voltages ranged from 1.1 V to 1.4 
V.  No measureable heating was observed for charging currents of 100 mA or less.  At 
higher current levels (above about 500 mA), modest heating occurred: temperature 
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increases were less than 15°C at the septum and 2°C at the casing.  The refill port was 
punctured one hundred times, and the resistance and varied over 0.27-1.4 Ω.  
 
8.2 Suggestions for Future Work 
 
  The tests for each system component and the system as a whole took place at the 
bench-top, rather than with in vitro or in vivo conditions.  The tests were designed to 
partially recreate conditions that would be experienced by the components and the system 
after implantation, while still being simple enough in nature to allow for a first-pass 
evaluation of sensor and device performance.  Crucially, the lessons learned with these 
first-pass evaluations – allow us to define more complete prototypes with associated key 
parameters and evaluation methods that accurately simulate medical conditions.   
The specifications for additional devices and components are described in more detail.  
Additionally, the performance of the preliminary systems is discussed in the context of 
each of these specifications.  Where needed, potential design improvements and 
additional bench-top methods for verifying that the design meets the specification are 
presented. 
Although bench-top testing methods allow for simple characterization, a main goal of 
this work is to demonstrate a fully function intrathecal drug delivery device.  To more 
rigorously display system performance, in vitro testing of an assembled system should be 
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8.2.1 Future Device Specifications 
The development of future devices should progress toward two goals: the first goal is 
the improvement of the VER of the system, and the second goal is the development and 
analysis of medical diagnostic and treatment techniques.   
There are several alterations to the preliminary prototypes that can yield higher 
system VER.  Early test results indicate that duty-cycle regulation provides more accurate 
and reliable control of the drug delivery rate.  A new bi-stable valve structure that is 
either open or closed may be smaller and easier to fabricate than the current multi-state 
stable PZT valves that are currently used.  Advances in the valve design using alternative 
actuation mechanisms and valve structures would allow for some scaling in the system.  
Additionally, efficient space employment in the housing coupled with spring 
advancements could yield significant VER improvements.  A restructuring of the second 
prototype can reduce the total system volume by 30 cm3 with no change in the included 
components.  The high VER prototype should have two reservoirs that each contain 10-
20 mL, flow regulation capabilities from 0.01 – 30 mL/hr, a five year battery life, 
embedded sensors, wireless communication, and a volume efficiency ratio of  at least 
50%.                                                                                                                                                               
Prototypes for medical diagnostic and delivery characterization could also be 
developed using modifications to more traditional devices.  For example, the 
COMDMAN 3000 drug pump uses a Freon pressurized reservoir held constant at 
between 50 - 60 kPa.  Drug delivery is realized by driving this fluid through a restrictive 
glass tube with tight tolerances on diameter.  The nominal flow rate is set but the length 
of the tube.  Research groups have altered this restrictor to use the CODMAN 3000 as an 
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independently set drug delivery device [Bae08].  One future work prototype could use a 
similar adaptation to a commercial intrathecal drug pump.  The adaptation could include 
embedding sensors or even adding a valve regulator to the output of the device.  A 
prototype fabricated in this way would have poor volume efficiency, but it could be more 
rapidly developed and deployed in in vivo medical studies to determine the diagnostic 
advantages of embedded sensors.  A prototype fabricated using this method should have 
an output pressure sensor, a method for flow regulation (either a valve, or pump), 
embedded electronics, and be compatible with long term implantation. 
 
8.2.2 In Vitro Testing 
Although good performance in initial bench-top testing provides confidence that the 
system architecture will perform as intended, in vitro testing will provide a more accurate 
assessment of the system.  The outlet of the device should run through tissue mediums 
that simulate the different profiles the catheter experiences including an outlet in a 
variable pressure saline cylinder.  The saline cylinder should have a slowly varying 
volume that correlates to the changes in intrathecal pressure that occur naturally due to 
various times of day or body movement.  The tests should be conducted without external 
changes made to the system for time periods varying from 8 hours up to two months with 
set delivery rates and schedule refills.  Additionally, several different delivery profiles 
and drug ratios should be tested to verify the versatility of the delivery scheme. 
After short term in vitro tests are conducted to verify system performance, long term 
experiments should be undertaken.  Longevity errors such as granuloma, catheter wear, 
valve failure, and reservoir consistency can be analyzed by conducting tests for several 
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months and beyond.  The system should also be verified for FDA requirements for 
implantable devices.  This includes a battery of tests that involve EMF radiation, 
communications power, further MRI compatibility, etc.  These tests are extremely 
important to verify the long-term sustainability of the system and allow development to 
proceed toward a manufacturable implant.  
 
8.2.3 In Vivo Testing 
The device modification type should be developed to acquire in vitro data and long-
term tests should be conducted to determine challenges with a valve regulated system.  
Preliminary in vivo tests should be conducted with the system to confirm the feasibility of 
long term implantation.  One such test should be the implantation of the device into a 
large animal model without any delivery functionality.  This test should determine the 
biocompatibility of the system and should provide indicators of potential foreign body 
response that may occur.  A second short-term test should be using the system as an 
external pump to regulate intrathecal delivery into a large animal model.  The CSF can be 
extracted at a location further in the spine while an indicator is delivered by the device.  If 
the extracted CSF demonstrates the expected indicator profile, the system should be 
delivering medication properly. 
Short term diagnostic tests should also be conducted.  An implanted device should be 
used to periodically monitor CSF pressure which can be compared to pressure taken by 
traditional means.  Once baselines are established, catheter occlusions and disconnects 
should be induced in the animal model.  Techniques should be developed to detect these 
acute catheter alterations in vivo from the output pressure sensor and functionality should 
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be verified during these tests.  Also, potential detection of slow changes in the catheter 
can be studied.  One such possibility is the detection of granuloma.  This can be tested for 
by ceasing delivery for 5-10 minutes.  After which, the outlet pressure sensor should 
detect the actual pressure in the CSF because no fluid will be flowing through the 
catheter; this sets the output of the system and the intrathecal space at equal pressures.  
Once this pressure is know, a set flow rate can be resumed.  The change in the outlet 
pressure sensor for this set flow rate can be measured and correlated to the resistance of 
the catheter.  If this technique is done at implantation (no granuloma) to establish a 
baseline, future tests can detect time alterations of the catheter tip.  Eventually, the 
catheters can be removed, and actual conditions can be compared to sensor data.  
After short term in vivo tests are conducted to verify basic system functionality in an 
animal model, long term tests should be initiated.  A long term large animal study should 
be conducted with statistically significant numbers, and also multiple control cases.  One 
control group should have a prototype system implanted without any medication delivery.  
A second control should be comprised of the implantation of a current commercial pump 
with well known delivery metrics.  Results from this long term animal study should 
provide significant data to support the design of a final system.  A final system should be 
designed based upon the improved VER architecture with additional resources to 
properly implement the medical diagnostic techniques developed using the medical 
prototypes.  The final system should then be used in human clinical trials and advanced 
through FDA approval for eventual adoption. 
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Appendix A: A low leakage liquid seal 
Micromachined valves are attractive for a variety of systems with applications 
ranging from biological analysis to orbital propulsion.  Performance metrics such as 
dynamic range, permitted leakage, response time, maximum pressure, power 
consumption, size, and material composition are generally determined by the target 
application [Las04, Oh06, Cha00].  For example, a Joule-Thompson cooler requires high 
pressure operation and high flow rates for successful operation [Zhu09, Aga04]. On the 
other hand, a micro gas chromatograph favors valves with a rapid response time to 
properly determine the chemical composition of an input [Aga05].  Valve performance is 
dependent upon several factors that include fabrication methods, material composition, 
and actuation mechanism.  For any set valve fabrication and assembly, there are design 
compromises that allow valve parameters to be adjusted to meet the needs of a specific 
application.     
For many systems, an ideal valve would not limit the flow rate when fully open and 
would also have no leakage when fully closed.  Eliminating leakage in micromachined 
gas valves has been a major challenge; non-uniformities in the valve seat or the presence 
of even minute particulates can prevent complete sealing.  This problem is further 
exacerbated by the use of valve actuation mechanisms that provide relatively modest 
sealing force.  In order to address this issue, researchers have explored the use of soft 
sealing materials for the valve seat [Jeo08, Yan99].  While such polymeric seals are 
suitable for a variety of valves and applications, the incorporation of such materials can 
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be a significant challenge for other valves.  The operating conditions and environments 
for certain valves may also limit the use of polymeric valve seats.  In such cases, a wet 
valve seat may provide a solution that is both simple and effective. 
Surface tension at solid-liquid interfaces has been exploited for controlling flow 
within microchannels [Ber93].  For example, hydrophilic and hydrophobic regions along 
flow channels have been used to modulate pressure driven flow [Bur98, Zha01].  
Capillary forces can dominate other forces at typical microchannel dimensions.  These 
forces are proportional to the length of the solid-liquid interface and decrease linearly 
with size, whereas forces that are proportional to area diminish more rapidly [Sch99].  
Based on this favorable scaling, capillary forces can be useful for sealing against gas 
leakage.   
In this paper, we explore how capillary force can be used to prevent gas leakage in a 
valve that operates by moving a valve seat against a plate to modulate the height of a 
flow channel.  The valve is similar to one reported in [Par08] and [Par09], but it utilizes a 
more elongated valve seat (Fig. A-1).  The valve seat is microfabricated on a silicon-on-
insulator (SOI) wafer and suspended above a glass substrate that has perforations for the 
flow inlet and outlet.  A piezoelectric stack mounted above the glass-silicon sandwich 
modulates the separation between the valve seat and substrate.   
The valve seat is designed in a starburst pattern that is axisymmetric with the gas inlet 
below it and the piezoelectric actuator above it.  The elongated valve seat creates a wide 
flow channel even at a relatively small separation from the substrate to compensate for 
actuation distances of less than 10 µm.  This reduces flow resistance, but also permits 
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higher leakage if a particle or structural non-uniformity occurs at any point along its 81 
mm long serpentine perimeter.  
 
(a)    (b) 
 
Fig. A-1: (a) The microvalve plate is designed from silicon and glass with a serpentine 
valve seat in a starburst pattern.  The valve membrane is pressed against the 
glass plate to close the valve.  The valve regulates gas, but because utilizes 
membrane suspension, a sealant can be introduced into the valve channel 
without leaking.  The valve also has embedded pressure sensors at the inlet and 
outlet. (b) A photograph of the top surface of the silicon microvalve assembled 
with a piezoelectric stack inside a ceramic housing.  
 
A capillary seal for gas flow is formed by introducing liquid – water or isopropyl 
alcohol (IPA) – into the region between the valve seat and substrate and then draining or 
evaporating it away from the other regions.  The liquid-gas interface formed in this gap 
provides a capillary force that seals the valve from gas flow when it is closed (Figure A-
2a).  When the valve is opened, surface tension and capillary forces drive the liquid 
toward places in the channel that have smaller gaps.  This permits retention of the liquid 
on the valve seat.  The axisymmetric actuation of the valve seat opens the inner points of 
the starburst pattern sooner then the outer edges.  This drives the sealant from the center 
of the valve seat to the edges when it is opened (Figure A-2b).   
The effectiveness of the capillary seal formed by the liquid in the flow channel is 
dependent upon both the liquid/solid and liquid/gas interfaces.  The seal pressure can be 
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determined mathematically from the liquid meniscus.  Using the Young-Laplace equation, 
the pressure drop across the meniscus (ΔP) can be determined from the liquid surface free 




Fig. A-2: (a) Liquid sealant is in the channel between the valve seat and the glass plate.  
On the high pressure (inlet) side of the channel, a meniscus is formed that 
generates forces that oppose the pressure.  This mechanism creates capillary 
forces that hold the valve sealed against pressure driven flow.  This reduces the 
leakage of a closed valve. (b) Color enhanced photographs of the wet valve seat, 
showing the meniscus receding from the inner starburst points that are closer to 
the actuator, when the valve is opened.  Prior to testing the valve for gas flow, 
the introduction and removal of isopropyl alcohol leaves a residual liquid as the 




P +×=Δ γ  (1) 
For a long serpentine valve seat, R2 is essentially infinite.  With a contact angle of 20° 
between water and glass, and a valve channel height of 1.4 µm, the differential pressure 
that the liquid seal should be able withstand at room temperature is approximately 92 kPa.   
The presence of a liquid seal also has an effect on flow characteristics when the valve 
is opened.  For short term effects, it can be assumed that the liquid volume on the valve 
seat is constant as it migrates toward the outer points of the starburst valve seat when the 
valve is opened.  Simulations that take this into account, assuming an initial gap of 1.3 
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µm, a linear actuation approximation of 0.05 µm/V, and a closing voltage of 10 V are 
presented in Figure A-3.  
The evaporation rate of the water used as a sealant can be determined from the mass 
transfer into gas flowing through the valve.  Analytical approximations of this effect have 
also taken into account gas flow across a set surface area of water exposed to various gas 
flow rates [War88, Huh70].  According to these models, at 25°C, with low humidity and 
fast gas flow rates, water for the seal should be retained for at least 11 days.  Once a 
valve seat dries out, it can be easily re-wetted.  For some applications, a non-volatile 
liquid such as oil may be more appropriate.  
 
Fig. A-3: Nitrogen flow through valves assembled with a water seal.  Gas pressures 
varied from 4.1-23.6 kPa and flow ranged from 400 mL/min down to below the 
measurable limit (<1 mL/min) when the valve was closed.  The liquid seal 
prevented pressure flow from generating significant leakage for gas flow.  Gas 
flow rates are compared to flow simulations assuming a constant liquid volume 
and valve geometry.  
 
For the purpose of this study, valves were fabricated by a process similar to one 
previously reported in [14].  The silicon valve seat was spaced 1.3-1.4 µm from the glass 
substrate.  This is a partially-open state; the gap is increased or decreased by the polarity 
and amplitude of the actuation voltage.  This spacing, which is the flow channel, was 
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primed with water after assembly.  The narrow valve channel area prevented the water 
from evaporating from the valve seat at a significant rate and allowed the valve to retain 
the liquid beyond thirty days in laboratory conditions.   
The fabricated valves were tested using nitrogen gas that was used to generate 
differential pressures ranging from 4.1 to 23.6 kPa across the valves while they were 
actuated from -30 to 60 volts (Figure A-3).  Dry valves remained open until they were 
actuated with at least 40 V (Figure A-4).  In contrast, the seal enhanced valves remained 
closed over an actuation range of 10 to 60 V for the entire range of tested pressures.  
Flow rates ranged from 403 mL/min down to flow rates below the measurable range of 
the test setup (less than 1 mL/min).   
 
Fig. A-4: Nitrogen and isopropyl alcohol flow through valves assembled with and without 
a water seal.  Gas pressures were maintained between 13.4 and 13.6 kPa and 
nitrogen flow ranged from 216 mL/min down to below the measurable limit (< 
1mL/min) when the valve was closed.  The liquid seal prevented pressure flow 
from generating significant leakage for gas flow, but it did not affect sealing for 
liquid flow.  Liquid sealing enhancement can be clearly seen as a both a closing 
voltage difference and a leakage difference for gas and liquid flow through an 
unenhanced valve.  
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The same valves were also tested with IPA flow to determine the closing point and 
leakage rates for liquid media, which also do not benefit from a capillary seal.  Alcohol 
flow rates for the valves at 13.3 kPa differential pressure ranged from 1.767 to 0.06 
mL/hr across the same voltage range.  The valves required 40 V actuation to close against 
liquid flow; the leakage rate was 0.0283 mL/hr. 
The ratio of the maximum gas flow rate to the leakage rate was at least 322 with a 
liquid seal while the ratio for a dry valve was 216.  This suggests that the liquid in the 
valve is effective at improving the seal and reducing leakage.  Additionally, the 
difference in closing voltages (10 V for a wet valve seat, 40 V when dry) suggests that 
the capillary seal effect is taking place when the channel gap is approximately 1.4 µm, 
which is consistent with the gap distance targeted during fabrication. 
These results indicate the effectiveness of capillary forces in providing a seal against 
inadvertent gas flow in a closed microvalve.  It has been tested with both IPA and water 
as sealants, and provides a significant seal improvement.  This technique is easy to 
implement and is potentially useful with a variety of liquids, materials, and pressures.   
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Appendix B: PCB Overview 
Introduction 
This effort requires a printed circuit board (PCB) with all of the chips and passive 
components necessary to drive the device from a single battery source.  In an effort to 
begin the transition to a final battery powered system with complete circuitry, the PCB 
has been laid out, fabricated, and populated.  Testing for every functional system except 
the wireless communication has been completed.  The MSP430F169 from Texas 
Instruments has been demonstrated to be programmable and can control every element of 
the board.  Additionally, errors and the necessary corrections for the first generation 
board (DualMed v1.00) are presented. 
 
Fig. B-1: PCB layout of the bottom and top sides of the DualMed v1.00 board.  
 




Fig. B-2:Photographs of the populated DualMed v1.00 board taken from the bottom (left), 
and the top (right).  The bottom has the connector ports for interfacing the board 
with everything else. 
 
PCB Errors 
Various elements of the DualMed PCB v1.00 have been tested, and the various known 
errors and solutions are assembled here.  The only untested element is the wireless 
communications. 
 
First issue: The RST_NMI pin on the JTAG communications bus was being set at the 
wrong voltage, and this prevented communication with a computer to program the 
microcontroller. 
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Problem:  See figure B-3.  The capacitor (C8) and the resistor (R5) to form the pull-up 
circuit were switched. 
 
Solution:  The easiest solution is to remove both of them and leave the RST_NMI pin 
disconnected.  It is optional for communication, and the current device programs 




Fig. B-3: The resistor and capacitor locations are reversed.  They can just be removed. 
 
Second issue: The output power amplifier can not drive the output above 9V regardless of 
the input from the DAC. 
 
Problem:  See figure B-4.  The on chip inductor is only 10nH.  The necessary inductor for 
full amplification should be 10 μH. 
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Solution:  The easiest solution is to remove the inductor, solder to the SW pad of the 
inductor and attach an external 10 μH between that pad and VCC.  The solution for future 
versions of the chip should just be to make it a 10 μH surface mount inductor with a 
current rating of at least 300 mA. 
 
 
Fig. B-4: The inductor is an order of magnitude small.  It needs to be replaced 
Third issue: The output power amplifier does not accurately track the control voltage 
input above 15V.  This is after the inductor problem is corrected. 
 
Problem:  See figure B-5.  The capacitor from Vout1 that is part of the charge pump is 
connected to the feedback pin instead of to ground.  An AC circuit leaks through this pin 
to the feedback node causing errors in the control voltage. 
 
Solution:  The easiest solution is to capacitor, solder to the Vout1 side of where the 
capacitor previously was, and attach an external 0.47 μF capacitor between this node and 
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ground.  A solution for a future PCB board will need to include a change in layout to 
correct this error. 
 
Fig. B-5:   The capacitor is incorrectly connected to FB1 instead of Ground.   
Additionally, the components currently on the board are only rated at about 20V.  So far, 
everything has worked properly up to 60V, but I suspect there may be lifetime issues with 
extended use and possible breakdown.  This should be corrected in the next assembly run, 
and may require a change in the layout to allow for larger components that meet this 
specification. 
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Appendix C:  Software Overview 
Introduction 
In order to successfully communicate and control an implantable drug delivery device, 
several elements are needed.  The most complex elements of this type of control system 
are the microcontroller and the wireless communication system.  In an effort to ease the 
transition to a final battery powered PCB with complete circuitry, these elements have 
been developed.  Preliminary programming for every functional system has been 
demonstrated.  The MSP430F169 from Texas Instruments was used with the CC1100 
wireless chip in the 433MHz bandwidth for development of the preliminary 
microcontroller and wireless protocols. 
 
System Overview 
The programming of the microcontroller (and by extension all peripherals) follow a 
very compartmentalized structure.  The device is initially powered, and undergoes the 
start up process.  This is also same process that would be undertaken if it was forced to 
re-boot wirelessly.  After it starts up, it goes into a loop where it “sleeps” for one minute 
to conserve power.  Upon waking, it checks for a wireless signal.  If there is an input 
signal, it suspends the loop as it processes all communications requests.  After 
communications are checked, all inputs (ADCs) are processed.  The input data is 
processed and if no changes are necessary, the device goes back to sleep.  Otherwise, 
outputs are changed to meet demands and the device goes back to sleep. 
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Fig C-1: Software block overview.  After startup, the system constantly loops through 
functions. 
 
1. Start Up:  the init() function 
Start up, or reset, is a relatively straightforward process.  All initial constants are 
fixed.  All communications protocols are implemented.  The watchdog timer is suspended.  
Within this function, there are several sub-functions.  The ADCs are initialized as inputs 
with 6 potential inputs.  The DACs are set as output ports with the correct multiplier 
ratios to match further processing needs.  The SPI init establishes the communications 
standards with the CC1100 chip and uploads the necessary parameters for 433 MHz 
communication.  Basically, this functionality occurs only once, but it sets all protocols 
and ports to do input, output, and wireless communications. 
 
2. Sleep Timer:  the lpm() function 
The TI MSP430 has several different low power modes.  These modes have several 
timer interrupts that can be triggered after certain delays, or changed on the input lines.  
The sleep situation requires the wireless receiver to be shut down (to conserve power), all 
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outputs to be held constant (to maintain flow), and an activation every minute.  To 
achieve this, low power mode three is used, and is exited out of with a timer event.  
When it is interrupted, it runs through various sub-functions starting with wireless().  
Sleeping power consumption is less than 10mW. 
 
3. Sensor Inputs:  the ADC_read() function 
The sensors are configured earlier on.  The sensor input function quickly reads six 
individual inputs. 
 
4. Wireless Communications:  the wireless() function 
The wireless system works by the microcontroller sending commands via the SPI 
interface to the CC1100.  The function starts by waking up the CC1100 from power 
saving mode.  It then checks for any incoming packets that would trigger full bi-
directional communication.  If it receives and activation command, it goes into receive 
mode and halts the rest of the process.  If it does not receive the communication packet, it 
puts the CC1100 back to sleep (power savings) and continues on.  In the communication 
mode, several packets are received.  They are coded with a (1) a validation bit, (2) a 
series of adjustment bits (i.e. adjust flow rate table position 5; reset; etc) and then (3) a set 
of values.  All the processing is done with arrays to make changing the values easy and 
seamless.  After a transmission finished packet is sent, all requested data is then output 
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5. Sensor Inputs:  the sensor() function 
The sensor inputs are activated every minute.  All of the inputs are attached to the 
multiplexed ADC.  The ADC’s are all very quickly read in sequential order and the 
values are stored for data processing later on.  The 6 inputs allow 3 inputs for each valve 
to be wired up. 
 
6. Data Processing:  the data_proc() function 
The data processing is the core of the control.  The input data is compared to the 
calibration functions (set as a polynomial array) to get an effective value (actual pressure, 
or other value).  These input values are then used to calculate flow rate and check for any 
system failures (like low battery or clogged catheter).  The flow rate is compared to the 
set rate (also in an array) and adjusted as necessary to maintain the set-point.  If there are 
errors, the error output is set. 
 
7. Change in output:  the output() function 
The output values from the data processing are taken and sent to the correct registers 
with the values adjusted to get the correct output.  Any error signal is activated or de-
activated and is sent to a digital output that will power a PZT buzzer.  Additional power 
management techniques (like turning off the valves etc) are also be implemented in this 
stage.   
 
Code in objective C 
 
#include "include.h" 
#include  <msp430x16x.h> 
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extern char paTable[]; 




unsigned int output = 0; 
unsigned int recieve = 0; 
unsigned int time_switch = 0; 
unsigned int r_time = 0; 
 
void main (void) 
{ 
  WDTCTL = WDTPW + WDTHOLD;                     // Stop WDT 
   
  P1DIR = 0x01;                             // set port to outputs 
  P1OUT = 0;                                // reset port outputs 
   
  //timer stuff 
  CCTL0 = CCIE;                                 // CCR0 interrupt enabled 
  CCR0 = 20000; 
  TACTL = TASSEL_2 + ID_3 + MC_1;               // SMCLK, upmode 
 
  TI_CC_SPISetup();                             // Initialize SPI port 
 
  TI_CC_PowerupResetCCxxxx();                   // Reset CCxxxx 
  writeRFSettings();                            // Write RF settings to config reg 
  TI_CC_SPIWriteBurstReg(TI_CCxxx0_PATABLE, paTable, paTableLen); //Write PATABLE 
 
   
  // Configure ports -- switch inputs, LEDs, GDO0 to RX packet info from CCxxxx 
   
  TI_CC_SW_PxIES = TI_CC_SW1+TI_CC_SW2+TI_CC_SW3+TI_CC_SW4;             //Int on falling edge 
  TI_CC_SW_PxIFG &= ~(TI_CC_SW1+TI_CC_SW2+TI_CC_SW3+TI_CC_SW4);         //Clr flags 
  TI_CC_SW_PxIE = TI_CC_SW1+TI_CC_SW2+TI_CC_SW3+TI_CC_SW4;              //Activate enables 
  TI_CC_LED_PxDIR = TI_CC_LED1 + TI_CC_LED2 + TI_CC_LED3 + TI_CC_LED4;  //Outputs 
  TI_CC_GDO0_PxIES |= TI_CC_GDO0_PIN;                                   // Int on falling edge (end of pkt) 
  TI_CC_GDO0_PxIFG &= ~TI_CC_GDO0_PIN;                                  // Clear flag 
  TI_CC_GDO0_PxIE |= TI_CC_GDO0_PIN;                                    // Enable int on end of packet 
   
   
   
   
  //testing sleep and idle 
 unsigned int i; 
   
  TI_CC_SPIStrobe(TI_CCxxx0_SIDLE);                                     //Put CCxxxx in Idle 
   
  TI_CC_SPIStrobe(TI_CCxxx0_SPWD);                                      // Go into power down mode 
  i = 5000;                              // Delay 
  do (i--); 
  while (i != 0);  
                                                                        
  _BIS_SR(LPM0_bits + GIE);                                             // Enter LPM0, enable interrupts 
   
  //My code transmit for loop 
 // for (;;) 
 // { 
 //   volatile unsigned int i; 
   
   
     
    // Build packet 
 //   txBuffer[0] = 2;                           // Packet length 
 //   txBuffer[1] = 0x01;                        // Packet address 
 //   txBuffer[2] = output;                        // Load output 
 
 //   output++; 
  //  if(output == 32) 
//      {output = 0; 
//      } 
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  //  RFSendPacket(txBuffer, 3);                 // Send value over RF 
 
 //   P2IFG &= ~TI_CC_GDO0_PIN;                  // After pkt TX, this flag is set. 
 
 //   i = 50000;                              // Delay 
 //   do (i--); 
 //   while (i != 0); 





// Timer A0 interrupt service routine 
#pragma vector=TIMERA0_VECTOR 
__interrupt void Timer_A (void) 
{ 
   unsigned int i; 
   
   
  if(recieve == 1) 
  { 
    r_time++; 
    P1OUT ^= 0x01;  
     
    if(r_time == 10) 
    { 
      P1OUT = 0;  
      TI_CC_SPIStrobe(TI_CCxxx0_SIDLE);  
       
      TI_CC_SPIStrobe(TI_CCxxx0_SPWD);                                     //Put CCxxxx in Idle 
      i = 5000;                              // Delay 
      do (i--); 
      while (i != 0);  
   
      r_time = 0; 
      recieve = 0;    
      time_switch = 0; 
    } 
  } 
   
  if(recieve == 0) 
  {  
    time_switch++; 
    
    if(time_switch == 99) 
    { 
      TI_CC_SPIStrobe(TI_CCxxx0_SIDLE);                                     //Put CCxxxx in Idle 
      i = 5000;                              // Delay 
      do (i--); 
      while (i != 0);  
       
       
       TI_CC_SPIStrobe(TI_CCxxx0_SRX);  
    } 
   
    if(time_switch == 100) 
    { 
       TI_CC_SPIStrobe(TI_CCxxx0_SIDLE); 
        
      TI_CC_SPIStrobe(TI_CCxxx0_SPWD);                                     //Put CCxxxx in Idle 
      i = 5000;                              // Delay 
      do (i--); 
      while (i != 0);  
        
       time_switch = 0; 
    } 








// The ISR assumes the int came from the pin attached to GDO0 and therefore 
// does not check the other seven inputs.  Interprets this as a signal from 
// CCxxxx indicating packet received. 
 
#pragma vector=PORT2_VECTOR 
__interrupt void port2_ISR (void) 
{ 
  char len=2;                               // Len of pkt to be RXed (only addr 
                                            // plus data; size byte not incl b/c 
                                            // stripped away within RX function) 
  if (RFReceivePacket(rxBuffer,&len))       // Fetch packet from CCxxxx 
  { 
    if (rxBuffer[1] == 01) 
    {     
      r_time = 0; 
      recieve = 1;// Toggle P1.1 using exclusive-OR 
    } 
  } 
   
   
  P2IFG &= ~TI_CC_GDO0_PIN;                 // Clear flag 









//  ADC DAC implementation 
//   
//   
//  Built with IAR Embedded Workbench Version: 3.21A 
//****************************************************************************** 
 
#define ROWS 10 
#define COLS 2 
 
#include  <msp430x16x.h> 
 








  WDTCTL = WDTPW + WDTHOLD;                     // Stop WDT 
  DAC_Program();                                // Program the DAC output 
  ADC_DAC_Init();                               // Initialize ADC12 
  ADC12CTL0 |= ENC;                             // Enable conversions 
   




void DAC_Program(void)                          // Initialize the DAC output program 
{   
  int row;                                      // The first value is the time  
        for (row = 0; row < ROWS; row++)        // Second value is the DAC output (to be replaced with flow rate) 
        { 
                DAC[row][0] = 10 * (row +1); 
                DAC[row][1] = row * .1 * 2048; 
        } 
         
}        
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void ADC_DAC_Init(void) 
{   
  P1DIR = 0x01;                             // set port to outputs 
  P1OUT = 0;                                // reset port outputs 
   
  //timer stuff 
  CCTL0 = CCIE;                                 // CCR0 interrupt enabled 
  CCR0 = 20000; 
  TACTL = TASSEL_2 + ID_3 + MC_1;               // SMCLK, upmode 
   
  // ADC stuff 
  P6SEL |= 0x01;                            // select A0 input 
  ADC12CTL0 = ADC12ON+SHT0_1+REF2_5V+REFON; // Setup ADC12 
  ADC12CTL1 = SHP;                          // Use sampling timer 
  ADC12MCTL0 = SREF_1;                      // Vr+=Vref+ 
  ADC12IE = 0x01;                           // Enable interrupt 
 
  
     
  //DAC stuff 
 
  DAC12_0CTL = DAC12IR + DAC12AMP_5 +DAC12ENC;  // Internal ref gain 1 





// Timer A0 interrupt service routine 
#pragma vector=TIMERA0_VECTOR 
__interrupt void Timer_A (void) 
{ 
   
  static unsigned int i = 0; 
  static unsigned int time = 0; 
  static unsigned int row_1 = 0; 
   
  if(i == 10)                              // Delay Sampling every 10 interrupts 
  { 
    i = 0; 
    time++; 
     
      for (row_1 = 0; row_1 < ROWS; row_1++)          // Check to see where if we are at a new stage 
      { 
            if(time == DAC[row_1][0] )            // If the time is at a new stage then change output                    
            { 
        
                DAC12_0DAT = DAC[row_1][1];       // Update with the new output 
                row_1++; 
         
                    if(time == DAC[ROWS-1][0])    // If we reach the end of a cycle then reset (ie... new day) 
                    time = 0; 
            }   
      } 
       
    ADC12CTL0 |= ADC12SC;                   // Sampling open 
  } 
  i++; 
   
} 
 
// ADC12 Interrupt Service Routine 
#pragma vector=ADC_VECTOR 
__interrupt void ADC12ISR (void) 
{ 
    results = ADC12MEM0;                    // Put ADC values on DAV             
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Appendix D: Fabrication Details 
 
The processing done for the third generation PZT microvalve manifolds took place 
during May-June 2009 in the Lurie Nanofabrication Facility (LNF) at the University of 
Michigan.  This appendix is meant to be used in conjunction with the third generation 
fabrication run sheet.  The run sheet is referenced by both number and with excerpts from 
the text itself.  This appendix also contains opinions and thoughts about potential future 
modifications that may either improve yield or ease of fabrication.  Fabrication changes 




(run sheet excerpts are italicized) 
 
Wafer: (100) N-type SOI: 20 μm device, 450 μm handle, 2 μm oxide, >5 Ω resistivity 
 500 µm 4” glass wafer from Plan Optik (PN: V015.04-0001) 
 
This is a deviation from the proposed 30 µm device wafer with a 400 µm handle.  These 
changes were made to reflect a more aggressive design that allows from smaller pressure 
sensor membranes.  Three SOI wafers were processed and several N-type blanks and 
glass wafers were used for process splits. 
 
1. SOI wafer processing 
a. Cleaning: Piranha clean 
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The wafers either come pre-cleaned (as the SOI wafers did), or can be cleaned once 
opened in the clean room.  This step is optional and can be ignored if the wafers are 
already clean. 
 
b. Thermal Oxidation 
 
This step did not occur in the original process.  It was added because Boron implantation 
at the energy levels originally proposed do not leave visible marks on the wafer.  This 
oxidation step was necessary to create the alignment marks for later lithography steps.  
The lithographical changes are required to properly align the metal interconnects to the 
doped resistors.  Three SOI wafers and two blanks were pre-cleaned and then oxidized.  
The thickness and timing of this step are not sensitive to process variations. 
 
c. Resistor Formation 
 
Once the thermal oxidation was completed, the resistors were patterned in using 
photoresist, and the underlying oxide was etched.  One blank wafer was cleaned to 
confirm that the oxide was completely etched, and the alignment marks were visible for 
future lithography. 
 
d. Ion Implantation 
 
Three SOI wafers and one blank wafer were sent for ion implantation to Innovion.  Total 
time from ship-out to wafer return was approximately one week.  An earlier process split 
utilizing two blank wafers demonstrated that the implantation parameters fell within 
simulation and process tolerances. 
 
e. Thermal Oxidation and Boron Drive-In 
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This step creates a field oxide and drives in the boron to properly create the resistors.  
This stage is very sensitive to variation in parameters, and could cause faulty resistors if 
not properly done. 
 
f. Via formation 
 
The metal layers for the second step in via formation were altered from platinum to gold.  
This change was made because the third generation valves do not have RTDs, and gold 
interconnects are used to solder external wires to the die.  This process change allows the 
removal of the platinum mask.  One SOI wafer was set aside at this stage as a process 
split.  Two SOI wafers and two single sided wafers were processed. 
 
g. Metal Interconnects 
 
Two SOI wafers and two single sided wafers were processed through this step (Figs. D1-
5).  This is the point where the single sided wafers were used to test the implantation.  
Preliminary tests on pad-to-pad resistances were conducted on single sided wafers that 
were removed from this process split.  The measured resistances varied from 
approximately 100 kΩ to 140 kΩ depending on the location of the pads and the 
Wheatstone bridge arrangement.  The expected resistance (based on simulation) was 
112.3 kΩ, so the range and results were well within expected tolerances.  The results 
suggested that the sensors and interconnects operate within tolerance. 
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Fig. D-1: A photograph of the gold traces 
of a two-valve third generation manifold 
 
Fig. D-2: A photograph of the gold traces 
of two third generation single valves.  
  
Fig. D-3: A photograph the reverse side of 
a pressure sensor membrane showing the 
piezoresistors and gold traces. 
Fig. D-4: A photograph the folded 
piezoresistor on the left side of the 




Fig. D-5: A photograph the long piezoresistor on the top side of the membrane.  The 
interconnect squares are visible on the left and right sides of the resistor. 
 
2. SOI wafer backside  processing 
a. Al pattern for STS 
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This step altered an etch step to a lift-off step.  Additionally, the process is sensitive to 
under exposure or under development because it can cause the small features in the valve 





As an alternative to using photo resist techniques to bond the carrier wafers, conductive 
oil was used.  This oil has the disadvantage of being more difficult to clean (it requires an 
IPA wipe down), but it has thermally conductive properties that allow for a more uniform 
deep etch.  Additionally, the second DRIE etch is sensitive to recipe variations.  Most 
DRIE steps either scallop in or out.  This corresponds to trenches either getting smaller as 
they get deeper (like a V), or getting wider as they get deeper (like an A).  If the recipe 
has a tendency to scallop out, the membrane can be undermined and weakened.  This 
happened in two of the early wafer splits, and the 20 µm thick valve seat membranes 
were undermined and broke apart.  In order to correct this, the recipe for the second etch 
was modified to scallop in.  Four single side and two SOI wafers were processed through 
this step. 
3. Glass wafer processing 
a-l. Cleaning through first etch 
 
BHF was used for the shallow etch for ease of masking and etching instead of HF nitric.  
This step otherwise was simply used to create the gap where the valve seat sits after 
anodic bonding.  Six glass wafers went through these steps with an recesses between 1.3-
1.4 µm. 
 
m-r. Through hole preparation and etch 
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A Cr/Au etch mask with the maximum thicknesses for both layers was used.  The 
evaporator can take up to nine wafers at once, so processing six glass wafers at a time is 
easier using evaporation when compared to sputtering.  Also, a mask processed this way 
with photoresist still on it is a better mask for long HF etches.  This has been 
demonstrated in papers, and through personal experience.  Six glass wafers were 
processed through this step.   
 
s. Use Al to prevent bonding at the center area. 
 
Instead of using a photoresist process, a shadow mask was used to deposit the aluminum.  
The photoresist was difficult to properly spin on the previously etched glass wafer with 
through holes.  Several photoresist etch techniques used when processing the second 
generation valve process were attempted and all had poor results.  Instead, DRIE etching 
of single sided wafers was used to make shadow masks.  The silicon shadow masks were 
aligned to the glass wafer using visual techniques (1 mm tolerance).  These masks make 
evaporation deposition of aluminum easier and faster with higher yield and retention then 
previous photoresist steps.  Three shadow masks were made, and three glass wafers were 
deposited with Al. 
 
4. Bonding 
a,b,c. Cleaning through the bond 
 
A blank glass wafer was stacked with the processed glass wafer during the anodic bond.  
This was necessary because Na from the glass migrates into the chuck if the glass side is 
down, and the gold forms a Eutectic bond with the carbon chuck if the device side of the 
wafer stack is down.  By adding a second glass wafer, the surface of the second wafer at 
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the glass to glass interface absorbed all of the migrating Na from the anodic bond itself.  
In order to compensate for this added glass wafer, the voltage of the anodic bond was 
increased to 800 volts.  The anodic bond was tested with two wafers, and demonstrates 
better bonding if a tack bond was NOT used in advance of the actual bond.  One test 
wafer and two SOI wafers were bonded during this step. 
 
d. Al removal in Al etch well 
 
This step took three days and two batches of aluminum etchant to fully remove the 
aluminum.  It works reliably with no problems otherwise 
 
e. Etch in DI water and soak in SI  
 
This step worked fine.  The DI soak was maintained for 2 days. 
 
 
f. Dry w/ hotplate or oven 
 
Two SOI wafers were placed into an oven at 65°.  This caused two pressure sensor 
membranes to burst as water rapidly evaporated and created pressure buildup inside the 
pressure sensor cavities.  Soaking the wafers in IPA before drying may prevent 





There were no issues with this step.  Final device yield was between 60 – 70%. 
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3nd Gen Micromachined Valve Runsheet 
Allan T Evans 
July 8, 2009 
 
 
Wafer: (100) N-type SOI: 20 μm device, 450 μm handle, 2 μm oxide, >5 Ω resistivity 
 500 µm 4” glass wafer from Plan Optik (PN: V015.04-0001) 
 
6. SOI wafer processing 
a. Cleaning: Piranha clean 
i. H2O2:H2SO4=1:1, 10 mins 
ii. DI water Rinse 5 min & Spin Rinse Dry 
b. Thermal Oxidation 
i. Pre-furnace Clean 
ii. B2 Furnace: Temperature: 1000ºC, Dry/Wet/Dry: 5/40/5 mins 
N2 anneal: 20 min, thickness: 2438 Å 
c. Resistor formation 
i. Pattern with PR (1827): 
1. HMDS 
2. 1827 PR: spread: 500 rpm 4sec, spin: 3000rpm 30 sec 
3. Expose 15 sec 
4. Develop 1 min (MF 319) 
ii. O2 plasma 60 sec (80 W) 
iii. Oxide etch in BHF 9 min 
iv. DI water rinse 
d. Ion Implantation 
i. Send out with PR and Oxide mask to INNOViON  
ii. Boron implantation: Dose: 1e13, Energy: 20 Kev, Tilt: 7 
e. Thermal Oxidation and Boron Drive-In 
i. Strip PR and PreFurnace Clean 
ii. B2 Furnace: Temperature: 1000ºC, Dry/Wet/Dry: 5/20/5 mins 
N2 anneal: 20 min, thickness:  ~1000 Å 
f. Via formation 
i. Pattern with PR (1827): 
1. HMDS 
2. 1827 PR: spread: 500 rpm 4sec, spin: 3000rpm 30 sec 
3. Expose 15 sec 
4. Develop 1 min (MF 319) 
ii. O2 plasma 60 sec (80 W) 
iii. Oxide etch in BHF 9 min 
iv. DI water rinse 
v. Metal deposition (for ohmic contact before PR removal) 
1. Descum 30 sec @ 80 W 
2. Ti/Pt/Au (50/500/1000 Å) 
3. lift off: 1~2 hours in acetone 
4. ultrasonic: 5 min in acetone, 5 min in IPA  
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5. rinse with DI water 
vi. Examine under microscope 
g. Metal Interconnects 
i. Pattern with PR (1827): same as above 
ii. Descum 
iii. Evaporate Cr/Au (300/1000 Å) Enerjet evaporator 
iv. Acetone lift off 
v. Followed by ultrasonic in 5 min acetone, 5 min IPA and DI water 
rinse 
7. SOI wafer backside processing 
a. Al pattern for STS 
i. Spin 1827 @2000 rpm on the front side (processed) of the wafer 
for protection and bake for 1 min @115ºC hot plate (can be longer) 
ii. Spin 1827 @ 3000 rpm and pattern on the back side for Al lift-off 
iii. Evaporate 4000 Å Al on the backside 
iv. Acetone lift-off 
v. PRS 2000, followed by DI rinse 
b. DRIE 
i. Wafer mounting 
1. use wafer mounting oil by STS 
2. mount to a blank carrier wafer 
ii. PR pattern for STS 
1. Spin 9260 @ 1500 rpm 
2. bake 30 mins @ 90ºC Oven 
3. Expose 80 secs using MA6 
4. Develop in AZ400K: DI H2O=1:3 for 4 mins 
iii. DRIE using STS for ~ 2 hours and 40 mins (check often near end) 
depth  near 400-420 μm 
iv. 2nd DRIE etch after PR strip and remount – 35 mins 
8. Glass wafer processing 
a. Piranha clean 
b. BHF dip for 5 mins 
c. DI rinse and spin rinse dry 
d. Evaporate Cr/Au (1000/5000 Å) for glass etch mask 
e. Pattern w/ 9260 @ 1000 rpm 
i. Bake 30 min @ 90ºC oven 
ii. Expose 90 secs using MA6 
iii. Develop in AZ400K:DI=1:3 for 2 mins 
f. Back side protection w/ 9260, use manual spinner(solitec) w/ rubber ring 
i. Spin 9260 @ 1000 rpm, bake 30 mins @ 90ºC oven 
g. O2 plasma 60 sec @ 80 W (right before the Au etch) 
h. Au etch – 4 min, DI rinse – 1 min, Cr etch – 2 min, DI rinse – 2 min 
i. BHF etch for 90 min   approximate depth is 1.4 µm 
j. Strip PR in PRS 2000 then measure the depth. 
k. Strip Au ~ 5 mins, strip Cr ~ 3 min 
l. Piranha clean 
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m. Evaporate Cr/Au (1000/4000 Å) on both sides twice 
n. Pattern the front side w/ 9260 (1000 rpm, 90 sec expose, 2 min develop) 
o. Hard bake in 110ºC oven 5 mins 
p. Pattern back side w/ 9260 
q. Get ready for HF etch 
i. Wrap the edges w/ parafilm 
ii. Cover up the alignment marks w/ white tape 
iii. O2 plasma on both sides (60 secs, 80 W) 
iv. Dip in DI H2O then Au etch 4 min 
v. Dip in DI H2O then Cr etch 4 min 
vi. Dip in DI H2O then Au etch 4 min 
vii. Dip in DI H2O then Cr etch 4 min 
viii. Etch in HF for 60 mins 
ix. Inspect the little holes are through 
r. Strip Au and Cr 
s. Use Al to prevent bonding at the center area 
i. STS blank silicon wafers all the way through to form shadow 
masks 
ii. Manually align glass wafers to shadow masks 
iii. Evaporate 1000 Å Al then lift-off shadow mask. 
9. Bonding 
a. Piranha clean glass wafer before bonding 
b. Use a second glass wafer as a Na catch in the bonder 
c. Anodic bonding at 800 V, 400ºC 
d. Al removal in Al etch well (several days) 
e. Rinse in DI water and soak in DI water for several hours. 
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Appendix E: System Housing Designs 
 
This section contains the machine drawings for the housings mechanically manufactured 
for the first and second prototypes presented in the body of the thesis.  All measurements 
are presented in millimeters with the values for inches in brackets. 
 
Half of the shell for the first generation prototype: 
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Bottom compartment for the second generation prototype: 
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